WO2005028434A2 - Novel heterocyclic compounds as hsp90-inhibitors - Google Patents

Novel heterocyclic compounds as hsp90-inhibitors Download PDF

Info

Publication number
WO2005028434A2
WO2005028434A2 PCT/US2004/031248 US2004031248W WO2005028434A2 WO 2005028434 A2 WO2005028434 A2 WO 2005028434A2 US 2004031248 W US2004031248 W US 2004031248W WO 2005028434 A2 WO2005028434 A2 WO 2005028434A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
aryl
heteroaryl
group
tautomer
Prior art date
Application number
PCT/US2004/031248
Other languages
English (en)
French (fr)
Other versions
WO2005028434A3 (en
Inventor
Srinivas R. Kasibhatla
Marcus F. Boehm
Kevin D. Hong
Marco A. Biamonte
Jiandong Shi
Jean-Yves Le Brazidec
Lin Zhang
David Hurst
Original Assignee
Conforma Therapeutics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200600594A priority Critical patent/EA010160B1/ru
Priority to CA002539548A priority patent/CA2539548A1/en
Priority to AU2004274507A priority patent/AU2004274507B2/en
Priority to NZ546611A priority patent/NZ546611A/en
Priority to MXPA06002997A priority patent/MXPA06002997A/es
Priority to JP2006527162A priority patent/JP2007505933A/ja
Priority to BRPI0414533-0A priority patent/BRPI0414533A/pt
Priority to CN2004800335230A priority patent/CN1882589B/zh
Application filed by Conforma Therapeutics Corporation filed Critical Conforma Therapeutics Corporation
Priority to EP04788954A priority patent/EP1670802A4/en
Publication of WO2005028434A2 publication Critical patent/WO2005028434A2/en
Priority to IL174375A priority patent/IL174375A0/en
Publication of WO2005028434A3 publication Critical patent/WO2005028434A3/en
Priority to NO20061396A priority patent/NO20061396L/no
Priority to AU2010202750A priority patent/AU2010202750B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Definitions

  • the invention relates in general to heterocyclics and related compounds and their broad-spectrum utility, e.g., in inhibiting heat shock protein 90 (HSP90)to thereby treat or prevent HSP90-mediated diseases.
  • HSP90 heat shock protein 90
  • HSP90& are ubiquitous chaperone proteins that are involved in folding, activation and assembly of a wide range of proteins, including key proteins involved in signal transduction, cell cycle control and transcriptional regulation.
  • HSP90 chaperone proteins are associated with important signaling proteins, such as steroid hormone receptors and protein kinases, including, e.g., Raf-1, EGFR, v-Src family kinases, Cdk4, and ErbB-2 ( Buchner J. TIBS 1999, 24, 136-141; Stepanova, L. et al. Genes Dev. 1996, 10, 1491-502; Dai, K. et al. J. Biol Chem. 1996, 271, 22030-4).
  • HSP70 p60 Hop/Stil, Hip, Bagl
  • HSP40 Hdj2/Hsj 1 immunophilins, p23, and p50
  • HSP90 may assist HSP90 in its function (see, e.g., Caplan, A. Trends in Cell Biol. 1999, 9, 262-68).
  • Ansamycin antibiotics e.g., herbimycin A (HA), geldanamycin (GM), and 17- allylaminogeldanamycin (17-AAG) are thought to exert their anticancerous effects, by tight binding of the N-terminus pocket of HSP90, thereby destabilizing substrates that normally interact with HSP90 (Stebbins, C.
  • HSP90 substrate destabilization occurs in tumor and non-transformed cells alike and has been shown to be especially effective on a subset of signaling regulators, e.g., Raf (Schulte, T. W. et al. Biochem. Biophys. Res. Commun. 1997, 239, 655-9; Schulte, T. W., et al. J. Biol. Chem. 1995, 270, 24585-8), nuclear steroid receptors (Segnitz, B.; U. GehringJ. Biol. Chem. 1997, 272, 18694-18701; Smith, D. F. et al. Mol. Cell.
  • Raf Schote, T. W. et al. Biochem. Biophys. Res. Commun. 1997, 239, 655-9
  • nuclear steroid receptors Segnitz, B.; U. Geh
  • HSP90 inhibitors have also been implicated in a wide variety of other utilities, including use as anti-inflammation agents, anti-infectious disease agents, agents for treating autoimmunity, agents for treating stroke, ischemia, multiple sclerosis, cardiac disorders, central nervous system related disorders and agents useful in promoting nerve regeneration (See, e.g., Rosen et al. WO 02/09696 (PCT/US01/23640); Degranco etal. WO 99/51223 (PCT US99/07242); Gold, U.S. Patent 6,210,974 BI; DeFranco et al., US Patent 6,174,875.
  • fibrogenetic disorders including but not limited to scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis, and pulmonary fibrosis also may be treatable with HSP90 inhibitors.
  • Still further HSP90 modulation, modulators and uses thereof are reported in Application Nos.
  • the present invention is directed towards heterocyclic compounds, particularly heterocyclic compounds and related analogs that show broad utility, e.g., by inhibiting HSP90 and treating and preventing diseases that are HSP90-dependent.
  • the invention comprises the heterocyclic compounds and related analogs as specified below in Formulae A, I, IA-E, II, HA-D, III, IIIA-B, and TV an IVA and heterocyclic compounds that are produced by a process of the invention.
  • stereoisomeric forms including the individual enantiomers and diastereomers, racemic mixtures, and diastereomeric mixtures, as well as polymorphs, solvates, esters, tautomers, pharmaceutically acceptable salts and prodrugs of these compounds.
  • Stereoisomers of the compounds of the present invention may be isolated by standard resolution techniques such as, for example, fractional crystallization and chiral column chromatography.
  • the invention provides compounds of Formula A, or a polymorph, solvate, ester, tautomer, diastereomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, which show utility for inhibiting HSP90 and/or treating and preventing diseases that are HSP90-dependent.
  • FIGURE 1 Various genuses and subgenuses of compounds of Formula A that are within the scope of the invention are illustrated in FIGURE 1. Particularly, the invention provides compounds of Formula 1-IV.
  • the invention provides compounds, or a polymorph, solvate, ester, tautomer, diastereomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof, which show utility for inhibiting HSP90 and/or treating and preventing diseases that are HSP90-dependent, that are prepared by the process comprising: reacting a compound of Formula Y and a compound of Formula Z, wherein: Y is represented by any of the following formulae:
  • Z is L'-R 4 -R 5 .
  • the present invention is directed to pharmaceutical compositions comprising the compounds of the invention, in particular, the compounds of Formulae A, I, II, III and IV and related analogs, and compounds formed by the process of the invention, and their polymorphs, solvates, esters, tautomers, diastereomer, enantiomers, pharmaceutically acceptable salts and prodrugs thereof, and one or more pharmaceutical excipients, for use in treatment or prevention of diseases that are HSP90- dependent.
  • the invention features a method of treating an individual having an HSP90-mediated disorder by administering to the individual a pharmaceutical composition that comprises a pharmaceutically effective amount of a compound of Formulae A, I, II, III or IV, or a polymorph, solvate, ester, tautomer, diastereomer, enantiomer, enantiomers pharmaceutically acceptable salt or prodrug thereof.
  • the invention provides a method for treating an individual having a disorder selected from the group of inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders, fibrogenetic disorders, proliferative disorders, tumors, leukemias, neoplasms, cancers, carcinomas, metabolic diseases, and malignant diseases.
  • the invention provides a method for treating an individual having a fibrogenetic disorder, such as, for example, scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis and pulmonary fibrosis.
  • a fibrogenetic disorder such as, for example, scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis and pulmonary fibrosis.
  • the invention provides a combination therapy comprising the administration of a pharmaceutically effective amount of a compound of Formulae A, I, II, III or IV and related analogs, or a polymorph, solvate, ester, tautomer, diastereomer, enantiomer, pharmaceutically acceptable salt and prodrug thereof, according to any of the preceding aspects or embodiments, and at least one therapeutic agent selected from the group of cytotoxic agents, anti-angiogenesis agents and anti-neoplastic agents.
  • the anti-neoplastic agent may be selected from the group of alkylating agents, anti- metabolites, epidophyllotoxins antineoplastic enzymes, topoisomerase inhibitors, procarbazines, mitoxantrones, platinum coordination complexes, biological response modifiers and growth inhibitors, hormonal/anti-hormonal therapeutic agents, and haematopoietic growth factors. Any of the above described aspects and embodiments of the invention can be combined where practical. The individual compounds, methods and compositions prescribed do not preclude the utilization of other, unspecified steps and agents, and those of ordinary skill in the art will appreciate that additional steps and compounds may also be combined usefully within the spirit of various aspects and embodiments of the invention.
  • Advantages of the invention depend on the specific aspect and embodiment and may include one or more of: ease of synthesis and/or formulation, solubility, and IC 50 relative to previously existing compounds in the same or different classes of HSP90 inhibitors.
  • FIGURE 1 shows various illustrative genuses and subgenuses of Formula A.
  • a "pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention, which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or a pharmaceutically active metabolite or residue thereof.
  • Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., by allowing orally administered compound to be more readily absorbed into blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system).
  • a "pharmaceutically acceptable salt” may be prepared for any compound of the invention having a functionality capable of forming a salt, for example, an acid or base functionality.
  • Pharmaceutically acceptable salts may be derived from organic or inorganic acids and bases.
  • Compounds of the invention that contain one or more basic functional groups, e.g., amino or alkylamino, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable organic and inorganic acids.
  • These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed.
  • Suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-napthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, prop
  • salts can likewise be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine.
  • a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine.
  • suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or tertiary amine.
  • alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
  • Illustrative examples of some of the bases that can be used include sodium hydroxide, potassium hydrox
  • Organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.
  • This invention also envisions the quatemization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quatemization. See, for example, Berge et al., supra.
  • prodrugs of the compounds of this invention include, but are not limited to, esters, carbonates, thiocarbonates, N-acyl derivatives, N- acyloxyalkyl derivatives, quaternary derivatives of tertiary amines, N-Mannich bases, Schiff bases, aminoacid conjugates, phosphate esters, metal salts and sulfonate esters.
  • Suitable positions for derivatization of the compounds of the invention to create "prodrugs” include but are not limited, 2-amino substitution. Those of ordinary skill in the art have the knowledge and means to accomplish this without undue experimentation.
  • Various forms of prodrugs are well known in the art.
  • prodrug derivatives see, e.g., a) Design of Prodrugs, Bundgaard, A. Ed., Elseview, 1985 and Method in Enzymology, Widder, K. et al., Ed.; Academic, 1985, vol. 42, p. 309-396; b) Bundgaard, H. "Design and Application of Prodrugs” in A Textbook of Drug Design and Development, Krosgaard-Larsen and H. Bundgaard, Ed., 1991, Chapter 5, p. 113-191; and c) Bundgaard, H., Advanced Drug Delivery Review, 1992, 8, 1-38. Each of which is incorporated herein by reference.
  • the term "prodrugs” as employed herein includes, but is not limited to, the following groups and combinations of these groups:
  • Hydroxy prodrugs Acyloxyalkyl esters; Alkoxycarbonyloxyalkyl esters; Alkyl esters; Aryl esters; and Disulfide containing esters.
  • alkyl alone or in combination, refers to an optionally substituted straight-chain, or optionally substituted branched-chain saturated hydrocarbon radical having from one to about thirty carbons, more preferably one to twelve carbons.
  • alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, tert-amyl, pentyl, hexyl, heptyl, octyl and the like.
  • cycloalkyl embraces cyclic alkyl radicals which include monocyclic, bicyclic, tricyclic, and higher multicyclic alkyl radicals wherein each cyclic moiety has from three to about eight carbon atoms.
  • cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • a "lower alkyl” is a shorter alkyl, e.g., one containing from one to about six carbon atoms.
  • alkenyl alone or in combination, refers to an optionally substituted straight-chain, or optionally substituted branched-chain hydrocarbon radical having one or more carbon-carbon double-bonds and having from two to about thirty carbon atoms, more preferably two to about eighteen carbons.
  • alkenyl radicals include ethenyl, propenyl, butenyl, 1,3-butadienyl and the like.
  • cylcoalkenyl refers to cyclic alkenyl radicals which include monocyclic, bicyclic, tricyclic, and higher multicyclic alkenyl radicals wherein each cyclic moiety has from three to about eight carbon atoms.
  • a "lower alkenyl” refers to an alkenyl having from two to about six carbons.
  • alkynyl refers to an optionally substituted straight-chain or optionally substituted branched-chain hydrocarbon radical having one or more carbon-carbon triple-bonds and having from two to about thirty carbon atoms, more preferably from two to about tweove carbon atoms, from two to about six carbon atoms as well as those having from two to about four carbon atoms.
  • alkynyl radicals include ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl and the like.
  • cycloalkynyl refers to cyclic alkynyl radicals which include monocyclic, bicyclic, tricyclic, and higher multicyclic alkynyl radicals wherein each cyclic moiety has from three to about eight carbon atoms.
  • a “lower alkynyl” refers to an alkynyl having from two to about six carbons.
  • heteroalkyl, heteroalkenyl and heteroalkynyl include optionally substituted alkyl, alkenyl and alkynyl structures, as described above, and which have one or more skeletal chain atoms selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorous or combinations thereof.
  • carbon chain embraces any alkyl, alkenyl, alkynyl, or heteroalkyl, heteroalkenyl, or heteroalkynyl group, which are linear, cyclic, or any combination thereof. If the chain is part of a linker and that linker comprises one or more rings as part of the core backbone, for purposes of calculating chain length, the “chain” only includes those carbon atoms that compose the bottom or top of a given ring and not both, and where the top and bottom of the ring(s) are not equivalent in length, the shorter distance shall be used in determining the chain length. If the chain contains heteroatoms as part of the backbone, those atoms are not calculated as part of the carbon chain length.
  • membered ring can embrace any cyclic structure, including aromatic, heteroaromatic, alicyclic, heterocyclic and polycyclic fused ring systems as described below.
  • membered is meant to denote the number of skeletal atoms that constitute the ring.
  • pyridine, pyran, and pyrimidine are six- membered rings and pyrrole, tetrahydrofuran, and thiophene are five-membered rings.
  • aryl alone or in combination, refers to an optionally substituted aromatic hydrocarbon radical of six to about twenty ring atoms, and includes mono- aromatic rings and fused aromatic ring.
  • a fused aromatic ring radical contains from two to four fused rings where the ring of attachment is an aromatic ring, and the other individual rings within the fused ring may be aromatic, heteroaromatic, alicyclic or heterocyclic.
  • aryl includes mono-aromatic ring and fused aromatic rings containing from six to about twelve carbon atoms, as well as those containing from six to about ten carbon atoms. Examples of aryl groups include, without limitation, phenyl, naphthyl, anthryl, chrysenyl, and benzopyrenyl ring systems.
  • lower aryl refers to an aryl having six to about ten skeletal ring carbons, e.g., phenyl and naphthyl ring systems.
  • heteroaryl refers to optionally substituted aromatic radicals containing from about five to about twenty skeletal ring atoms and where one or more of the ring atoms is a heteroatom such as, for example, oxygen, nitrogen, sulfur, selenium and phosphorus.
  • heteroaryl includes optionally substituted mono-heteroaryl radicals and fused heteroaryl radicals having at least one heteroatom (e.g., quinoline, benzothiazole).
  • a fused heteroaryl radical may contain from two to four fused rings and where the ring of attachment is a heteroaromatic ring, the other individual rings within the fused ring system may be aromatic, heteroaromatic, alicyclic or heterocyclic.
  • heteroaryl also includes mono-heteroaryls or fused heteroaryls having from five to about twelve skeletal ring atoms, as well as those having from five to about ten skeletal ring atoms.
  • heteroaryls include, without limitation, furanyl, benzofuranyl, chromenyl, pyridyl, pyrrolyl, indolyl, quinolinyl, pyridyl-N-oxide, pyrimidyl, pyrazinyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, benzothiozole, benzimidazole, benzoxazoles, benzothiadiazole, benzoxadiazole, benzotriazole, quinolines, isoquinolines, indoles, purinyl, indolizinyl, thienyl and the like and their oxides.
  • lower heteroaryl refers to a heteroaryl having five to about ten skeletal ring atoms, e.g., pyridyl, thienyl, pyrimidyl, pyrazinyl, pyrrolyl, or furanyl.
  • alicyclic alone or in combination, refers to an optionally substituted saturated or unsaturated nonaromatic hydrocarbon ring system containing from three to about twenty ring atoms.
  • the term alicyclic includes mono-alicyclic and fused alicyclic radicals.
  • a fused alicyclic may contain from two to four fused rings where the ring of attachment is an alicyclic ring, and the other individual rings within the fused-alicyclic radical may be aromatic, heteroaromatic, alicyclic and heterocyclic.
  • the term alicyclic also includes mono-alicyclic and fused alicyclic radicals containing from three to about twelve carbon atoms, as well as those containing from three to about ten carbon atoms.
  • alicyclics include, without limitation, cyclopropyl, cyclopropenyl, cyclobutyl, cyclopentyl, cyclodecyl, cyclododecyl, cyclopentadienyl, indanyl, and cyclooctatetraenyl ring systems.
  • the term "lower alicyclic” refers to an alicyclic having three to about ten skeletal ring carbons, e.g., cyclopropyl, cyclopropenyl, cyclobutyl, cyclopentyl, decalinyl, and cyclohexyl.
  • heterocyclic refers to optionally substituted saturated or unsaturated nonaromatic ring radicals containing from five to about twenty ring atoms where one or more of the ring atoms are heteroatoms such as, for example, oxygen, nitrogen, sulfur, and phosphorus.
  • alicyclic includes mono-heterocyclic and fused heterocyclic ring radicals.
  • a fused heterocyclic radical may contain from two to four fused rings where the attaching ring is a heterocyclic, and the other individual rings within the fused heterocyclic radical may be aromatic, heteroaromatic, alicyclic or heterocyclic.
  • heterocyclic also includes mono-heterocrclic and fused alicyclic radicals having from five to about twelve skeletal ring atoms, as well as those having from five to about ten skeletal ring atoms.
  • Example of heterocyclics include without limitation, tetrahydrofuranyl, benzodiazepinyl, tetrahydroindazoleyl, dihyroquinolinyl, and the like.
  • lower heterocyclic refers to a heterocyclic ring system having five to about ten skeletal ring atoms, e.g., dihydropyranyl, pyrrolidinyl, indolyl, piperidinyl, piperazinyl, and the like.
  • alkylaryl or “araalkyl,” alone or in combination, refers to an aryl radical as defined above in which one H atom is replaced by an alkyl radical as defined above, such as, for example, tolyl, xylyl and the like.
  • arylalkyl alone or in combination, refers to an alkyl radical as defined above in which one H atom is replaced by an aryl radical as defined above, such as, for example, benzyl, 2-phenylethyl and the like.
  • heteroarylalkyl refers to an alkyl radical as defined above in which one H atom is replaced by a heteroaryl radical as defined above, each of which may be optionally substituted.
  • alkoxy refers to an alkyl ether radical, alkyl- O-, wherein the term alkyl is defined as above.
  • alkoxy radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like.
  • aryloxy alone or in combination, refers to an aryl ether radical wherein the term aryl is defined as above. Examples of aryloxy radicals include phenoxy, benzyloxy and the like.
  • alkylthio refers to an alkyl thio radical, alkyl-S-, wherein the term alkyl is as defined above.
  • arylthio alone or in combination, refers to an aryl thio radical, aryl-S- , wherein the term aryl is as defined above.
  • heteroarylthio refers to the group heteroaryl-S-, wherein the term heteroaryl is as defined above.
  • acyl refers to a radical -C(0)R where R includes alkyl, alkenyl, alkynyl, aryl, heteroaryl, alicyclic, heterocylic, arylalkyl or heteroarylalkyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroryl, alicylic, heterocylic, arylalkyl or heteroaryl alkyl groups may be optionally substituted.
  • acyloxy refers to the ester group -OC(0)R, where R is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, alicyclic, heterocyclic, arylalkyl, or heteroarylalkyl wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, alicyclic, heterocyclic, arylalkyl or heteroarylalkyl may be optionally substituted.
  • carbboxy esters refers to -C(0)OR where R is alkyl, aryl or arylalkyl, wherein the alkyl, aryl and arylalkyl groups may be optionally substituted.
  • carbboxamido refers to
  • alkyl, aryl, heteroaryl, alicyclic, heterocyclic, arylalkyl and heteroarylalkyl wherein the alkyl, aryl, heteroaryl, alicyclic, heterocyclic, or arylalkyl groups may be optionally substituted.
  • halogen includes F, CI, Br and I.
  • haloalkyl, haloalkenyl, haloalkynyl and haloalkoxy include alkyl, alkenyl, alkynyl and alkoxy structures, as described above, that are substituted with one or more fluorines, chlorines, bromines or iodines, or with combinations thereof.
  • perhaloalkyl, perhaloalkyloxy and perhaloacyl refer to alkyl, alkyloxy and acyl radicals as described above, that all the H atoms are substituted with fluorines, chlorines, bromines or iodines, or combinations thereof.
  • cycloalkyl, arylalkyl, aryl, heteroaryl, alicyclic, heterocyclic, alkyl, alkynyl, alkenyl, haloalkyl, and heteroalkyl include optionally substituted cycloalkyl, arylalkyl, aryl, heteroaryl, alicyclic, heterocyclic, alkyl, alkynyl, alkenyl, haloalkyl and heteroalkyl groups.
  • alkylamino refers to the group -NHR where R is independently selected from alkyl.
  • dialkylamino refers to the group -NRR' where R and R' are alkyls.
  • sulfuride refers to a sulfur atom covalently linked to two atoms; the formal oxidation state of said sulfur is (II).
  • thioether may be used interchangebly with the term “sulfide.”
  • sulfoxide refers to a sulfur atom covalently linked to three atoms, at least one of which is an oxygen atom; the formal oxidation state of said sulfur atom is
  • sulfurone refers to a sulfur atom covalently linked to four atoms, at least two of which are oxygen atoms; the formal oxidation state of said sulfur atom is (VI).
  • the terms “optional” or “optionally” mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
  • aryl optionally mono- or di-substituted with an alkyl means that the alkyl may but need not be present, or either one alkyl or two may be present, and the description includes situations where the aryl is substituted with one or two alkyls and situations where the aryl is not substituted with an alkyl.
  • Optionally substituted groups may be substituted or unsubstituted.
  • the substituents of an "optionally substituted” group may include, without limitation, one or more substituents independently selected from the following groups or designated subsets thereof: lower alkyl, lower alkenyl, lower alkynyl, lower aryl, heteroaryl, alicyclic, heterocyclic, arylalkyl, heteroarylalkyl, lower alkoxy, lower aryloxy, amino, alkylamino, dialkylamino, diarylalkylammo, alkylthio, arylthio, heteroarylthio, oxo, oxa, carbonyl (-C(O)), carboxyesters (-C(O)OR), carboxamido (-C(0)NH 2 ), carboxy, acyloxy, -H, halo, -CN, -N0 2 , -N 3 , -SH, -OH, -C(0)CH 3 ,
  • An optionally substituted group may be unsubstituted (e.g., -CH 2 CH 3 ), fully substituted (e.g., -CF 2 CF 3 ), monosubstituted (e.g., -CH 2 CH 2 F) or substituted at a level anywhere in- between fully substituted and monosubstututed (e.g., -CH 2 CF 3 ).
  • pyridine- 1-oxy also means "pyridine-N-oxy.”
  • a "pharmacological composition” refers to a mixture of one or more of the compounds described herein, or pharmaceutically acceptable salts thereof, with other chemical components, such as pharmaceutically acceptable carriers and/or excipients. The purpose of a pharmacological composition is to facilitate administration of a compound to an organism.
  • pharmaceutically acceptable carrier means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body.
  • a pharmaceutically-acceptable material such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt;
  • gelatin e.g., ethylene glycol
  • excipients such as cocoa butter and suppository waxes
  • oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil
  • glycols such as propylene glycol
  • polyols such as glycerin, sorbitol, mannitol and polyethylene glycol
  • esters such as ethyl oleate and ethyl laurate
  • (13) agar (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide
  • a physiologically acceptable carrier should not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
  • An “excipient” refers to an inert substance added to a pharmacological composition to further facilitate administration of a compound. Examples of excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
  • a "pharmaceutically effective amount” means an amount which is capable of providing a therapeutic and/or prophylactic effect.
  • a typical daily dose (administered in single or divided doses) will contain a dosage level of from about 0.01 mg/kg to about 50- 100 mg/kg of body weight of an active compound of the invention.
  • Preferred daily doses generally will be from about 0.05 mg/kg to about 20 mg/kg and ideally from about 0.1 mg/kg to about 10 mg/kg.
  • Factors such as clearance rate, half-life and maximum tolerated dose (MTD) have yet to be determined but one of ordinary skill in the art can determine these using standard procedures.
  • the preferred therapeutic effect is the inhibition, to some extent, of the growth of cells characteristic of a proliferative disorder, e.g., breast cancer.
  • a therapeutic effect will also normally, but need not, relieve to some extent one or more of the symptoms other than cell growth or size of cell mass.
  • a therapeutic effect may include, for example, one or more of 1) a reduction in the number of cells; 2) a reduction in cell size; 3) inhibition (i.e., slowing to some extent, preferably stopping) of cell infiltration into peripheral organs, e.g., in the instance of cancer metastasis; 3) inhibition (i.e., slowing to some extent, preferably stopping) of tumor metastasis; 4) inhibition, to some extent, of cell growth; and/or 5) relieving to some extent one or more of the symptoms associated with the disorder.
  • the term IC50 refers to an amount, concentration or dosage of a particular test compound that achieves a 50% inhibition of a maximal response in an assay that measures such response.
  • the "IC 5 0" value of a compound of the invention can be greater for normal cells than for cells exhibiting a proliferative disorder, e.g., breast cancer cells.
  • the value depends on the assay used.
  • a "standard” is meant a positive or negative control.
  • a negative control in the context of HER2 expression levels is, e.g. , a sample possessing an amount of HER2 protein that correlates with a normal cell.
  • a negative control may also include a sample that contains no HER2 protein.
  • a positive control does contain HER2 protein, preferably of an amount that correlates with overexpression as found in proliferative disorders, e.g., breast cancers.
  • the controls may be from cell or tissue samples, or else contain purified ligand (or absent ligand), immobilized or otherwise.
  • one or more of the controls may be in the form of a diagnostic "dipstick.”
  • selective targeting is meant affecting one type of cell to a greater extent than another, e.g., in the case of cells with high as opposed to relatively low or normal HER2 levels.
  • X 1 and X 2 are the same or different and each is nitrogen or -CR 6 ;
  • X 3 is nitrogen or -CR 3 wherein R 3 is hydrogen, OH, a keto tautomer, -OR 8 , -CN, halogen, lower alkyl, or -C(0)R 9 ;
  • X 4 is nitrogen or a group CR 6 when X 3 is nitrogen, and X 4 is -CR 6 R 7 when X 3 is ⁇
  • R 1 is halogen, -OR 8 , -SR 8 , or lower alkyl
  • R 2 is -NR 8 R 10
  • R 5 is alkyl, aryl, heteroaryl, alicyclic, or heterocyclic, each of which is optionally bi-or tricyclic, and optionally substituted with H, halogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl, lower alicyclic, araalkyl, aryloxyalkyl, alkoxyalkyl, perhaloalkyl, perhaloalkyloxy, perhaloacyl, -N 3 , -SR 8 , -OR 8 , -CN, -C0 2 R 9 , -N0 2 , or - NR
  • Xi and X 2 are the same or different and each is nitrogen or -CR 6 ;
  • R 1 is halogen, -OR 8 , -SR 8 , or lower alkyl;
  • R 2 is -NR 8 R 10 ;
  • R3 is hydrogen, -OH or keto tautomer, -OR 8 , halogen, -CN, lower alkyl, or-C(0)R9;
  • R 5 is alkyl, aromatic, heteroaromatic, alicyclic, heterocyclic, each of which is optionally bi- or tricyclic, and optionally substituted with H, halogen, lower alkyl, -SR 8 , -OR 8 ,
  • R 1 is selected from halogen, hydroxyl, lower alkoxy, lower thioalkyl and C ⁇ alkyl; and R 2 is -NH 2; R3 is hydrogen.
  • R 1 is selected from halogen, hydroxyl, lower alkoxy, lower thioalkyl or CM alkyl; optionally, R 2 is NH 2 .
  • R 4 is -CH 2 -.
  • R 1 is halogen, hydroxyl, lower alkoxy, lower thioalkyl, or C alkyl; and R 2 is optionally NH 2 , R 4 is -(CH 2 )-, and R 5 is phenyl, benzyl, or pyridyl, all optionally substituted with H, halogen, lower alkyl, -SR 8 , -OR 8 (or cyclic ethers such as methylenedioxy), -CN, -C0 2 R 9 , -N0 2 , or -NR 8 R 10 ; R 8 is hydrogen, lower alkyl, lower aryl or -(CO)R 9 ; R is lower alkyl, lower aryl, lower heteroaryl, -NR 8 R 10 or -OR 11 ; R 11 is lower alkyl or lower aryl; and R 10 is hydrogen or lower alkyl.
  • R 1 is halogen
  • R 2 is -NH 2
  • R 4 is -CH 2 -
  • R 6 is H or halogen
  • R 5 is phenyl optionally substituted with H, halogen, C 1- alkyl, C 1- alkoxy, C alkylthio, perhaloalkyl, perhaloalkyloxy, -CN, -N0 2 , -NH 2 or -C0 2 R n .
  • R 1 is halogen
  • R 2 is -NH 2
  • R 4 is -CH 2 -
  • R 6 is H
  • R 5 is 2-halo-3, 5-dimethoxyphenyl optionally substituted with H, halogen, C alkyl, C alkoxy, C M alkylthio, perhaloalkyl, perhaloalkyloxy, -CN, -N0 2 , -NH 2 , or -C0 2 R n at the para (4-) position.
  • R 1 is chloro
  • R 2 is -NH 2
  • R 4 is -CH 2 -
  • R 6 is H
  • R 5 is 2- chloro-3, 4,5-trimethoxyphenyl.
  • R 1 is chloro
  • R 2 is -NH 2
  • R 4 is -CH 2 -
  • R 6 is H
  • R 5 is 2- bromo-3, 4,5-trimethoxyphenyl.
  • R 5 is selected from 2-iodo- 3, 4,5-trimethoxyphenyl, 2-fluoro-3,4,5-trimethoxyphenyl, or 2-bromo-3,4,5- trimethoxyphenyl. Any of the foregoing embodiments can be combined where feasible and appropriate.
  • the invention provides compounds of Formula I:
  • X 1 and X 2 are the same or different and each is nitrogen or -CR 6 ;
  • Ri is halogen, -OR 8 , -SR 8 or lower alkyl;
  • R 2 is -NRsRio;
  • R 3 is hydrogen, OH or a keto tautomer, -OR 8 , halogen, -CN, lower alkyl or -C(0)R 9 ;
  • R 6 is hydrogen, halogen, lower alkyl, -SR 8 , -OR 8 , -NRsRio, -N3, or -C(0)Rc.;
  • R 5 is alkyl, aromatic, heteroaromatic, alicyclic, heterocyclic, all optionally bi- or tricyclic, and all optionally substituted with H, hal
  • Rj is halogen, hydroxyl, lower alkoxy, lower thioalkyl, or CM alkyl; and R 2 is NH 2 .
  • Ri is halogen; R 2 is NH 2 ; and R 4 is ⁇ CH 2 -.
  • the invention provides compounds of Formula IA:
  • Xi and X 2 are the same or different and each is nitrogen or a group -CR ;
  • R 1 is halogen, -OR 8 , -SR 8 , or lower alkyl;
  • R 2 is -NR 8 R 10 ;
  • R 5 is alkyl, aromatic, heteroaromatic, alicyclic, heterocyclic, all optionally bi- or tricyclic, and all optionally substituted with H, halogen, lower alkyl, -SR 8 , -OR 8 , -CN, -C0 2 R 9 , -N0 2 , or -NR 8 R 10 ;
  • R 6 is hydrogen, halogen, lower alkyl, -SR 8 , -OR 8 , -NR 8 R 10 ,
  • Ri is halogen, hydroxyl, lower alkoxy, lower thioalkyl, or C alkyl; and R 2 is NH 2 .
  • Ri is halogen; R 2 is NH 2 , R 4 is -CH 2 -.
  • the invention provides compounds of Formula IB:
  • R° is selected from hydrogen, halogen, lower alkyl, -SR 8 , -OR 8 , -CN, and -NHR 8
  • R 1 is halogen, -OR 11 , -SR 11 or lower alkyl
  • R 2 is -NHR 8
  • R 3 is selected from the group consisting of hydrogen, halogen, -SR 8 , -OR 8 , -CN, - C(0)R 9 , -C(0)OH, -N0 2 , -NR 8 R 10 , lower alkyl, lower alkenyl, lower alkynyl, lower perhaloalkyl, aryl, heteroaryl, alicyclic and heterocyclic, all optionally substituted, wherein: the aryl, heteroaryl, alicyclic and heterocyclic groups are optionally mono-, bi
  • R 10 and R 10 taken together optionally form a ring of 3-7 ring atoms and optionally 1-3 of the ring atoms are heteroatoms selected from the group of O, S and N;
  • R 10 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl or lower heteroaryl;
  • R 11 is lower alkyl, lower alkenyl, or lower alkynyl, lower heteroaryl or lower aryl;
  • R 12 is hydrogen or lower alkyl.
  • each of the aryl, heteroaryl, alicyclic or heterocyclic group is monocyclic or bicyclic.
  • R° is hydrogen, halogen, -SH, -OH, or-CN; R 1 is halogen; and R 2 is -NHR 8 , where R 8 is hydrogen or -C(0)R 9 .
  • R 1 is chloro or bromo
  • R 2 is -NHR 8 , where R 8 is hydrogen or -C(0)R 9
  • R 3 is hydrogen, halogen, OR 8 , SR 8 , NR 8 R 10 , lower alkyl, lower alkenyl, or lower alkynyl, lower perhaloalkyl, lower aryl, or lower heteroaryl.
  • R° is hydrogen, halogen or -CN;
  • R 2 is -NHR 8 , where R 8 is hydrogen or -C(0)R 9 ; and
  • R 4 is -CH 2 -.
  • R° is hydrogen, halogen, -SH, -OH or -CN;
  • R 1 is halogen;
  • R 2 is -NH 2 ,
  • R 3 is hydrogen, halogen, -OR 8 , -SR 8 , -NR 8 R 10 , lower alkyl, lower alkenyl, lower alkynyl, perhaloalkyl, lower aryl, or lower heteroaryl, wherein R 8 is hydrogen, lower alkyl, lower aryl, or -C (O)R ;
  • R 4 is -CH 2 -;
  • R 5 is aryl or heteroaryl, wherein each of said aryl and heteroaryl is monocyclic or bicyclic and is substituted with 3 to 5 substituents.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is a phenyl having at least three substituents.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is a pyridyl having at least two substituents.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is 1-oxy-pyridyl (N-oxy-pyridyl) having at least two substituents.
  • R° is hydrogen, halogen, lower alkyl, -SR 8 , -OR 8 , -CN or -NHR 8 ;
  • R 1 is halogen, -OR 11 , -SR 11 or lower alkyl;
  • R ,2 is -NH 2;
  • R 4 is -CHR 12 -, -C(O)-, -C(S)-, -S(O)- or -S0 2 -;
  • R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein: the aryl group is substituted with 3 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, the heterocyclic group is substituted with 3 to 5 substituents, and the substituents on R 5 are selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower alkynyl, -SR 8 , -OR 8 , -CN, - C(0)OH, -C(0)R 9 , -N0 2 , -NR 8 R 10 , lower aryl, heteroaryl, alicyclic, lower heterocyclic, arylalkyl, heteroarylalkyl, amino, alkylamino, dialkylamino, diarylalkylammo, oxo, oxa, perhaloalkyl, perhaloalkoxy, perhalo
  • R 9 is H, lower alkyl, lower aryl, lower heteroaryl, -NR 10 R 10 , or -OR 11 , wherein R 10 and R 10 taken together optionally form a ring of 3-7 ring atoms and optionally 1-3 of the ring atoms are heteroatoms selected from the group of O, S and N;
  • R 10 is hydrogen, lower alkyl, lower heteroaryl, lower aryl, lower alkenyl, or lower alkynyl;
  • R 11 is lower alkyl, lower alkenyl, or lower alkynyl, lower heteroaryl or lower aryl;
  • R 12 is hydrogen or lower alkyl; and R° and R 10 when taken together optionally form an exocyclic double bond which is optionally substituted, or optionally form a ring of 3-7 ring atoms and optionally 1-3 of the ring atoms are heteroatoms selected from the group of O, S and N.
  • R 1 is halogen or lower alkyl
  • R 4 is -CHR 12 -
  • R 5 is aryl or heteroaryl, wherein each of said aryl and heteroaryl is monocyclic or bicyclic and is substituted with 3 to 5 substituents.
  • R° is hydrogen or -NHR s
  • R 1 is halogen, -OR 1 * , -SR 1 * or lower alkyl
  • R 10 is hydrogen or lower alkyl.
  • R° is hydrogen;
  • R 1 is halogen;
  • R 4 is -CH 2 -;
  • R 5 is aryl or heteroaryl, wherein each of said aryl and heteroaryl is monocyclic or bicyclic and is substituted with 3 to 5 substituents; and
  • R 10 is hydrogen.
  • R 1 is halogen, -OR 11 , -SR 11 or lower alkyl
  • R 2 is -NH
  • R 3 is selected from the group consisting of hydrogen, halogen, -SR 8 , -OR 8 -CN, - C(0)R 9 , -C(0)OH, -N0 2 , -NR 8 R 10 , lower alkyl, lower alkenyl, lower alkynyl, lower perhaloalkyl, aryl, heteroaryl, alicyclic, heterocyclic, all optionally substituted, wherein: the aryl, heteroaryl, alicyclic and heterocyclic groups are optionally mono-, bi- or tri-cyclic, R 8 and R 10 taken together optionally form a ring of 3-7 ring atoms and optionally 1-3 of the ring atoms are heteroatoms selected from the group of O
  • R 1 is halogen
  • R 3 is hydrogen, halogen, -OR 8 , -SR 8 , -NR 8 R 8 , lower alkyl, lower alkenyl, or lower alkynyl, lower perhaloalkyl, lower aryl, or lower heteroaryl, wherein R 8 is hydrogen, lower alkyl, lower alkenyl, or lower allcynyl, lower aryl, lower heteroaryl, or - C (O)R 9 ;
  • R 4 is -CH 2 -;
  • R 5 is aryl or heteroaryl, wherein each of said aryl and heteroaryl is monocyclic or bicyclic and is substituted with 3 to 5 substituents, and
  • R 10 is hydrogen or lower alkyl.
  • R 1 is halogen;
  • R 3 is hydrogen;
  • R 4 is -CH 2 -;
  • R 5 is aryl or heteroaryl, wherein each of said aryl and heteroaryl is monocyclic or bicyclic and is substituted with 3 to 5 substituents; and
  • R 1 ° is hydrogen.
  • R 1 is halogen, -OR 11 , -SR 11 or lower alkyl
  • R 2 is -NH 2
  • R 3 is selected from the group consisting of hydrogen, halogen, -SR 8 , -OR 8 ,-CN, - C(0)R 9 , -C(0)OH, -NO2, -NR 8 R 10 , lower alkyl, lower alkenyl, lower alkynyl, lower perhaloalkyl, aryl, heteroaryl, alicyclic, heterocyclic, all optionally substituted, wherein: the aryl, heteroaryl, alicyclic and heterocyclic groups are optionally mono-, bi- or tri-cyclic, R 8 and R 10 taken together optionally form a ring of 3-7 ring atoms and optionally 1-3 of the ring atoms are heteroatoms selected from the group of O,
  • R 5 is aryl or heteroaryl, wherein each of said aryl and heteroaryl is monocyclic or bicyclic and is substituted with 3 to 5 substituents.
  • R 1 is chloro or bromo
  • R 5 is phenyl, pyridyl or 1-oxy-pyridyl (N-oxy-pyridyl), each of which has at least two substituents. It should be understood that any of the foregoing embodiments can be combined where feasible and appropriate.
  • Illustrative species of the compounds of Formula IB are described in TABLE 1. Prodmgs which can be employed with the compound of the invention include, but are not limited to, those listed in the Definition section above.
  • Xi and X 2 are the same or different and each is nitrogen or -CR ;
  • Ri is halogen, -OR 8 , -SR 8 , or lower alkyl;
  • R 2 is -NRsRio;
  • R 6 is hydrogen, halogen, lower alkyl, -SR 8 , -OR 8 , -NR 8 R ⁇ o, -N 3 , -CN, or -
  • R 5 is alkyl, aryl, heteroaryl, alicyclic, or heterocyclic, all optionally bi- or tricyclic, and all optionally substituted with H, halogen, lower alkyl, -SR 8 , OR 8 , -CN, - C0 2 R 9 , -N0 2 , or -NR 8 R ⁇ 0 ;
  • R 8 is hydrogen, lower alkyl, lower aryl, or -(CO)R 9 ;
  • R 9 is lower alkyl, lower aryl, lower heteroaryl, -NR 8 R ⁇ o or-ORn; Rio is hydrogen or lower alkyl, R 11 is lower alkyl or lower aryl.
  • R is halogen, hydroxyl, lower alkoxy, lower thioalkyl, or C alkyl; and R 2 is NH 2 .
  • Ri is halogen; R 2 is NH 2 , R 4 is -CH 2 -.
  • R 4 is -(CH 2 )-;
  • R 5 is phenyl, benzyl, or pyridyl, and is independently optionally substituted with H, halogen, lower alkyl, - SR 8 , -OR 8 (or cyclic ethers such as methylenedioxy), -CN, -C0 2 R 9 , -N0 2 , or - NR 8 R 10 ;
  • R 8 is hydrogen, lower alkyl, lower aryl or -(CO)R 9 ;
  • R 9 is lower alkyl, lower aryl, lower heteroaryl, -NR 8 R 10 or -OR 11 ;
  • R 11 is lower alkyl or lower aryl; and
  • R 10 is hydrogen or lower alkyl.
  • R 1 is halogen
  • R 2 is -NH 2
  • R 4 is - CH 2 -
  • R 6 is H or halogen
  • R 5 is phenyl optionally substituted with H, halogen, C M alkyl, C M alkoxy, C M alkylthio, perhaloalkyl, perhaloalkyloxy, -CN, -N0 2 , -NH 2 or -C0 2 R ⁇ .
  • R 1 is halogen
  • R 2 is -NH 2
  • R 4 is - CH 2 -
  • R 6 is H
  • R 5 is 2-halo-3,5dimethoxyphenyl optionally substituted with H, halogen, C 1- alkyl, C alkoxy, CM alkylthio, perhaloalkyl, perhaloalkyloxy, -CN, -N0 2 , -NH 2 , or -C0 2 R ⁇ at the para (4-) position.
  • R 1 is chloro
  • R 2 is -NH 2
  • R 4 is - CH 2 -
  • R 6 is H
  • R 5 is 2-chloro-3,4,5-trimethoxyphenyl.
  • R 1 is chloro
  • R 2 is -NH 2
  • R 4 is - CH 2 -
  • R 6 is H
  • R 5 is 2-bromo-3, 4,5-trimethoxyphenyl.
  • Ri is chloro
  • R 2 is -NH 2
  • R 4 is -CH 2 -
  • R 6 is H
  • R 5 is 2-iodo-3, 4,5-trimethoxyphenyl.
  • Ri is chloro
  • R 2 is -NH 2
  • R 4 is -CH 2 -
  • R 6 is LT
  • R 5 is 2-fluoro-3, 4,5-trimethoxyphenyl.
  • Ri is bromo
  • R is -NH 2
  • R is -CH 2 -
  • R 6 is H
  • R 5 is 2-bromo-3, 4,5-trimethoxyphenyl.
  • Ri is bromo
  • R 2 is -NH 2
  • R 4 is -CH 2 -
  • R 6 is H
  • R 5 is 2-iodo-3,4,5-trimethoxyphenyl.
  • i is bromo
  • R 2 is -NH 2
  • R 4 is -CH2-
  • R 6 is H
  • R 5 is 2-iodo-3, 4,5-trimethoxyphenyl.
  • R 1 is bromo
  • R 2 is -NH 2
  • R 4 is -CH 2 -
  • R 6 is H
  • R 5 is 2-fluoro-3, 4,5-trimethoxyphenyl.
  • R 1 is chloro
  • R 2 is -NH 2
  • R 4 is -CH 2 -
  • R 6 is halo
  • R 5 is 2-chloro-3,4,5-trimethoxyphenyl.
  • R 1 is chloro
  • R 2 is NH 2
  • R 4 is -CH 2 -
  • R 6 is halo
  • R 5 is 2-bromo-3, 4,5-trimethoxyphenyl.
  • R 1 is bromo
  • R 2 is -NH 2
  • R 4 is -CH 2 -
  • R 6 is halo
  • R 5 is 2-chloro-3, 4,5-trimethoxyphenyl.
  • R 1 is bromo
  • R 2 is -NH 2
  • R 4 is -CH 2 -
  • R ⁇ is halo
  • R 5 is 2-bromo-3,4,5-trimethoxyphenyl.
  • the invention provides compounds of Formula IIA:
  • Ri is halogen, -OR 8 , -SR 8 or lower alkyl
  • R 2 is -NR 8 R ⁇ o
  • Re is hydrogen, halogen, lower alkyl, -SR 8 , -OR 8 , -NR 8 R ⁇ o, -N 3 , -CN or C(0)R 9
  • R 5 is alkyl, aromatic, heteroaromatic, alicyclic, heterocyclic, all optionally bi- or tricyclic, and all optionally substituted with H, halogen, lower alkyl, -SR 8 , -OR 8 , -CN, -C0 2 R 9 , -N0 2 , or -NR 8 R ⁇
  • Ri is halogen, hydroxyl, lower alkoxy, lower thioalkyl, or C M alkyl; and R 2 is NH 2 .
  • Ri is halogen; R 2 is NH 2 , R 4 is -CH 2 -.
  • the invention provides compounds of Formula IIB:
  • Ri is halogen, -OR 8 , -SR 8 or lower alkyl
  • R 2 is - NR 8 R I0
  • R 6 is hydrogen, halogen, lower alkyl, -SR 8 , -OR 8 , -NR 8 R ⁇ o, -N 3 , -CN or -C(0)R 9
  • R 5 is alkyl, aryl, heteroaromatic, alicyclic, heterocyclic, all optionally bi- or tricyclic, and all optionally substituted with H, halogen, lower alkyl, -SR 8 , -OR 8 , -CN, - C0 2 R 9 , -N0 2 , or-NRsRio
  • R is hydrogen, lower alkyl, lower aryl, or
  • R is halogen, hydroxyl, lower alkoxy, lower thioalkyl, or C M alkyl; and R 2 is -NH 2 .
  • Ri is halogen; R 2 is -NH 2 ; and R 4 is
  • the invention provides compounds of Formula IIC:
  • R 1 is halogen or lower alkyl
  • R 2 is -NR 8 R 10
  • R 4 is -CHR 12 -
  • R 3 is hydrogen, halogen, or -CN
  • R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein the aryl group is substituted with 3 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, wherein when the heteroaryl is substituted with only two substituents, the two substituents must form part of an optionally substituted fused ring, the alicyclic group is substituted with 3 to 5 substituents, the heterocyclic group is substituted with 3 to 5 substituents, and the subsituents are selected from the group of halogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl, lower alicyclic, arylal
  • R 1 is halogen or lower alkyl
  • R 2 is -NR 8 R 10
  • R 3 is hydrogen, halogen, or -CN
  • R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein the aryl group is substituted with 3 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, wherein when the heteroaryl is substituted with only two substituents, the two substituents must form part of an optionally substituted fused ring, the alicyclic group is substituted with 3 to 5 substituents, the heterocyclic group is substituted with 3 to 5 substituents, and the subsituents are selected from the group of halogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl, lower alicyclic, arylal
  • R 1 is halogen or methyl; and R 2 is -NHR 8 , where R 8 is hydrogen or -C(0)R 9 .
  • R 1 is halogen.
  • R 2 is -NH 2 and R 3 is hydrogen.
  • R 1 is halogen;
  • R 2 is -NH 2 ;
  • R 3 is hydrogen;
  • R 5 is aryl or heteroaryl, wherein each of said aryl and heteroaryl groups is monocyclic or bicyclic, the aryl group is substituted with 4 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, wherein when the heteroaryl is substituted with only two substituents, the two substituents must form part of an optionally substituted fused ring.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is a phenyl having 3 to 5 substituents.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is a pyridyl having 3 to 5 substituents.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is an 1-oxy-pyridyl (N-oxy-pyridyl) having 3 to 5 substituents.
  • each of the aryl, heteroaryl, alicyclic or heterocyclic group is monocyclic or bicyclic.
  • R 1 is halogen or methyl; and R 2 is -NHR 8 , where R 8 is hydrogen or -C(0)R 9 .
  • R 1 is halogen.
  • R 1 is halogen;
  • R 2 is -NH 2 ;
  • R 3 is hydrogen;
  • R 5 is aryl or heteroaryl, wherein each of the aryl and heteroaryl groups is monocyclic or bicyclic, the aryl group is substituted with 4 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, wherein when the heteroaryl is substitute with only two substituents, the two substituents must form part of an optionally substituted fused ring.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is a phenyl having 3 to 5 substituents.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is a pyridyl having 3 to 5 substituents.
  • the invention provides compounds, or polymorphs, solvates, esters, tautomers, pharmaceutically acceptable salts or prodmgs thereof, prepared by the process comprising: reacting a compound of formula Y and a compound of formula Z, wherein: Y is represented by any one of the following formulae:
  • L 1 is halogen, NR 8 R 10 _ triflate, tosylate, or mesylate;
  • R 4 is -CHR 12 -,
  • R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein: the aryl group is substituted with 3 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, wherein when the heteroaryl is substituted with only two substituents, the two substituents must form part of an optionally substituted fused ring, the alicyclic group is substituted with 3 to 5 substituents, the heterocyclic group is substituted with 3 to 5 substituents, and the subsituents are selected from the group of halogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl, lower alicyclic, arylalkyl, aryloxy, aryloxyalkyl, alkoxyalky
  • R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, optionally mono- or bicyclic.
  • R 4 is -CH 2 -.
  • L 1 is -CI, -Br or NH 2 ;
  • R 5 is aryl or heteroaryl, wherein the aryl group is substituted with 4 to 5 substituents.
  • Y is a substituted purine.
  • the reaction is performed in a solvent comprising a member selected from the group of DMF, THF and DMSO.
  • the reaction is performed in a solvent that comprises DMF.
  • Compounds for use in the method of treatment are inhibitors of HSP90 of the following Formula IIC, or a polymorph, solvate, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodmg thereof,
  • R 1 is halogen, -OR 11 , -SR 11 , -NHR 8 , hydrogen, or lower alkyl
  • R 2 is -NR 8 R 10
  • R is hydrogen, halogen, -N 3 , or -CN
  • R 5 is alkyl, aryl, heteroaryl, alicyclic, or heterocyclic, all optionally substituted with halogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl, lower alicyclic, arylalkyl, aryloxy, aryloxyalkyl, alkoxyalkyl, perhaloalkyl, perhaloalkyloxy, perhaloacyl, -N 3 , -SR 8 , -OR 8 , -CN, -C(0)R 9
  • R 3 is hydrogen, halogen or -CN;
  • R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, all optionally substituted with halogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl, lower alicyclic, arylalkyl, aryloxy, aryloxyalkyl, alkoxyalkyl, perhaloalkyl, perhaloalkyloxy, perhaloacyl, -N 3 , -SR 8 , -OR 8 , -CN, -C(0)R 9 , -N0 2 , - NR 8 R 10 , phosphonate, or phosphonic acid.
  • R 1 is halogen or methyl and R 2 is —NHR 8 , where R 8 is hydrogen or -C(0)R 9 .
  • R is -NH 2 and R is hydrogen.
  • R 4 is -CH 2- .
  • R 1 is halogen;
  • R 2 is -NH 2 ;
  • R 3 is hydrogen;
  • R 4 is -CH 2 -;
  • R 5 is aryl and heteroaryl, the aryl and heteroaryl groups are monocyclic or bicyclic, the aryl group is substituted with 4 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, wherein when the heteroaryl is substituted with two substituents, the two substituents must form part of an optionally substituted fused ring.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is a phenyl having 3 to 5 substituents.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is a pyridyl having 3 to 5 substituents.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is an 1-oxy-pyridyl (N-oxy-pyridyl) having 3 to 5 substituents.
  • Ri is halogen, -OR 8 , -SR 8 or lower alkyl
  • R 2 is -NRsRio
  • R 3 is hydrogen, -OH or keto tautomer, -OR 8 , halogen, -CN, lower alkyl or - C(0)R 9
  • R 5 is alkyl, aryl, heteroaryl, alicyclic, heterocyclic, all optionally bi- or tricyclic, and all optionally substituted with H, halogen, lower alkyl, -SR 8 , -ORg, - CN, -C0 2
  • Ri is halogen, hydroxyl, lower alkoxy, lower thioalkyl, or C M alkyl; and R 2 is NH 2 .
  • Ri is halogen; R 2 is NH 2 , and R 4 is -CH 2 -.
  • R 1 is halogen, -OR 11 , -SR 11 or lower alkyl
  • R 2 is -NHR 8
  • R 3 is selected from the group consisting of hydrogen, halogen, -SR 8 , -OR 8 , -CN, -C(0)R 9 , -C0 2 H, -N0 2 , -NR 8 R 10 , lower alkyl, lower alkenyl, lower alkynyl, lower perhaloalkyl, aryl, heteroaryl, alicyclic and heterocyclic, all optionally substituted, wherein: the aryl, heteroaryl, alicyclic and heterocyclic groups are optionally mono-, bi- or tri-cyclic; R 8 and R 10 taken together optionally form a ring of 3-7 ring atoms and optionally 1-2 of the group
  • R 1 is halogen or lower alkyl
  • R 2 is -NHR 8 , where R 8 is hydrogen or -C(0)R 9
  • R 5 is aryl or heteroaryl, each of said aryl and heteroaryl groups is monocyclic or bicyclic.
  • R 2 is -NH 2 ;
  • R 3 is selected from hydrogen, halogen, -SR 8 , -OR 8 , -CN, -NR 8 R 10 , lower alkyl, lower alkenyl, lower alkynyl, lower perhaloalkyl, lower aryl, lower heteroaryl, lower alicyclic, lower heterocyclic,
  • R 8 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl or lower heteroaryl, and R 8 and R 10 taken together optionally form a ring of 3-7 ring atoms and optionally 1-3 of the ring atoms are heteroatoms selected from the group of O, S and N; and
  • R 5 is aryl or heteroaryl, each of said aryl and heteroaryl groups is monocyclic or bicyclic.
  • R 1 is halogen or lower alkyl
  • R 2 is -NH 2
  • R 4 is -(CH 2 )-
  • R 5 is aryl, heteroaryl, alicyclic or heterocyclic, each of said aryl, heteroaryl alicyclic or heterocyclic groups is monocyclic or bicyclic.
  • R 1 is halogen;
  • R 2 is -NH 2 ;
  • R 3 is hydrogen, halogen, -SR 8 , -OR 8 , lower alkyl, lower aryl, lower heteroaryl, or -NR R , R and R taken together optionally form a ⁇ ng of 3-7 ⁇ ng atoms and optionally 1-3 of the ring atoms are heteroatoms selected from the group of O, S and N;
  • R 4 is -CH 2 -;
  • R 5 is aryl or heteroaryl, wherein each of said aryl and heteroaryl groups is monocyclic or bicyclic.
  • R 1 is chloro or bromo
  • R 5 is a phenyl having 3 to 5 substituents.
  • R 1 is chloro or bromo
  • R 5 is a pyridyl having 3 to 5 substituents.
  • R 1 is chloro or bromo
  • R 5 is an 1-oxy-pyridyl (N-oxy-pyridyl) having 3 to 5 substituents.
  • R 1 is halogen, -OR 11 , -SR 11 or lower alkyl
  • R 2 is -NHR 8
  • R 4 is -CHR 12 -, -C(O), -C(S), -S(O)-, or -S0 2 -
  • R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein the aryl group is substituted with 3 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, the heterocyclic group is substituted with 3 to 5 substituents, and the substituents on R 5 are selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower alkynyl, -SR 8 , -OR 8 , -CN, -C(0)OH
  • R 2 is -NHR 8 , where R 8 is hydrogen or -C(0)R 9 ;
  • R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, all optionally mono-, bi- or tri-cyclic; and
  • R 9 is lower alkyl, lower alkenyl, lower alkynl, lower aryl or lower heteroaryl.
  • R 1 is halogen or lower alkyl
  • R 2 is -NHR 8 , where R 8 is hydrogen or -C(0)R 9
  • R 4 is -CH 2 -
  • R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, all optionally mono-, bi- or tri-cyclic.
  • Z is L'-R 4 -R 5 ; wherein: L 1 is halogen, -NR R 10 , triflate, tosylate, or mesylate; R 4 is -(CHR 12 )-, -C(O), -C(S), -S(0 , or -S0 2 -; R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein the aryl group is substituted with 3 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, the heterocyclic group is substituted with 3 to 5 substituents, and the substituents on R 5 are selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower allcynyl, -SR 8 , -OR 8 , -CN, -C(0)OH, -C(0)R 9 , -N0 2 and -NR 8 R
  • R 8 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl, lower heteroaryl or -C(0)R 9 ;
  • R 9 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl, lower heteroaryl, -NR 10 R 10 or -OR 1 * , R 10 and R 10 taken together optionally form a ring of 3-7 ring atoms and optionally 1-3 of the ring atoms are heteroatoms selected from the group of O, S and N;
  • R 10 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower aryl or lower heteroaryl;
  • R 11 is lower alkyl, lower alkenyl, lower alkynyl, lower aryl or lower heteroaryl;
  • R 12 is hydrogen or lower alkyl
  • R 21 is halogen, -OR 8 , -SR 8 or lower alkyl
  • R 22 is -NR 8 R 10 ;
  • R 23 is hydrogen, -OH or its keto tautomer, -OR 8 , halogen, -CN, lower alkyl, lower aryl or -C(0)R 9 ;
  • R >24 is -CHO, -NH 2 , -N0 2 or -NO;
  • R 25 is halogen or -OH;
  • R 26 is -C(0)NH 2 or C(0)OEt; and R 27 is -NH 2 , -OH or halogen.
  • R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, optionally mono- or bicyclic.
  • L 1 is -CI, -Br or -NH 2 ;
  • R is -CH 2 -; and
  • R 5 is aryl or heteroaryl.
  • Y is a pyrazolopyrimidine.
  • said reaction is performed in a solvent comprising a member selected from the group of DMF, THF and DMSO.
  • the said reaction is performed in a solvent that comprises DMF.
  • Xi and X 2 are the same or different and each is nitrogen or CR ⁇ ;
  • Ri is halogen, -OR 8 , -SR 8 , or lower alkyl;
  • R 2 is -NR 8 R l0 ;
  • R 5 is alkyl, aryl, heteroaryl, alicyclic, or heterocyclic, all optionally bi-or tricyclic, and all optionally substituted with H, halogen, lower alkyl, -SR 8 , -OR 8 , -CN, -C0 2 R 9 , -N0 2 , or -NR 8 R ⁇ 0 ;
  • R 8 is hydrogen, lower alkyl
  • R 1 is halogen, hydroxyl, lower alkoxy, lower thioalkyl, or C M alkyl; and R 2 is -NH 2 .
  • R is halogen, hydroxyl, lower alkoxy, lower thioalkyl, or C M alkyl; and R 2 is -NH 2 ; R4 is -CH 2 -, -C(O), -C(S), - S0 2 -. .
  • a tautomer, pharmaceutically acceptable salt thereof, or prodmg thereof R 1 is halogen or C alkyl; and R 2 is NH 2 , R t is -CH 2 -.
  • R is -C(O) or -CH 2 -; R 1 is halogen, lower alkoxy or C M alkyl; and R is NH 2 .
  • R 1 is halogen, -OR 11 , -SR 11 or lower alkyl
  • R 2 is -NHR 8
  • R 4 is -CHR 12 -, -C(O)-, -C(S)-, -S(O)- or -S0 2 -
  • R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein: the aryl group is substituted with 3 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, the heterocyclic group is substituted with 3 to 5 substituents, and the substituents are selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower alkynyl, -SR 8 , -
  • each of the aryl, heteroaryl, alicyclic or heterocyclic group is monocyclic or bicyclic.
  • R 1 is halogen; and R 2 is -NHR 8 , where R 8 is hydrogen or -C(0)R 9 .
  • R 1 is chloro or bromo
  • R 2 is -NHR 8 , where R 8 is hydrogen or -C(0)R 9
  • R 4 is lower alkyl.
  • R 2 is -NHR 8 , where R 8 is hydrogen or -C(0)R 9
  • R 4 is -CH 2 -.
  • R 1 is halogen;
  • R 2 is -NH 2 ,
  • R 4 is -CH 2 -;
  • R 5 is aryl or heteroaryl, wherein each of the aryl and heteroaryl is monocyclic or bicyclic and is substituted with 3 to 5 substituents.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is a phenyl having at least three substituent.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is a pyridyl having at least two substituent.
  • R 1 is chloro or bromo
  • R 2 is -NH 2
  • R 5 is 1-oxy-pyridyl (N-oxy-pyridyl) having at least two substituent.
  • the invention provides compounds, or polymo ⁇ hs, solvates, esters, tautomers, pharmaceutically acceptable salts or prodmgs thereof, prepared by the process comprising: reacting a compound of formula Y and a compound of formula Z, wherein: Y is a represented by any one of the following formulae:
  • Z is L'-R 4 -R 5 ; wherein: L 1 is halogen, -NR 8 R 10 ,triflate, tosylate, ormesylate; R 4 is -CHR 12 -, -C(O)-, -C(S)-, -S(0 or -S0 2 -; R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein: the aryl group is substituted with 3 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, the heterocyclic group is substituted with 3 to 5 substituents, and the substituents are selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower alkynyl, -SR 8 , -OR 8 , -CN, -C(0)OH, -C(0)R 9 , -N0 2 and -NR 8 R 10 ,
  • L 1 is -CI, -Br or -NH 2 ;
  • R 5 is aryl or heteroaryl.
  • R 4 is -CH 2 -.
  • R 5 is aryl, heteroaryl, alicyclic, or heterocyclic, optionally mono- or bicyclic.
  • Li is -CI, -Br or -NH 2 ; R 4 is -CH 2 -; and R 5 is aryl or heteroaryl.
  • Y is a triazolopyrimidine.
  • Y is a triazole.
  • Y is a pyrimidine.
  • the reaction is performed in a solvent comprising a member selected from the group of DMF, THF and DMSO.
  • the reaction is performed in a solvent that comprises DMF.
  • Compounds of interest in Table 1 are: 2, 3, 17, 18, 27, 28, 62, 63, 77, 78, 92, 93, 129, 130, 238, 239, 242, 243, 245, 246, 247, 248, 249, 250, 251, 252, 253, 267, 268, 287, 288 291 , 292, 293, 294, 295, 296, 297, 298 312, 313, 332, 333, 334, 335, 336, 337, 338, 339 351, 352, 365, 366, 384, 385, 398, 3.99 400, 401, 402, 403, 404, 405, 417, 418, 431, 432 433, 434, 435, 436, 437, 438, 450, 451 464, 465, 483, 484, 497, 498, 530, 531, 549, 550 562, 563, 574, 575, 577, 578, 589, 590 592, 593, 604, 605, 607,
  • Compounds of interest in Table 4 are: compounds 2, 3, 13, 82, 83, 162, 163, 168, 169, 174, 175,180, 181,186, 187,192, 193,198,199,204,205,210,211,228,229,230,231, 232, 233, 234, 235, 236, 237, 250, 251, 262, 263, 268, 269, 274, 275, 280, 281, 286, 287, 292, 293, 298, 299, 304, 305, 310, 311, 316, 317, 328, 329, 338, 372, 373, 380 and 381 (with those selected being 162, 163, 168, 169, 174, 175, 180, 181, 186, 187, 192, 193, 198, 199, 204, 205, 228, 229, 262, 263, 268, 269, 274, 275, 280, 281, 286, 287, 292, 293, 316, 317, 328, and 329.) III.
  • Synthesis of the Compounds of the Invention may be accomplished by various methods known in the art, including those described in, for example, Montgomery, J. Med. Pharm. Chem., 1962, 5, 15-24; Sircar, U.S. Patent 4,772,606, 1988; Sircar, U.S. Patent 4,748,177, 1988; Hans, U.S. Patent 5,110,818, 1992; Gillespie, PCT publication No. WO 02/055521; Matsuda, JP 10025294 A2, 1998; Hans, U.S. Patent 5,110,818, 1992 and U.S. Publication No. US 2003/0078413.
  • the synthesis of the several embodiments of the invention is illustrated. The process is applicable to other subgenus. A.
  • the starting materials or the intermediates of Formula 1, 4, 5, and I can exist in tautomeric forms as shown in Fig. 1, and both forms are indiscriminately used in this patent.
  • Method 1.1.3 The compounds of Formula 4 can be obtained by treatment of a -haloketone of Formula 8 wherein X is a halogen with ammonia or an synthetic equivalent thereof.
  • Method 1.1.5 The compounds of Formula 4 wherein R 3 is H can be obtained by Pd-mediated intramolecular cyclization of alkynes of Formula 10, wherein Z in as electron- withdrawing group such as, e.g., tosyl-, or EtC00 2 -.
  • Method 1.1.6 The compounds of Formula 4 wherein R 3 is AcO- can be obtained by intramolecular Friedel-Crafts acylation of precursors of Formula 11 (E. D. Edstrom, J. Org. Chem. 1993, 58, 403).
  • Method 1.1.7 The compound of Formula 4, wherein R° is H, R 6 is OH, and R 7 is NH 2 , can be prepared by treating/ the compound of Formula 12 with an -haloaldehydes of the formula R 3 -CHX-CHO. See, D.M. Williams, J. Chem. Soc, Perkin Trans 1, 1997, 1171; C. J. Barnett, Org. Proc Res. Devop. 1999, 3, 184; A. Gangjee, J. Med. Chem. 2001, ⁇ , 1993.
  • Method 1.1.8 The compounds of Formula 4, wherein R 6 is OH and R 7 is NH 2 can be obtained by treating the compound of Formula 13 with an aldehyde of the formula R 3 -CHO. See,
  • Leaving groups include but are not limited to, e.g., halogen, triflate, tosylate, mesylate, triphenylphosphonium (generated under Mitsunobu conditions, e.g. PPh 3 /DEAD) etc. See Kasibhatla, PCT publication number WO 03/037860.
  • electrophiles can be prepared from the substituted benzene derivatives using various methods reported in the literature, see Jerry March, Advanced Organic
  • the compound NH 2 -R 4 -R 5 is obtained by treating L'-R 4 -R 5 with ammonia at temperatures of 20-160 °C in a pressure vessel.
  • the corresponding amines where L 1 is -NH 2 can be prepared by a variety of methods, for instance from compounds where L 1 is leaving group such as chloride, bromide, tosylate, mesylate etc. using ammonia, or with sodium azide followed by hydrogenation. 3. Further Elaboration of the ring systems 3.1.
  • Compounds of Formula IA, wherein R° is H can be lithiated and treated with electrophiles (e.g., I 2 , ArCHO) to provide compounds of Formula IA wherein R° is, e.g. - I or -CH(OH)Ar.
  • electrophiles e.g., I 2 , ArCHO
  • R° is, e.g. - I or -CH(OH)Ar.
  • Compounds of Formula ⁇ A, wherein R 1 is -NH 2 can be converted to halides by a Balz-Schiemann (F) or Sandmeyer reaction (CI, Br, I) by means of a nitrosylating agent (NaN0 2 /H + , NOBF 4 , RONO) and a halogen donor (BF 4 _ , CuX 2 , SbX 3 where X is halogen).
  • Compounds of Formula IA, wherein R 1 is alkyl can be prepared from compounds of Formula 4 where R 1 is halogen and trialkyl aluminum or dialkyl zinc (A. Holy, J. Med. Chem. 1999, 42, 2064).
  • R 1 is a halide
  • R 1 is -NH 2 , -OH, -SH, -OR 8 , -SR 8 with standard reagents, e.g., NH 3 , NaOH, thiourea, R 8 0 " , R 8 S " , with or without a catalyst (e.g. Pd, Ni, Cu, Lewis acid, H) (e.g., B. G. Ugarkar, J. Med. Chem. 2000, 43, 2883-2893 and 2894-2905).
  • a catalyst e.g. Pd, Ni, Cu, Lewis acid, H
  • Compounds of Formula IA, wherein R 2 is -NH 2 can be converted to halides by a Balz-Schiemann (F) or Sandmeyer reaction (CI, Br, I) by means of a nitrosykting agent (Na VH 1" , NOBF 4 , RONO) and a halogen donor (BF4-, CuX 2 , SbX 3 ).
  • Compounds of Formula IA, wherein R 2 is a halide can be converted to compounds wherein R 2 is -NH 2 , -OH, -SH, -OR 8 , -SR 8 with standard reagents, e.g.
  • Compounds of Formula IA, wherein R 3 is Br can be metalkted with BuLi, and treated with an electrophile such as Mel to give a compound of Formula IA, wherein R 3 is methyl.
  • Compounds of Formula IA, wherein R 1 is -CI and R 3 is -Br can undergo selective metaltechnisch at R 3 (J. S. Pudlo, J. Med. Chem. 1990, 33, 1984).
  • Compounds of Formula IA, wherein R° is -OH and R 3 is H can be be monalkykted or bis-alkykted to give compounds of Formula ID, wherein R 1 is an alkyl group. The alkylation can be effected in the presence of a base such as KHMDS, LHMDS, LDA etc.
  • Leaving groups include but are not limited to, e.g., halogen, triflate, tosylate or mesykte.
  • R 5 R 5 can be further modified as needed, for example by halogenation, nitration, palladium coupling of halogen, Friedel-Crafts alkykom/acylation, etc or these modifications can also be done before alkylation, see Jerry March, Advanced Organic Chemistry.
  • the heteroaromatic rings can also be oxidized to their corresponding N-oxides using various oxidizing agents such as H 2 0 2 , 0 3 , MCPBA etc. in polar solvents such as CH 2 C1 2 , CHC1 3 , CF 3 COOH etc. See Jerry March, Advanced Organic Chemistry, 4th edition, Chapter 19. Examples of modifications are suggested in Scheme 7.
  • Scheme 7 Permutations of the order of events As mentioned above, the events (1) assembly of the bicyclic system (2) appendage of the R 5 -R 4 - moiety, and (3) further elaboration of the ring systems do not necessarily have to be made in the sequence (l)-(2)-(3), and it may be beneficial to proceed in a different sequence.
  • Scheme 8 shows a synthesis in which the order of events is not (l)-(2)-(3), but is (2)-(l)-(3). First R 5 is appended via an aromatic nucleophilic substitution, then the bicyclic system is constructed, and finally it is elaborated.
  • Method 4.1.1 The compound of Formula 18, wherein R is CI and R is NH 2 , can be prepared by treating the compound of Formula 17 with R 5 -R 4 -NH 2 in butanol at reflux in presence of a base such as K 2 C0 3 , Cs 2 C0 3 or iPrNEt 2 . (A.B. Reitz J. Med. Chem. 1994, 37, 3561).
  • Method 4.1.2 The compound of Formula 19, wherein R 1 is CI and R is NH 2 , can be prepared by refluxing the compound of Formula 18 in chloroform or dichloroethane in presence of an halogenating reagent such as bromine, N-bromosuccinimide, iodine or N- iodosuccinimide and an acid such as acetic acid or p-toluenesulfonic acid. (A.P. Phillips J. Am. Chem. Soc. 1952, 74, 3922).
  • an halogenating reagent such as bromine, N-bromosuccinimide, iodine or N- iodosuccinimide
  • an acid such as acetic acid or p-toluenesulfonic acid.
  • Method 4.1.3 The compound of Formula 20, wherein R 1 is CI and R 2 is NH 2 , can be prepared by coupling the compound of Formula 19 with trimethylsilylacetylene under Sonogashira conditions followed by hydroboration using dichlorohexylborane and oxidation using hydrogen peroxide in presence of sodium hydroxide. (Sonogashira coupling: E. C. Taylor Tetrahedron , 1992, 48, 8089. Hydroboration/oxidation: G. Zweifel J. Am. Chem. Soc. 1976, 98, 3184).
  • Method 4.1.4 The compound of Formula 21, wherein R 1 is CI and R is NH 2 , can be prepared by heating the compound of Formula 20 in a polar aprotic solvent such as THF, DME or dioxane in presence of oxalyl chloride, thionyl chloride, mesyl chloride or alkyl chloroformate and a base such as iPrNEt 2 or pyridine. It can also be prepared by treating the compound of Formula 20 with coupling reagents such DCC/HOBt, DCC/DMAP or EDCI/HOBt. (R.C. Larock Comprehensive Organic Transformations Second Edition, pi 870).
  • Scheme 9 Method 4.3
  • Scheme 10 shows a putative synthesis in which the order of events is not (l)-(2)-(3), but is (l)-(3)-(2)-(3).
  • the bicyclic ring is constructed, then it is elaborated, then the R 4 -R 5 moiety is appended, and finally the bicyclic ring system is further elaborated (deprotection).
  • P Ac, t-Boc, etc.
  • R is for instance a pyridine, it can be converted to a N-oxide either before or after alkylation.
  • Method 1 From purines: The compounds of Formula IIC (see, Scheme 12) can be synthesized from the commercially available starting heterocycle, for example compounds of Formula 2 where R 6 is -CI, -Br or -OH, R 7 is -NH 2 and R 8 is -H are commercially available from Aldrich, AlfaAesar, etc. Accordingly, Formula 2 can be alkykted in the presence of a base such as K 2 C0 3 , NaH, Cs 2 C0 3 , DBU etc.
  • a base such as K 2 C0 3 , NaH, Cs 2 C0 3 , DBU etc.
  • Leaving groups include but are not
  • Scheme 12 limited to, e.g., halogen, triflate, tosylate , mesykte etc See Kasibhatla, PCT publication number WO 03/037860.
  • Compounds of Formula I, wherein R 1 is -OH can be converted to halides using standard conditions POCl 3 , POBr 3 etc with/without the presence of base such as Et N, N,N-diethykniline, (i-pr) 2 NEt etc. in polar solvents such as CH 3 CN, CH 2 C1 2 etc.
  • R 1 is -OR 11 , -SR 11 , or -NHR 8 where R 11 is alkyl, R 8 is hydrogen, lower alkyl, lower aryl, or -C(0)R 9 , where R 9 is lower alkyl, lower aryl, lower heteroaryl, -NR 10 R 10 , or -OR 11 , where R 10 is independently hydrogen or lower alkyl, can be prepared from compounds of Formula IIC wherein R 1 is halogen reacting with HOR 1 * , HSR 1 ' or NH 2 R 8 in presence of a base such as K 2 C0 3 or NaH and a polar solvent such as DMF or THF.
  • a base such as K 2 C0 3 or NaH
  • a polar solvent such as DMF or THF.
  • Compounds of Formula IIC where R 8 is -C(0)R 9 can be prepared when R 1 is hydroxyl by simple acylation.
  • Compounds of Formula IIC where R 1 is alkyl can be prepared from compounds of Formula II where R 1 is halogen and trialkyl aluminum or dialkyl zinc. (See Holy, J. Med. Chem. 1999, 42, 2064).
  • R 5 especially when it is aryl or heteroaryl can be further modified as needed, for example by halogenation, nitration, palladium coupling of halogen, Friedel-Crafts alkykom/acytechnisch, etc. or these modifications can also be done before alkylation, see Jerry March, Advanced Organic Chemistry.
  • the heteroaromatic rings can also be oxidized to their corresponding N-oxides using various oxidizing agents such as H 2 0 2 , 0 3 , MCPBA etc in polar solvents such as CH 2 C1 2 , CHC1 3 , CF 3 COOH etc See Jerry March, Advanced Organic Chemistry, 4th edition, Chapter 19.
  • Compounds of Formula IIC where R 3 is halogen can be prepared from Formulae 1 or 2 using halogenating agents such as Br 2 , NBS, NCS, NIS etc. in polar solvents such as DMF, water, or suitable buffer solution. See Herdewijn, J. Med. Chem. 1995, 38, 3838.
  • compounds of Formula 2 where R 8 is iodo can also be made using procedures known in the literature, e.g., Burger, J. Org. Chem. 2000, 65, 7825. These can be further modified as needed; for example, where R 3 is -N 3 , or -CN by reacting with an azide such as NaN 3 , LiN 3 etc. or cynide such as KCN or NaCN in polar solvents such as DMF, DMSO etc. See Halbfinger, J. Med. Chem. 1999, 42, 1625; Jacobson, J. Med. Chem. 1999, 42, 5325. 2.
  • compounds of Formula IIC can be further modified as necessary.
  • compounds of Formula IIC can also be synthesized from Formula 7, 2- amino-4, 6-dichloro pyrimidine (see Scheme 14). Reaction of Formula 7 withNH 2 -R 4 - R 5 in solvents such as EtOH, BuOH etc. in presence of organic bases such as Et 3 N, (ipr) 2 Net, etc. followed by reaction with diazonium salt prepared from 4-chloroaniline
  • compounds of Formula 8 where R 16 is NH 2 can be made from the commercially available 2,5-diamino-4,6-dihydroxy pyrimidine as described in Daluge, U.S. Patent 5,917,042 (1999), See Scheme 15.
  • Leaving groups include but are not limited to, e.g., halogen, triflate, tosylate, mesykte etc. to give compounds of Formula 10.
  • the ring closure can be achieved using many methods reported in the literature, Alhede, J. Org. Chem., 1991, 2139 and references cited therein to give guanines of Formula II, wherein R 1 is OH. These compounds can be converted to the
  • these steps can be reversed as shown in Scheme 16 via Formula 11 .
  • we can also construct these 2-aminopyrimidine rings from Formula 4, wherein R 14 is -OH or halide, R 13 is -C(0)OEt and R 15 is -H by reacting with guanidine hydrochloride as described in Chowdhury, J. Med. Chem. 1999, 42, 4300.
  • Benzyl type electrophiles (Fig. 2 supra) can be prepared as described above in Section III.A.2.2.1 using various methods reported in the literature, see Jerry March, Advanced Organic Chemistry, 4* edition; Larock, Comprehensive Organic Transformations, 1989,VCH, New York.
  • Li is -Br can be prepared by reduction followed by halogenation of the benzoic acid or aldehyde derivatives .
  • These benzyl derivatives can also be prepared by benzylic oxidation or benzylic halogenation.
  • benzyl ring can be done before or after the corresponding amines where Li is -NH 2 can be prepared from the compounds where Li is leaving group such as chloride, bromide, tosylate, mesykte etc. using ammonia.
  • Synthesis of pyridyl methyl type electrophile Pyridyl methyl type electophiles can be prepared from many methods reported in the literature including those identified in Section III.A.2.2.2. Further modification of the pyridyl ring can be done after the purine alkylation see Scheme 16.
  • the skrting materials and the intermediates of the Formula 1, 2, 3, or 4 can exist in tautomeric forms as shown in Fig 5, and both forms are indiscriminately used in this patent.
  • Scheme 18 The compounds of Formula 3 can be prepared from pyrimidines as outlined in Scheme 18. For instance:
  • Method 1.1.1 The compound of Formula 3, wherein R 6 is -CI, R 7 is -NH 2 , and R 3 is -H, is readily prepared by treating 2-amino-4,6-dichloro-pyrimidine-5-carbaldehyde (Formula 1) with hydrazine, see, F. Seek , Heterocycles 1985, 23, 2521; F. Seek, Helv. Chim. Acta 1986, 69, 1602; and R O. Dempcy, WO 03/022859.
  • Method 1.1.2 The compounds of Formula 3, wherein R 6 is CI, R 7 is NH 2 and R 3 is alkyl, aryl, or heteroaryl have not been previously reported. They can be made by converting a compound of Formula 1 to a compound of Formula 5 in two steps: i) Nucleophilic addition to the carbonyl group; and ii) Oxidation of the resulting alcohol. In a subsequent step, the compound of Formula 5 is converted to the compound of Formula 3 by reaction with hydrazine, or an equivalent thereof.
  • Method 1.1.3 The compounds of Formula 3 wherein R 3 is NH 2 can be obtained by treatment of a nitrile of Formula 6 with hydrazine (See A. M.
  • Method 1.1.4 The compounds of Formula 3 wherein R is OH can be obtained by treatment of an acid, ester, or activated ester (or equivalent thereof) of Formula 7 with hydrazine (Ciba, Patent UK 884,151 (1961)).
  • the compounds of Formula 3 can also be made from pyrazoles of Formula 2 (Scheme 19). There are a variety of methods by which the 6-membered ring can be formed (e.g. R. J. Bontems, J. Med. Chem, 1990, 33, 211 and references therein). For instance:
  • Leaving groups include but are not limited to, e.g., halogen, triflate, tosylate , mesykte, triphenylphosphonium (generated under Mitsunobu conditions, e.g. PPh 3 /DEAD) etc. (See Kasibhatla, WO 03/037860.) / ⁇ I,
  • Compounds of Formula IIIA, wherein R 1 is alkyl can be prepared from compounds of Formula 3 where R 1 is halogen and trialkyl aluminum or dialkyl zinc (A. Holy, J. Med. Chem. 1999, 42, 2064).
  • Compounds of Formula IIIA, wherein R 1 is a halide can be converted to compounds wherein R 1 is -NH 2 , -OH, -SH, -OR, -SR with standard reagents, e.g. NH 3 , NaOH, thiourea, RO " , RS “ , with or without a catalyst (e.g.
  • R 3 Compounds of Formula IIIA, wherein R 3 is H, can be converted to compounds of Formula IIIA wherein R 3 is a halogen (e.g. NCS, NBS, NIS, Br 2 , ICl, I 2 /KOH) (See F. Seek et al, Helv. Chim. Acta 1999, 82, 105).
  • R 3 is a halogen
  • Compounds of Formula IIIA, wherein R 3 is a halogen can be functionalized by Pd-cakyzed reactions ((a) Sonogashira coupling: E. C. Taylor et al, Tetrahedron , 1992, 48, 8089. (b)carboxytechnisch: J. W.
  • R 3 is MeO
  • R 5 especially when it is aryl or heteroaryl, can be further modified as needed, for example by halogenation, nitration, palladium coupling of halogen, Friedel-Crafts alkylation/acylation, etc. or these modifications can also be done before alkylation, see Jerry March, Advanced Organic Chemistry.
  • heteroaromatic rings can also be oxidized to their corresponding N-oxides using various oxidizing agents such as H 2 0 2 , 0 3 , MCPBA etc. in polar solvents such as CH 2 C1 2 , CHC1 3 , CF 3 COOH etc See Jerry March, Advanced Organic Chemistry, 4th edition, Chapter 19. Examples of modifications are suggested in Scheme 21.
  • Scheme 21 Permutations of the order of events As mentioned above, the events (1) assemby of the bicyclic system (2) appendage of the R 5 -R 4 - moiety, and (3) further elaboration of the ring systems do not necessarily have to be made in the sequence of (l)-(2)-(3), and it may be beneficial to proceed in a different sequence.
  • Scheme 6 shows a putative synthesis in which the order of events is not (l)-(2)-(3), but is (l)-(3)-(2). First the bicyclic system is prepared, then it is elaborated, and finally R 5 is appended via an alkylation.
  • Scheme 23 shows a putative synthesis in which the order of events is not (l)-(2)-(3), but is (2)-(l)-(3).
  • R 5 group is appended to a pyrimidine via an aromatic nucleophilic substitution, then the bicyclic ring system is constructed, and finally a series of functional group interconversions yields the compound of Formula IIIA.
  • P Protecting Group
  • R 5 is, for instance, a pyridine, it can be converted to a N-oxide either before or after alkylation.
  • Formula 2 where R 11 is -N0 2 may then be reduced with zinc and formic acid or sodium dithionite to give compounds of Formula 2 where R u is -NH 2 , see Dempcy, U.S. Publication No. 2003/0078413 Al.
  • Compounds of Formula IVA can then be prepared by diazotization with an alkali metal nitrite such as NaN0 2 in inorganic acids such as HC1, followed by in situ cyclization. See Beauchamp, U.S. Patent 4,714,701; Meier, U.S. Patent 5,204,353. These compounds of Formula IVA can be further modified as necessary.
  • Formula 2 where R 11 is H can be treated with diazonium salts such as 4- chloroaniline diazonium salt prepared from 4-chloroaniline and NaN0 2 inorganic acids such as HC1 to give pyrimidine 5-azo- analog, that can be reduced with zinc dust in EtOH/AcOH (1:1) solution to give compounds of Formula 2, where R n is -NH 2 , see Meier, U.S. Patent 5,204,353.
  • compounds of Formula IVA can be prepared from the commercially available substituted diamino pyrimidines compounds of Formula 1 where R 9 is -OH or halogen, R 10 is amino or protected amino or any group that can be converted to amino, such as SMe, R 11 & R 12 are -NH 2 , (see Scheme 26) following the diazotization method described earlier in Method 1 to give compounds of Formula 4.
  • Formula 4 can be alkykted in the presence of a base such as K 2 C0 3 , NaH, Cs 2 C0 3 , DBU etc. with/without the presence of halide such as Nal, KI, (Bu) 3 NI etc., and in a polar solvent such as DMF, THF, DMSO etc.
  • L'-R 4 -R 5 where L 1 is a leaving group. Leaving groups include but are not limited to, e.g. , halogen, triflate, tosylate, mesykte etc. See Kasibhatla, PCT WO 03/037860.
  • Compound of Formula I can also be prepared from compounds of Formula D using Mitsunobu alkylation conditions using L ⁇ ⁇ -R 5 where L 1 is hydroxyl. See Kozai, Chem. Pharm. Bull, 1999, 47(4), 574-575).
  • Leaving groups include but are not limited to, e.g., halogen, triflate, tosylate, mesykte etc. to give compounds of Formula 6.
  • the ring closure can be achieved using many methods reported in the literature, Alhede, J. Org. Chem., 1991, 2139 and references cited therein to give compounds of Formula I, wherein R 1 is -OH. These compounds can be converted to the compounds of Formula I, wherein R 1 is -Cl using POCl 3 as described earlier. Alternately, we can also construct from Formula 3, wherein R 14 is -OH or halide, R 13 is -C(0)OEt by reacting with guanidine hydrochloride as described in Chowdhury, J. Med. Chem. 1999, 42, 4300.
  • the compound R 4 -R 5 -NH 2 is obtained by treating R 4 -R 5 -L * with ammonia at temperatures of 20-160 °C in a pressure vessel, wherein L 1 is leaving group such as chloride, bromide, tosylate, mesykte etc. using ammonia, or with sodium azide followed by hydrogenation. 4. Further elaboration of the ring systems. These modifications can be done at any stage depending upon the incompatibility of the functional groups present. 4.1 Functional group interconversions of R 1 Compounds of Formula IVA, wherein R is -OH, can be converted to halides using standard conditions POCl 3 , POBr etc.
  • Compounds of Formula IVA, wherein R 1 is alkyl can be prepared from compounds of Formula 4 where R 1 is halogen and trialkyl aluminum or dialkyl zinc (A. Holy J. Med. Chem. 1999, 42, 2064).
  • Compounds of Formula IVA, wherein R 1 is a halide can be converted to compounds wherein R 1 is -NH 2 , -OH, -SH, -OR 8 , -SR 8 with standard reagents, e.g. NH 3 , NaOH, thiourea, R 8 0 " , R 8 S " , with or without a catalyst (e.g. Pd, Ni, Cu, Lewis acid, ⁇ t) (e.g. B. G. Ugarkar, /.
  • a catalyst e.g. Pd, Ni, Cu, Lewis acid, ⁇ t
  • Compounds of Formula IVA, wherein R 2 is -NH 2 can be converted to halides by a Balz-Schiemann (F) or Sandmeyer reaction (Cl, Br, I) by means of a nitrosykting agent (Na VH*, NOBF 4 , RONO) and a halogen donor (BF4 " , CuX 2 , SbX 3 where Xis a halogen).
  • Compounds of Formula IVA, wherein R 2 is a halide can be converted to compounds wherein R 2 is -NH 2 , -OH, -SH, -OR 8 , -SR 8 with standard reagents, e.g. NH 3 ,
  • R 5 R 5 can be further modified as needed, for example by halogenation, nitration, palladium coupling of halogen, Friedel-Crafts alkykom/acytechnisch, etc or these modifications can also be done before alkylation, see Jerry March, Advanced Organic Chemistry.
  • the heteroaromatic rings can also be oxidized to their corresponding N-oxides using various oxidizing agents such as H 2 0 2 , 0 3 , MCPBA etc. in polar solvents such as CH 2 C1 2 , CHC1 3 , CF 3 COOH etc See Jerry March, Advanced Organic Chemistry, 4th edition, Chapter 19. Examples of modifications are suggested in Scheme 28.
  • R 5 is for instance a pyridine, it can be converted to a N-oxide either before or after alkylation.
  • the present invention is directed to the clinical use of the heterocyclics, in particular, the pyrazolopyrimidines and their related analogs of Formulae A, I-IV, and their polymorphs, solvates, esters, tautomers, diastereomers, enantiomers, pharmaceutically acceptable salts and prodrugs thereof, for use in treatment or prevention of diseases that are HSP90-dependent.
  • a disorder such as inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorder, neurological disorders, fibrogenetic disorders, proliferative disorders, tumors, leukemias, neoplasms, cancers, carcinomas, metabolic diseases, and malignant disease.
  • the fibrogenetic disorders include but are not limited to scleroderma, polymyositis, systemic lupus, rheumatoid arthritis, liver cirrhosis, keloid formation, interstitial nephritis and pulmonary f ⁇ brosis.
  • the present invention features pharmaceutical compositions comprising the compound of Formulae A, I-IV, or a polymo ⁇ h, solvate, ester, tautomer, enantiomer, diastereomer, pharmaceutically acceptable salt thereof, or prodrug thereof, of any of the preceding aspect and embodiments and one or more pharmaceutical excipients.
  • Those of ordinary skill in the art are familiar with formulation and administration techniques that can be employed with the compounds and methods of the invention, e.g., as discussed in Goodman and Gilman, The Pharmacological Basis of Therapeutics, (current edition), Pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, PA.
  • the compounds utilized in the methods of the instant invention may be administered either alone or in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition, according to standard pharmaceutical practices.
  • the compounds can be administered orally or parenterally, including the intraventous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
  • the therapeutic or pharmaceutical compositions of the invention can be administered locally to the area in need of treatment.
  • This may be achieved by, for example, but not limited to, local infusion during surgery, topical application, e.g., cream, ointment, injection, catheter, or implant, said implant made, e.g., out of a porous, non-porous, or gelatinous material, including membranes, such as siakstic membranes, or fibers.
  • topical application e.g., cream, ointment, injection, catheter, or implant
  • said implant made, e.g., out of a porous, non-porous, or gelatinous material, including membranes, such as siakstic membranes, or fibers.
  • the administration can also be by direct injection at the site (or former site) of a tumor or neoplastic or pre-neopkstic tissue.
  • the compounds or compositions of the invention can be delivered in a vesicle, e.g., a liposome (see, for example, Langer, Science 1990, 249, 1527-1533; Treat et al., Liposomes in the Therapy of Infectious Disease and Cancer, Lopez- Bernstein and Fidler, Ed., Liss, N.Y., pp. 353-365, 1989).
  • a vesicle e.g., a liposome
  • the compounds and pharmaceutical compositions used in the methods of the present invention can also be delivered in a controlled release system.
  • a pump may be used (see, Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201; Buchwald et al. Surgery, 1980, 88, 507; Saudek et al.
  • compositions used in the methods of the instant invention can also contain the active ingredient in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as microcrystalline cellulose, sodium crosscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
  • the tablets may be un-coated or coated by known techniques to mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a water soluble taste masking material such as hydroxypropylmethyl-cellulose or hydroxypropylcellulose, or a time delay material such as ethyl cellulose, or cellulose acetate butyrate may be employed as appropriate.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate.
  • dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin,
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachisd oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
  • compositions may be preserved by the addition of an anti-oxidant such as butykted hydroxyanisol or alpha-tocopherol.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
  • an anti-oxidant such as ascorbic acid.
  • the compounds and pharmaceutical compositions used in the methods of the instant invention may also be in the form of an oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally- occurring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening agents, flavoring agents, preservatives and antioxidants.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous solution. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • the sterile injectable preparation may also be a sterile injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase. For example, the active ingredient may be first dissolved in a mixture of soybean oil and lecithin.
  • the oil solution then introduced into a water and glycerol mixture and processed to form a microemulsion.
  • the injectable solutions or microemulsions may be introduced into a patient's blood-stream by local bolus injection. Alternatively, it may be advantageous to administer the solution or microemulsion in such a way as to maintain a constant circulating concentration of the instant compound.
  • a continuous intravenous delivery device may be utilized. An example of such a device is the Deltec CADD-PLUSTM model 5400 intravenous pump.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension for intramuscular and subcutaneous administration.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3- butane diol.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the compounds of the present invention used in the methods of the present invention may also be administered in the form of suppositories for rectal administration of the drug.
  • compositions can be prepared by mixing the inhibitors with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
  • creams, ointments, jellies, solutions or suspensions, etc. containing a compound or composition of the invention can be used.
  • topical application can include mouth washes and gargles.
  • the compounds used in the methods of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles and delivery devices, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the methods, compounds and compositions of the instant invention may also be used in conjunction with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated.
  • the instant compounds may be useful in combination with known anti-cancer and cytotoxic agents.
  • the instant methods and compounds may also be useful in combination with other inhibitors of parts of the signaling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation.
  • the methods of the present invention may also be useful with other agents that inhibit angiogenesis and thereby inhibit the growth and invasiveness of tumor cells, including, but not limited to VEGF receptor inhibitors, including ribozymes and antisense targeted to VEGF receptors, angiostatin and endostatin.
  • antineopkstic agents examples include, in general, and as appropriate, alkykting agents, anti-metabolites, epidophyllotoxins, antineoplastic enzymes, topoisomerase inhibitors, procarbazines, mitoxantrones, platinum coordination complexes, biological response modifiers and growth inhibitors, hormonal/anti-hormonal therapeutic agents and haematopoietic growth factors.
  • alkykting agents include, in general, and as appropriate, alkykting agents, anti-metabolites, epidophyllotoxins, antineoplastic enzymes, topoisomerase inhibitors, procarbazines, mitoxantrones, platinum coordination complexes, biological response modifiers and growth inhibitors, hormonal/anti-hormonal therapeutic agents and haematopoietic growth factors.
  • exemplary classes of antineoplastic include the anthracyclines, vinca drugs, mitomycins, bleomycins, cytotoxic nucleosides, epothilones, discodermol
  • Particularly useful members of those classes include, for example, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin or podo-phyllotoxin derivatives such as etoposide, etoposide phosphate or teniposide, melphakn, vinbkstine, vincristine, leurosidine, vindesine, leurosine, paclitaxel and the like.
  • antineoplastic agents include estramustine, carbopktin, cyclophosphamide, bleomycin, gemcitibine, ifosamide, melphakn, hexamethyl mekmine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, pyridobenzoindole derivatives, interferons and interleukins.
  • the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.
  • a suitable amount of compound is administered to a mammal undergoing treatment for cancer, for example, breast cancer.
  • Administration typically occurs in an amount of between about 0.01 mg/kg of body weight to about 100 mg/kg of body weight per day (administered in single or divided doses), more preferably at least about 0.1 mg/kg of body weight per day.
  • a particular therapeutic dosage can include, e.g., from about 0.01 mg to about 1000 mg of compound, and preferably includes, e.g., from about 1 mg to about 1000 mg.
  • the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.1 mg to 1000 mg, preferably from about 1 mg to 300 mg, more preferably 10 mg to 200 mg, according to the particular application.
  • the amount administered will vary depending on the particular IC 5 0 value of the compound used and the judgment of the attending clinician taking into consideration factors such as health, weight, and age. In combinational applications in which the compound is not the sole active ingredient, it may be possible to administer lesser amounts of compound and still have therapeutic or prophylactic effect.
  • the pharmaceutical preparation is in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small amounts until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
  • the amount and frequency of administration of the compounds and compositions of the present invention used in the methods of the present invention, and if applicable other chemotherapeutic agents and/or radiation therapy, will be regulated according to the judgment of the attending clinician (physician) considering such factors as age, condition and size of the patient as well as severity of the disease being treated.
  • the chemotherapeutic agent and/or radiation therapy can be administered according to therapeutic protocols well known in the art. It will be apparent to those skilled in the art that the administration of the chemotherapeutic agent and/or radiation therapy can be varied depending on the disease being treated and the known effects of the chemotherapeutic agent and/or radiation therapy on that disease.
  • the therapeutic protocols can be varied in view of the observed effects of the administered therapeutic agents (i.e., antineoplastic agent or radiation) on the patient, and in view of the observed responses of the disease to the administered therapeutic agents.
  • the compounds of the invention need not be administered in the same pharmaceutical composition as a chemotherapeutic agent, and may, because of different physical and chemical characteristics, be administered by a different route.
  • the compounds/compositions may be administered orally to generate and maintain good blood levels thereof, while the chemotherapeutic agent may be administered intravenously.
  • the determination of the mode of administration and the advisability of administration, where possible, in the same pharmaceutical composition, is well within the knowledge of the skilled clinician.
  • the initial administration can be made according to established protocols known in the art, and then, based upon the observed effects, the dosage, modes of administration and times of administration can be modified by the skilled clinician.
  • the particular choice of compound (and where appropriate, chemotherapeutic agent and/or radiation) will depend upon the diagnosis of the attending physicians and their judgment of the condition of the patient and the appropriate treatment protocol.
  • the compounds/compositions of the invention may be administered concurrently (e.g., simultaneously, essentially simultaneously or within the same treatment protocol) or sequentially, depending upon the nature of the proliferative disease, the condition of the patient, and the actual choice of chemotherapeutic agent and/or radiation to be administered in conjunction (i.e., within a single treatment protocol) with the compound/composition.
  • the compound/composition and the chemotherapeutic agent and/or radiation need not be administered simultaneously or essentially simultaneously, and the initial order of administration of the compound/composition, and the chemotherapeutic agent and/or radiation, may not be important.
  • the compounds/compositions of the invention may be administered first followed by the administration of the chemotherapeutic agent and/or radiation; or the chemotherapeutic agent and/or radiation may be administered first followed by the administration of the compounds/compositions of the invention.
  • This alternate administration may be repeated during a single treatment protocol. The determination of the order of administration, and the number of repetitions of administration of each therapeutic agent during a treatment protocol, is well within the knowledge of the skilled physician after evaluation of the disease being treated and the condition of the patient.
  • the chemotherapeutic agent and/or radiation may be administered first, especially if it is a cytotoxic agent, and then the treatment continued with the administration of the compounds/compositions of the invention followed, where determined advantageous, by the administration of the chemotherapeutic agent and/or radiation, and so on until the treatment protocol is complete.
  • the practicing physician can modify each protocol for the administration of a compound/composition for treatment according to the individual patient's needs, as the treatment proceeds.
  • the attending clinician in judging whether treatment is effective at the dosage administered, will consider the general well-being of the patient as well as more definite signs such as relief of disease-related symptoms, inhibition of tumor growth, actual shrinkage of the tumor, or inhibition of metastasis.
  • Size of the tumor can be measured by standard methods such as radiological studies, e.g, CAT or MRI scan, and successive measurements can be used to judge whether or not growth of the tumor has been retarded or even reversed. Relief of disease-related symptoms such as pain, and improvement in overall condition can also be used to help judge effectiveness of treatment.
  • HSP90 competitive binding assays and functional assays can be performed as known in the art substituting in the compounds of the invention. Chiosis et al. Chemistry & Biology 2001, 8, 289-299, describe some of the known ways in which this can be done.
  • competition binding assays using, e.g., geldanamycin or 17-AAG as a competitive binding inhibitor of HSP90 can be used to determine relative HSP90 affinity of the compounds of the invention by immobilizing the compound of interest or other competitive inhibitor on a gel or solid matrix, preincubating HSP90 with the other inhibitor, passing the preincubated mix over the gel or matrix, and then measuring the amount of HSP90 that retains or does not retain on the gel or matrix.
  • Downstream effects can also be evaluated based on the known effect of HSP90 inhibition on function and stability of various steroid receptors and signaling proteins including, e.g., Rafl and HER2.
  • Compounds of the present invention induce dose- dependent degradation of these molecules, which can be measured using standard techniques.
  • HSP90 Inhibition of HSP90 also results in up-regu irritation of HSP90 and related chaperone proteins that can similarly be measured. Antiproliferative activity on various cancer cell lines can also be measured, as can morphological and functional differentiation related to HSP90 inhibition.
  • Many different types of methods are known in the art for determining protein concentrations and measuring or predicting the level of proteins within cells and in fluid samples. Indirect techniques include nucleic acid hybridization and amplification using, e.g., polymerase chain reaction (PCR).
  • HER2 expression in breast cancer cells can be determined with the use of an immunohistochemical assay, such as the Dako HercepTM test (Dako Corp., Carpinteria, CA).
  • the HercepTM test is an antibody staining assay designed to detect HER2 overexpression in tumor tissue specimens. This particular assay grades HER2 expression into four levels: 0, 1, 2, and 3, with level 3 representing the highest level of HER2 expression.
  • Accurate quantitation can be enhanced by employing an Automated Cellular Imaging System (ACIS) as described, e.g., by Press, M. et al. Modern Pathology 2000, 13, 225A.
  • ACIS Automated Cellular Imaging System
  • Antibodies, polyclonal or monoclonal can be purchased from a variety of commercial suppliers, or may be manufactured using well-known methods, e.g., as described in Harlow et al. Antibodies: A Laboratory Manual, 2nd ed; Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1988.
  • HER2 overexpression can also be determined at the nucleic acid level since there is a reported high correlation between overexpression of the HER2 protein and amplification of the gene that codes for it. One way to test this is by using RT-PCR.
  • the genomic and cDNA sequences for HER2 are known.
  • Specific DNA primers can be generated using standard, well-known techniques, and can then be used to amplify template already present in the cell. An example of this is described in Kurokawa, H. et al. Cancer Res. 2000, 60, 5887-5894.
  • PCR can be standardized such that quantitative differences are observed as between normal and abnormal cells, e.g., cancerous and noncancerous cells.
  • Well known methods employing, e.g., densitometry can be used to quantitate and/or compare nucleic acid levels amplified using PCR.
  • fluorescent in situ hybridization (FISH) assays and other assays can be used, e.g., Northern and/or Southern blotting.
  • this nucleic acid probe can be conjugated to a fluorescent molecule, e.g., fluorescein and or rhodamine, that preferably does not interfere with hybridization, and which fluorescence can later be measured following hybridization.
  • a fluorescent molecule e.g., fluorescein and or rhodamine
  • NucleicAcid-TAMRA-p-3' sequence NucleicAcid-TAMRA-p-3' sequence.
  • ACIS-based approaches as described above can be employed to make the assay more quantitative (de la Torre-Bueno, J., et al. Modern Pathology 2000, 13, 221 A).
  • Immuno and nucleic acid detection can also be directed against proteins other than HSP90 and HER2, which proteins are nevertheless affected in response to HSP90 inhibition.
  • the following examples are offered by way of illustration only and are not intended to be limiting of the full scope and spirit of the invention.
  • the samples were diluted to typically 0.1-1 mg/mL in MeOH or CH 3 CN and the injection volumes were typically 10 ⁇ L.
  • the column was not heated, and UV detection was effected at 254 run.
  • 'H-NMR spectra were recorded on a Bruker Avance 400 MHz spectrometer. The chemical names were generated using the Beilstein Autonom 2.1 software.
  • Variant 2 A solution of the aromatic compound (7 mmol) and n-halosuccinimide (NCS, NBS, or NIS, 1.06 equiv) in acetic acid (40 mL) was heated to 40-90 °C for 0.3-1 h. Evaporation, work-up (EtOAc) and flash chromatography afforded the desired halogenated benzene.
  • Step 1 2-Chloromethyl-4-methoxy-3,5-dimethylpyridine-l -oxide
  • the title compound was obtained by oxidation of 2-chloromethyl-4-methoxy-3,5- dimethyl-pyridine according to the general procedure 2.1.
  • Step 2 2-Chloro-6-chloromethyl-4-methoxy-3,5-dimethylpyridine
  • the title compound was obtained by treating 2-chloromethyl-4-methoxy-3,5- dimeth.ylpyridine-1 -oxide with POCI 3 according to the general procedure 2.6.
  • HPLC Rt 6.757 min.
  • 1H-NMR (CDCI3) ⁇ 4.64 (s, 2H), 3.79 (s, 3H), 2.35 (s, 3H), 2.33 (s, 3H).
  • Example 3 4-Chloro-2-chloromethyl-3,5-dimethyl-pyridine
  • Step 1 2,3,5-Collidine-N-oxide 2,3,5-Collidine-N-oxide was obtained by oxidation of 2,3,5-collidine according to the general procedure 2.1 in 70% yield.
  • HPLC Rt 3.96 min.
  • 'H-NMR (CDCI3) ⁇ 8.03 (s, IH), 6.90 (s, IH), 2.47 (s, 3H), 2.31 (s, 3H), 2.24 (s, 3H).
  • Step 2 4-Bromo-2,3,5-collidine-N-oxide 2,3,5-collidine-N-oxide (1.3 g, 10 mmol) and K 2 C0 3 (2.9 g, 20 mmol) were suspended in 10 mL of CC1 4 . Bromine (1 mL, 20 mmol) was added dropwise, and the reaction mixture was heated to reflux for 2 h. Work-up (EtOAc) and flash chromatography (10% MeOH/EtOAc) afforded the title compound as a solid (1.05 g, 51% yield). HPLC Rt: 5.24 min.
  • Step 4 4-Bromo-3,5-dimethyl-pyridin-2-yl methanol
  • a suspension of acetic acid 4-bromo-3,5-dimethyl-pyridin-2-yl methyl ester (0.26 g, 1.0 mmol) and K 2 C0 3 (excess) in MeOH (5 mL) was heated to 50 °C for 15 min.
  • Work-up (CHC1 3 ), evaporation, and filtration through a silica gel pad (eluent: 100% EtOAc) gave the title compound as a white solid (0.19 g, 88% yield).
  • Rf (50% Hexane/EtOAc): 0.5.
  • Step 1 2-chloromethyl-3,5-dimethyl-pyridin-4-ol
  • the title compound was obtained by heating 2-chloromethyl-4-methoxy-3,5- dimethyl-pyridine hydrochloride in toluene as described in the patent by Tarbit, et al WO 99/10326.
  • Step 2 4-bromo-2-chloromethyl-3,5-dimethyl pyridine
  • a mixture of 2-chloromethyl-3,5-dimethyl-pyridin-4-ol (8.2 g, 47.8 mmol) and POBr 3 (60g, 209 mmol) was stirred at 130 °C for 3 h.
  • the resulting viscous oil was cooled to r.t. and poured onto ice water.
  • Step l 4-bromo-2-chloromethyl-3,5-dimethyl pyridine
  • PBr 3 8.0 mL, 85.1 mmol, 5.8 equiv.
  • a catalytic amount of DMF (0.50 mL, 6.4 mmol, 0.44 equiv.) was added, whereupon the suspension rapidly turned into an orange solution.
  • the reaction was still incomplete as judged by HPLC. The temperature was raised to 110 °C and the reaction was prolonged for 30 min, at which point it was complete.
  • Step 2c HC1, MeOH Step 1.
  • Octanoic acid (4-chloro-5-phenylaminomethyl-7H-pyrrolo[2,3- d]pyrimidin-2-yl)-amide
  • a solution of octanoic acid ⁇ 5-[(dibenzykmino)-methyl]-4-oxo-4,7-dihydro-3H- pyrrolo[2,3-d]pyrimidin-2-yl ⁇ -amide (2.42 g, 3 mmol) and aniline (10 mL) was heated to 90 °C in a selaed tube overnight, concentrated, filtered, and washed with MeOH (2 mL x3) to give the title compound (1.1 g, 57% ).
  • Step 1 Octanoic acid (4-chloro-5-[(methyl-phenyl-amino)-methyl]-7H- pyrrolo[2,3-d]pyrimidin-2-yl)-amide
  • the title compound was obtained by treating octanoic acid ⁇ 5-[(dibenzykmino)- methyl]-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl ⁇ -amide (2.42 g, 3 mmol) and N-methykniline (10 mL) as in step 1 of the previous example.
  • HPLC Rt 6.325 min.
  • Step 2 4-Chloro-7-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-5- [(methyl-phenyl-amino)-methyl]-7H-pyrrolo[2,3-d]pyrimidin-2-ykmine
  • the title compound was obtained by alkylation of octanoic acid ⁇ 4-chloro-5- [(methyl-phenyl-amino)-methyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl ⁇ -amide with 2- chloromethyl-4-methoxy-3,5-dimethyl-pyridine and deprotection with 4N HCl as in step 2 of the previous example.
  • HPLC Rt 4.844 min.
  • N- ⁇ 7-Acetyl-5-[2-(tert-butyl-diphenyl-siknyloxy)-ethyl]-4- chloro-7H-pyrrolo[2,3-d]pyrimidin-2-yl ⁇ -acetamide A solution of crude N- ⁇ 7-acetyl-5-[2-(tert-butyl-diphenyl-siknyloxy)-ethyl]-4- oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl ⁇ -acetamide (26.4 g, 51 mmol), BnNEt 3 Cl (23.2 g, 102 mmol), PhNMe 2 (19.6 mL, 153 mmol) and POCl 3 (9.3 mL, 77 mmol) in CH 3 CN (100 mL) was heated to 80 °C for 1.5 h.
  • Step 8 N-[5-[2-(tert-Butyl-diphenyl-siknyloxy)-ethyl]-4-chloro-7-(4- methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin- 2-y ⁇ ]-acetamide
  • a mixture ofN- ⁇ 5-[2-(tert-butyl-diphenyl-siknyloxy)-ethyl]-4-chloro-7H- pyrrolo[2,3-d]pyrimidin-2-yl ⁇ -acetamide (344 mg, 0.70 mmol), 2-chloromethyl-4- methoxy-3,5-dimethyl-pyridine hydrochloride (175 mg, 0.77 mmol), K 2 C0 3 (516 mg, 3.7 mmol) and DMF (3.0 mL) was stirred at rt overnight.
  • Example A rHSP90 Competitive Binding Assay
  • Five microgram of purified rHSP90 protein (Stressgen, BC, Canada, #SPP-770) in phosphated buffered saline (PBS) was coated on 96 well plates by incubating overnight at 4°C. Unbound protein was removed and the coated wells were washed twice with 200 ⁇ L PBS.
  • DMSO controls considered as untreated samples
  • test compounds were then added at 100-30-10-3-1-0.3 ⁇ M dilutions (in PBS), the plates mixed for 30 seconds on the plate shaker, and then incubated for 60 min. at 37 °C.
  • biotin-GM biotinykted-geldanamycin
  • biotin-GM biotinykted-geldanamycin
  • biotin-GM biotinykted-geldanamycin
  • the wells were washed again twice with 200 ⁇ L PBS, before the addition of 20 ⁇ g/mL streptavidin- phycoerythrin (streptavidin-PE) (Molecular Probes, Eugene, OR) and incubation for 60 min. at 37°C.
  • streptavidin-PE streptavidin- phycoerythrin
  • Relative fluorescence units was measured using a SpectraMax Gemini XS Spectiofluorometer (Molecular Devices, Sunnyvale, CA) with an excitation at 485 nm and emission at 580 nm; data was acquired using SOFTmax ® PRO software (Molecular Devices Corporation, Sunnyvale, CA).
  • Example B Cell Lysate Binding Assay MCF7 breast carcinoma cell lysates were prepared by douncing in lysing buffer
  • Example C HER2 Degradation Assay MCF7 breast carcinoma cells (ATCC) were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and 10 mM HEPES, and plated in 24 well plates (50% confluent). Twenty-four hrs later (cells are 65-70% confluent), test compounds were added and incubated overnight for 16 h. For the less potent compounds, the amounts added were 100 ⁇ M, 30 ⁇ M, 10 ⁇ M and 1 uM, and for more potent compounds, the amounts added were 1 ⁇ M, 0.3 ⁇ M, 0.1 ⁇ M, 0.03 ⁇ M, 0.01 ⁇ M and 0.003 ⁇ M.
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • HEPES fetal bovine serum
  • the wells were washed with 1 mL phosphate buffered saline (PBS), and 200 ⁇ L trypsin was added to each well. After trypsinization was complete, 50 ⁇ L of FBS was added to each well. Then 200 ⁇ L cells was transferred to 96 well plates. The cells were pipetted up and down to obtain a single cell suspension. The plates were centrifuged at 2,500 rpm for 1 min using a Sorvall Legend RTTM tabletop centrifuge (Kendro Laboratory Products, Asheville, NC). The cells were then washed once in PBS containing 0.2% BSA and 0.2% sodium azide (BA buffer).
  • PBS phosphate buffered saline
  • PE conjugated anti HER2/Neu antibody Becton Dickinson, #340552
  • PE conjugated anti-keyhole limpet hemacyanin [KLH] Becton Dickinson, #340761
  • control antibody was added at a dilution of 1 :20 and 1 :40 respectively (final concentration was 1 ⁇ g/mL) and the cells were pipeted up and down to form a single cell suspension, and incubated for 15 mins. The cells were washed twice with 200 ⁇ L BA buffer, and resuspended in 200 ⁇ L BA buffer, and transferred to FACSCAN tubes with an additional 250 ⁇ L BA buffer.
  • % HER2 degraded [(MFI untreated cells - MFI treated cells)/MFl untreated cell] x 100
  • IC 50 is defined as the concentration at which there was 50% degradation of the HER2/Neu protein.
  • Example D MTS Assay MTS assays measures the cytotoxicity of geldanamycin derivatives.
  • MTS (3- (4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium is a tetrazolium dye that is converted to a formazan product by dehydrogenase enzymes of metabolically active cells (Corey, A. et al. "Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture," Cancer Commun. 1991, 3, 207-212).
  • % viable cells (Abs at 490 nm treated cells / Abs at 490 nm untreated cells) x 100
  • IC 50 was defined as the concentration of the compound which gave rise to 50% viable cell number.
  • the following solvents could also be used: THF, EtOH, or i-PrOH.
  • Method 2 The free base (50 mmol) was heated in i-PrOH (6 L) until it dissolved. The solution was allowed to cool to r.t. and a solution of HCl in i-PrOH (75 mmol) was added slowly dropwise. The hydrochloride crystallized out of solution within a few minutes, and was collected by filtration, washed (acetone) and dried. The sulfate and mesykte salts were also prepared in this manner.
  • the hydrochloride salts can also be made by adding CH 3 COCl to the alcoholic solution of the pyridine or free base derivative.
  • Method 3 To a suspension of free base (5 mmol) in MeOH (50 mL) was added a solution of methane sulfonic acid in MeOH (75 mmol) was added slowly dropwise. The mixture became clear within a few minutes, upon addition of i-PrOH (50-100 mL) the salt precipitated out and was collected by filtration, washed with i-PrOH, ether and dried. These methods can be applied to prepare all other salts.
  • Variant 2 A solution of the aromatic compound (7 mmol) and N- halosuccinimide (NCS, NBS, or NIS, 1.06 equiv) in acetic acid (40 mL) was heated to 40-90 °C for 0.3-1 h. Evaporation, work-up (EtOAc) and flash chromatography afforded the desired halogenated benzene.
  • General procedure 3.2 Preparation of benzylic alcohols Benzoic acid derivatives were reduced to the corresponding benzylic alcohols according to the procedure given by Bhaskar et al. J. Org. Chem. 1991, 56, 5964-5965. 4. Specific Examples
  • Example 59 N-9 and N-7 alkylation of purines.
  • a suspension of purine (28.4 mmoles), benzyl halide (28.7 mmoles) in dry DMF (80 mis) was treated with K2C03 (31.2 mmoles) at 70 °C for Mrs.
  • Extraction with EtOAc and chromatography EtOAc/Hexanes (1:1) yielded pure N9 and N-7 alkykted products. All HPLC was performed per the following parameters: HPLC Column: Zorbax 300 SB-C 18, 5 microns, 4.6 x 150 mm.
  • HPLC Instrument Agillent 1100
  • HPLC Reagent A 0.1 %TF A/Water
  • HPLC Reagent B 0.05% TFA/CH3CN
  • HPLC Method 5%B to 100%B in 7 minutes. The following compounds were prepared in this manner. 1.1 6-Chloro-9-(2,5-dimethoxy-benzyl)-9H- ⁇ urin-2-ykmine.
  • HPLC R.t. 5.194 min. 1.2 6-Chloro-9-(4,5-dimethoxy-2-nitro-benzyl)-9H-purin-2-ykmine.
  • 1.3 6-Chloro-9-(2,5-dichloro-benzyl)-9H-purin-2-ykmine.
  • Example 60 Halogenation of purines. To a solution of purine (6.6 mmoles) in acetate buffer/MeOH/THF or acetic acid or dichloromethane, bromine or N-chlorosuccinimide or N-Iodosuccinimide (8.7 mmoles) was added. While bromination can be done at room temperature, chlorination and iodination can be done at 60C to 90 C in 2 hours. Same HPLC conditions as stated in Example 59 were used. The following compounds were prepared in this manner: 2.1 8-Bromo-6-chloro-9-(2,5-dimethoxy-benzyl)-9H-purin-2-ykmine. HPLC R.t. 6.150 min.
  • HPLC R.t. 6.676 min 2.10 9-(2-Bromo-3,4,5-trimethoxy-benzyl)-6-methoxy-9H-purine.
  • HPLC R.t. 6.952 min 2.12 6,8-Dichloro-9-(2,6-dichloro-3,4,5-trimethoxy-benzyl)-9H-purin-2- ylamine.
  • Example 61 Displacement of 6-halogenated-purines.
  • 6-halogenated purines can be replaced by H, R, NHR, OR, SR using known procedures, e.g., as described inJ. Med. Chem. 1999, 42, 2064-2086. Same HPLC conditions as stated in Example 59 were used. The following compounds were prepared in this manner: 3.1 9-(3,4,5-Trimethoxy-benzyl)-9H-purin-2-ykmine. HPLC R.t. 4.123 min. 3.2 2 -Amino -9-(2 -bromo-3,4,5 -trimethoxy-benzyl)-9H-purine-6 -thiol. HPLC R.t. 4.931 min.
  • Example 62 Acylation of 2-amino-purines
  • 2-amino-purine can be acykted in acetic anhydride with catalytic amount of concentrated sulfuric acid or in acetic acid and catalytic amount of fuming nitric acid at room temperature. Same HPLC conditions as stated in Example 59 were used. The following compounds were prepared in this manner: 4.1 N-[6-Chloro-9-(3,4,5-trimethoxy-benzyl)-9H-purin-2-yl]-acetamide. HPLC R.t. 5.744 min. 4.2 N-[9-(2-Bromo-3,4,5-trimethoxy-benzyl)-6-chloro-9H-purin-2-yl]- acetamide. HPLC R.t. 5.603 min.
  • Example 63 N-[9-(2-Bromo-3,4,5-trimethoxy-benzyl)-6-chloro-9H-purin-2-yl]-N- methylacetamide or Methylation of compound 4.2.
  • compound 4.2 Example 62 above
  • iodomethane NaH was added.
  • Extraction with EtOAc and chromatography yield 5. HPLC R.t. 6.177 min.
  • Example 64 Synthesis of 6-methyl purines
  • the title compound was obtained by suspended purine (0.19 mmole) and tetrakis(tripl ⁇ enylphosphino)-palkdium (0.019 mmole) in dry THF (3mls) before treating with trimethykluminum (2M in toluene, 0.44 mmole) under nitrogen. The solution was refluxed for 3 hours before cooling down to room temperature. Diluted the reaction mixture with toluene (5 mis) before quenching the reaction with methanol (0.5 mis) followed by ammonium chloride (1 mmole). The mixture was refluxed for 2 hours and filtered, while hot, on Celite. See J. Med.
  • Example 65 9-(4-Bromo-3,5-dimethyl-pyridin-2-yl)-6-chloro-9H-purin-2-ylamine
  • the title compound was obtained by alkykting 2-amino-6-chloropurine with 4- bromo-2-bromomethyl-3,5-dimethyl-pyridine according to the general procedure 1.1.
  • Step 1 2,3,5-Collidine-N-oxide Oxidation of 2,3,5-collidine according to the general procedure 2.1 gave 2,3,5- collidine-N-oxide. Yield: 70%.
  • Step 2 4-Bromo-2,3,5-collidine-N-oxide 2,3,5-collidine-N-oxide (1.3 g, 10 mmol) and K 2 C0 3 (2.9 g, 20 mmol) were suspended in 10 mL of CC1 4 . Bromine (1 mL, 20 mmol) was added dropwise, and the reaction mixture was heated to reflux for 2 h. Work-up (EtOAc). and flash chromatography (10% MeOH/EtOAc) afforded the product as a solid (1.05 g, 51% yield). HPLC Rt: 5.239 min.
  • Step 4 4-Bromo-3,5-dimethyl-pyridin-2-yl methanol
  • acetic acid 4-bromo-3,5-dimethyl-pyridin-2-yl methyl ester (0.26 g, 1.0 mmol) and K 2 C0 3 (excess) in MeOH (5 mL) was heated to 50 °C for 15 min.
  • Work-up (CHCI3), filtration through a silica gel pad (eluent: 100% EtOAc) and evaporation gave the title compound as a white solid (0.19 g, 88% yield).
  • Rf (50% Hexane/EtOAc): 0.5.
  • Step 1 2-chloromethyl-3,5-dimethyl-pyridin-4-ol
  • Step 2 4-bromo-2-chloromethyl-3,5-dimethyl pyridine
  • a neat mixture of 2-chloromethyl-3,5-dimethyl-pyridin-4-ol (8.2 g, 47.8 mmol) and POBr 3 (60g, 209 mmol) was stirred at 130 °C for 3 h.
  • the resulting viscous oil was cooled to r.t. and poured onto ice water.
  • the pH was adjusted to 10 with solid KOH.
  • Step 1 4-bromo-2-chloromethyl-3,5-dimethyl pyridine
  • PBr 3 8.0 ml, 85.1 mmol, 5.8 equiv.
  • a catalytic amount of DMF (0.50 ml, 6.4 mmol, 0.44 equiv.) was added, whereupon the suspension rapidly turned into an orange solution.
  • the reaction was still incomplete as judged by HPLC. The temperature was raised to 110 °C and the reaction was prolonged for 30 min, at which point it was complete.
  • Example 66 9-(4-bromo-3,5-dimethyl-pyridin-2-yl methy ⁇ )-6-chIoro-9H-purin-2- ylamine, phos hate salt
  • the title compound was obtained by treating 9-(4-bromo-3,5-dimethyl-pyridin-2- yl methyl)-6-chloro-9H-purin-2-ykmine with H 3 P0 4 according to the general procedure 2.7.
  • HPLC Rt 5.294 min.
  • Example 67 9-(4-bromo-3,5-dimethyl-pyridin-2-yl methy ⁇ )-6-chIoro-9H-purin-2- ylamine, hydrochloric acid salt
  • the title compound was obtained by treating 9-(4-bromo-3,5-dimethyl-pyridin-2- yl methyl)-6-chloro-9H-purin-2-ykmine with HCl according to the general procedure 2.7.
  • Example 68 9-(4-bromo-3,5-dimethyl-l-oxy-pyridin-2-yI methyl)-6-chloro-9H- purin-2-ylamine
  • the title compound was obtained by oxidation of 9-(4-bromo-3,5-dimethyl- pyridin-2-yl)-6-chloro-9H-purin-2-ykmine according to the general procedure 2.1.
  • Example 69 6-bromo-9-(4-bromo-3,5-dimethyl-pyridin-2-yl methyl) -9H-purin-2- ylamine
  • 6-brorno-9H-purin-2-ykmine 2.4 g, 11 mmol
  • 4-bromo-2- chloromethyl-3,5-dimethyl pyridine 3.5 g, 15 mmol
  • K 2 C0 3 2.07 g, 15 mmol
  • DMF 50 mL
  • Work-up and flash chromatography gave the title compound as a white solid (2.6 g, 56 %).
  • Example 70 6-bromo-9-(4-bromo-3,5-dimethyI-l-oxy-pyridin-2-yl methyl) -9H- purin-2-yIamine
  • the title compound was obtained by oxidation of 6-bromo-9-(4-bromo-3,5- dimethyl-pyridin-2-yl methyl) according to the general procedure 2.1 (52% yield).
  • 'H-NMR (CDCI3) ⁇ 8.47 (s, IH), 8.07 (s, IH), 5.56 (s, 2H), 5.06 (s, 2H), 2.81(s, 3H), 2.35 (s, 3H).
  • Example 71 2-(2-Amino-6-chloro-purin-9-ylmethyl)-3,5-dimethyl-pyridin-4-ol
  • the title compound was obtained by alkykting 6-chloro-9H-purin-2-ykmine with 2-chloromethyl-3,5-dimethylpyridin-4-ol according to the general procedure 1.1.
  • Example 72 6-Chloro-9- (4-ethoxy-3,5-dimethyl-pyridin-2-yImethyl)-9H-purin-2- ylamine
  • the title compound was obtained by O-alkytechnische-formation of 2-(2-amino-6-chloro-purin- 9-ylmethyl)-3,5-dimethyl-p ridin-4-ol with ethyl iodide using the general procedure 2.6.
  • Example 75 6-Chloro-9-(4-isopropoxy-3,5-dimethyl-pyridin-2-yImethyI)-9H- purin-2-ylamine
  • the title compound was obtained by 0-alkytechnische-formation of 2-(2-amino-6-chloro-purin- 9-ylmethyl)-3,5-dimethyl-pyridin-4-ol with isopropyl iodide using the general procedure 2.6.
  • HPLC Rt 4.571 min.
  • Example 76 6-Chloro-9-(4-cyclopropylmethoxy-3,5-dimethyI-pyridin-2-ylmethy ⁇ )- 9H-purin-2-ylamine
  • the title compound was obtained by 0-alkytechnische-formation of 2-(2-amino-6-chloro-purin- 9-ylmethyl)-3,5-dimethyl-pyridin-4-ol with cyclopropylmethyl iodide using the general procedure 2.6.
  • HPLC Rt 4.709 min.
  • Example 79 Acetic acid 2-[2-(2-amino-6-chloro-purin-9-ylmethyl)-3,5-dimethyI- pyridin-4-yloxy] -ethyl ester
  • the title compound was obtained by 0-alkykom of 2-(2-amino-6-chloro-purin- 9-ylmethyl)-3,5-dimethyl-pyridin-4-ol with 2-bromoethyl acetate using the general procedure 2.6.
  • Example 80 Acetic acid 3-[2-(2-amino-6-chloro-purm-9-ylmethyI)-3,5-dimethyl- pyridin-4-y!oxy]-propyI ester
  • the title compound was obtained by 0-alkytechnische-in- 9-ylmethyl)-3,5-dimethyl-pyridm-4-ol with 2-chloropropyl acetate the general procedure 2.6.
  • Example 81 6-Chloro-9-(3,5-dimethyl-4-propoxy-pyridin-2-ylmethyl)-9H-purin-2- ylamine
  • the title compound was obtained by O-alkytechnische-formation of 2-(2-amino-6-chloro-purin- 9-ylmethyl)-3,5-dimethyl-pyridin-4-ol according to the general procedure 2.6.
  • Example 82 6-Chloro-9-(4-chloro-3,5-dimethyl-pyridin-2-ylmethyI)-9H-purin-2- ylamine
  • Step 1 4-Chloro-2-chloromethyl-3,5-dimethyl pyridine
  • the title compound was obtained by treating 2-chloromethyl-3,5-dimethyl- pyridin-4-ol with POCl 3 according to the general procedure 2.4 (74% yield).
  • HPLC Rt 5.543 min.
  • Step 2 6-chloro-9-(4-chloro-3,5-dimethyl-l-oxy-pyridin-2-yl methyl) -9H-purin-2-ykmine
  • 6-chloro-9H-purin-2-ykmine 7 g, 41 mmol
  • 4-chloro-2- chloromethyl-3,5-dimethyl pyridine 8.2 g, 43 mmol
  • K 2 C0 3 10 g, 72 mmol
  • DMF 200 mL
  • Example 83 6-ChIoro-9-(4-chloro-3,5-dimethyl-l-oxy-pyridin-2-yl methyl) -9H- purin-2-ylamine
  • the title compound was obtained by oxidation of 6-chloro-9-(4-chloro-3,5- dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ykmine according to the general procedure 2.1 (56% yield).
  • Examples 84 6-Chloro-9-(3,5-dimethyl-pyridin-2-yl methyl) -9H-purin-2-ylamine
  • Step 1 Acetic acid 3,5-dimethyl-pyridin-2-yl methyl ester
  • the title compound was prepared from 2,3,5-collidine-N-oxide (see example 1) according to the general procedure 2.2.
  • Step 2 3,5-Dimethyl-pyridin-2-yl methanol
  • the title compound was obtained by deacetykom of acetic acid 3,5-dimethyl- pyridin-2-yl methyl ester according to the general procedure 2.3.
  • HPLC Rt 2.909 min.
  • Step 3 2-Bromomethyl-3,5-dimethyl pyridine
  • the title compound was obtained from 3,5-dimethyl-pyridin-2-yl methanol according to the general procedure 2.5.
  • Example 85 6-Bromo-9-(4 ⁇ methoxy-3,5-dimethyl-pyridin-2-ylmethyI)-9H-purin-2- ylamine
  • the title compound was obtained by alkylation of 6-bromo-9H-purin-2-ykmine with 2-chloromethyl-4-methoxy-3,5-dimethylpyridine according to the general procedure 1.1.
  • PLC Rt 4.138.
  • Example 86 6-Bromo-9-(4-methoxy-3,5-din ethyl-pyridin-2-ylmethyl)-9H-purin-2- ylamine, phosphate salt
  • the title compound was obtained by treating 6-bromo-9-(4-methoxy-3,5- dimethyl-pyridin-2-ylmethyl)-9H-purin-2-yk ⁇ nine with H 3 P0 4 according to the general procedure 2.7.
  • HPLC Rt 4.138.
  • Example 87 6-Bromo-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2- ylamine, hydrochloride salt
  • the title compound was obtained by treating 6-bromo-9-(4-methoxy-3,5- dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ylan ⁇ ine with HCl according to the general procedure 2.7.
  • HPLC Rt 4.138.
  • Example 88 6-Bromo-9-(4-methoxy-3,5-dimethyl-l-oxy-pyridin-2-ylmethyl)-9H- purin-2-ylamine
  • the title' compound was obtained by oxidation of 6-bromo-9-(4-methoxy-3,5- dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ylamine according to the general procedure 2.1.
  • 'H-NMR (CDC1 3 ) ⁇ 8.55 (s, IH), 8.06 (s, IH), 5.50 (s, 2H), 5.12 (s, 2H), 3.76 (s, 3H), 2.60 (s, 3H), 2.25 (s, 3H).
  • m z (%) 379.1 (M+l, 100%), 381.1 (M+3, 100%).
  • Method 1 The title compound was obtained by alkykting 6-chloro-9H-purin-2-ykmine with 2-chloromethyl-4-methoxy-3,5-dimethylpyridine (or its HCl salt) according to the general procedure 1.1.
  • Method 2 The title compound could also be obtained by 0-methykom of 6-chloro-9-(4- hydroxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ykmine according to the procedure 2.6 (KOH, Mel, DMF, 80 °C, 5 min). HPLC Rt: 3.980 min.
  • Step 1 (4-Methoxy-3,5-dimethyl-pyridin-2-yl)-methykmine A solution of 2-chloromethyl-4-methoxy-3,5-dimethyl-pyridine hydrochloride in 7N methanolic ammonia was placed in a pressure vessel and to 100 °C for 16 h.
  • Step 3 Synthesis of 6-chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2- ylmethyl)-9H-purin-2-ylamine
  • the cyclization with trimethylorthoformate in presence of acid to prepare purines can be done. See similar reaction, example 48.
  • Example 90 6-chloro-9-(4-methoxy-3,5-dimethyI-pyridin-2-ylmethyl)-9H-purin-2- ylamine, phosphate salt
  • the title compound was obtained treating 6-chloro-9-(4-methoxy-3,5-dimethyl- pyridin-2-ylmethyl)-9H-purin-2-ykmine with H 3 P0 4 according to the general procedure 2.7.
  • Example 91 6-ChIoro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2- ylamine, sulphate salt
  • the title compound was obtained treating 6-chloro-9-(4-methoxy-3,5-dimethyl- pyridin-2-ylmethyl)-9H-purin-2-ylamine with H 2 S ⁇ according to the general procedure 2.7.
  • Example 92 6-Chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2- ylamine, hydrochloride salt
  • the title ' compound was obtained treating 6-chloro-9-(4-methoxy-3,5-dimethyl- pyridin-2-ylmethyl)-9H-purin-2-ykmine with HCl according to the general procedure 2.7.
  • Example 93 6-Chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyI)-9H-purin-2- ylamine, mesylate salt
  • the title compound was obtained treating 6-chloro-9-(4-methoxy-3,5-dimethyl- pyridin-2-ylmethyl)-9H-purin-2-ylamine with MeSOaH according to the general procedure 2.7.
  • Example 94 N-[6-Chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethy ⁇ )-9H- purin-2-yl] -acetamide
  • a suspension of 6-chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H- purin-2-ykmine (80 mg, 0.25 mmol) in acetic acid anhydride (2.2 g) was treated with one drop of concentrated H 2 S0 4 and stirred at r.t. for 5 min. Work-up (EtOAc), drying (MgS0 ) and evaporation gave the title compound as a white solid.
  • Example 95 6-Chloro-9-(4-methoxy-3,5-dimethyl-l-oxy-pyridin-2-ylmethyI)-9H- purin-2-ylamine
  • the title compound was obtained by oxidation of 6-chloro-9-(4-methoxy-3,5- dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ykmine according to the general procedure 2.1.
  • 'H-NMR (CDC1 3 ) ⁇ 8.55 (s, IH), 8.06 (s, IH), 5.52 (s, 2H), 5.07(s, 2H), 3.76 (s, 3H), 2.61 (s, 3H), 2.25 (s, 3H).).
  • m z (%) 335.1(M+1, 100%), 337.1 (M+3, 34%).
  • Example 96 6-Chloro-9-(4-methoxy-3,5-dimethyl-l-methoxy-pyridinium-2- methyl)-9H-purin-2-ylamine methyl sulfate salt
  • a suspension of 6-chloro-9-(4-methoxy-3,5-dimethyl-l-oxy-pyridin-2-ylmethyl)- 9H-purin-2-ykmine (0.2 g, 0.56 mmol) in DCM (10 ml) was heated to reflux.
  • Dimethyl sulfate (1.12 mmol) was added dropwise (Tarbit WO 99/10326) and heating was continued for 3h. Filtration and washing (hot acetone) gave the title compound as a beige solid.
  • Example 97 6-Chloro-9-(6-chloro-4-methoxy-3 ,5-dimethyl-pyridin-2-ylmethy ⁇ )- 9H-purin-2-ylamine
  • Method 1 6-Chloro-9-(4-methoxy-3,5-dimethyl-l-oxy-pyridin-2-ylmethyl)-9H-purin-2- ylamine was treated with POCl 3 according to the general procedure 2.4. Flash chromatography gave the title compound as a white solid. HPLC Rt: 5.741 min.
  • Step 1 2-Chloromethyl-4-methoxy-3,5-dimethylpyridine-l-oxide
  • the title compound was obtained by oxidation of 2-chloromethyl-4-methoxy-3,5- dimethylpyridine according to the general procedure 2.1.
  • Step 2 2-Chloro-6-chloromethyl-4-methoxy-3,5-dimethylpyridine
  • the title compound was obtained by treating 2-chloromethyl-4-methoxy-3,5- dimethylpyridine- 1-oxide with POCl 3 according to the general procedure 2.4.
  • HPLC Rt 6.757 min.
  • Step 3 6-Chloro-9-(6-chloro-4-methoxy-3,5-dimethyl-pyridin-2- ylmethyl)-9H-purin-2-ykmine
  • the title compound was obtained by alkylation of 6-chloro-9H-purin-2-ykmine with 2-chloro-6-chloromethyl-4-methoxy-3,5-dimethylpyridine according to the general procedure 1.1.
  • Example 98 6-ChIoro-9-(5-methoxy-4-methoxymethyl-6-methyl-pyridin-3- ylmethyl)-9H-purin-2-ylamine
  • Step 1 Acetic acid 3-acetoxy-5-hydroxymethyl-2-methyl-pyridin-4- ylmethyl ester
  • HPLC Rt 3.08 min.
  • 'H-NMR (CDCI3) ⁇ 8.41 (s, IH), 5.20 (s, 2H), 4.80 (s, 2H), 2.40 (s, 3H), 2.38 (s, 3H), 2.03 (s, 3H).
  • Step 2 Acetic acid 3-acetoxy-5-bromomethyl-2-methyl-pyridin-4- ylmethyl ester The title compound was obtained from Acetic acid 3-acetoxy-5-hydroxymethyl-
  • Step 3 6-Chloro-9-(5-acetoxy-4-acetoxymethyl-6-methyl-pyridin-3- ylmethyl)-9H-purin-2-ykmine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with acetic acid 3-acetoxy-5-bromomethyl-2-methyl-pyridin-4-ylmethyl ester according to the general procedure 1.1.
  • Step 4 6-Chloro-9-(5-hydroxy-4-hydroxymethyl-6-methyl-pyridin-3- ylmethyl)-9H-purin-2-ykmine
  • a suspension of 6-chloro-9-(5-acetoxy-4-acetoxymethyl-6-methyl-pyridin-3- ylmethyl)-9H-purin-2-ykmine and K 2 C0 3 (excess) in MeOH was heated to 50 °C for 15 min. Filtration, work-up (EtOAc) and purification by preparative TLC gave the title compound.
  • Example 99 Synthesis of 6-Chloro-9-(5-ethoxy-4-hydroxymethyl-6-methyl-pyridin- 3-ylmethyl)-9H-purin-2-ylamine
  • Example 101 6-Chloro-9-(3-methoxy-5-methoxymethyI-4-methyl-pyridin-2- ylmethy ⁇ )-9H-purin-2-ylamine
  • Step 1 3-Methoxy-5-methoxymethyl-2,4-dimethyl-pyridine
  • the title compound was obtained by treating a solution of 5-hydroxymethyl-2,4- dimethyl-pyridin-3-ol hydrochloride (1 g, 5.2 mmol) in DMF with Mel (2.28 g, 15 mmol) and NaH (0.6 g, 50 mmol) for 1 h at 0 °C.
  • HPLC Rt 2.835 min.
  • Example 102 6-Chloro-9-(5-chloro-6-methoxy-pyridin-3-ylmethyl)-9H-purin-2- ylamine Step 1: (5-Chloro-6-methoxy-pyridin-3-yl)-methanol (5,6-Dichloro-pyridin-3-yl)-methanol was dissolved in a saturated solution of NaOMe in MeOH and heated to reflux overnight.
  • Step 3 6-Chloro-9-(5-chloro-6-methoxy-pyridin-3-ylmethyl)-9H-purin- 2-ykmine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with
  • Example 103 6-chloro-9-(3,4-dimethoxy-pyridin-2-yImethyI)-9H-purin-2-ylamine The title compound was obtained by alkylation of 2-amino-6-chloropurine with
  • Example 104 6-chloro-9-(3-methoxy-6-methyI-pyridm-2-ylmethyl)-9H-purin-2- ylamine
  • Step 1 (3-Methoxy-6-methyl-pyridin-2-yl)-methanol
  • the title compound was obtained by 0-methykom of 2-hydroxymethyl-6- methyl-pyridin-3-ol according to the general procedure 2.6.
  • H- NMR (CDC1 3 ) ⁇ 7.05-7.1 l(m, 2H), 4.72-4.71 (d, 2H), 4.47-4.49 (t, IH), 3.84 (s, 3H), 2.51 (s, 3H).
  • Step 2 2-Bromomethyl-3-methoxy-6-methyl-pyridine
  • the title compound was obtained from (3-Methoxy-6-methyl-pyridin-2-yl)- methanol according to the general procedure 2.5.
  • ⁇ -NMR (CDC1 3 ) ⁇ 7.06-7.12 (m, 2H), 4.61 (s, 2H), 3.89 (s, 3H), 2.49 (s, 3H).
  • Step 3 6-chloro-9-(3-methoxy-6-methyl-pyridin-2-ylmethyl)-9H-purin- 2-ykmine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 2-bromomethyl-3- methoxy-6-methylpyridine according to the general procedure 1.1.
  • Example 105 6-Chloro-9-(5-methoxy-4,6-dimethyl-pyridin-3-ylmethyI)-9H-purin- 2-ylamine
  • Step 1 (5-Methoxy-4,6-dimethyl-pyridin-3-yl)-methanol
  • HPLC Rt 3.114 min. * H- NMR (CDCI 3 ) ⁇ 8.08 (s, IH), 4.67 (s, 2H), 3.74 (s, 3H), 2.49 (s, 3H), 2.33 (s, 3H).
  • Step 2 5-Bromomethyl-3-methoxy-2,4-dimethyl-pyridine
  • the title compound was obtained from (5-methoxy-4,6-dimethyl-pyridin-3-yl)- methanol according to the general procedure 2.5.
  • 'H-NMR (CDC1 3 ) ⁇ 8.22 (s, IH), 4.50 (s, 2H), 3.764(s, 3H), 2.54 (s, 3H), 2.37 (s, 3H).
  • Step 3 6-Chloro-9-(5-methoxy-4,6-dimethyl-pyridin-3-ylmethyl)-9H- purin-2-ykmine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 5-bromomethyl-3- methoxy-2,4-methylpyridine according to the general procedure 1.1.
  • HPLC Rt 3.7387 min.
  • Example 106 9-(4-Methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2-yIamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 2-chloromethyl-4-methoxy-3,5-dimethylpyridine hydrochloride according to the general procedure 1.1.
  • Example 107 6-Chloro-9-(3,5-dimethoxy-4-methyl-benzyl)-9H-purin-2-ylami ⁇ e
  • Step 1 (3,5-Dimethoxy-4-methyl-phenyl)-methanol
  • the title compound was obtained by reducing 3,5-dimethoxy-4-methyl-benzoic acid as described by Bhaskar et al. J. Org. Chem. 1991, 56, 5964-5965.
  • HPLC Rt 5.352.
  • Step 2 5-Bromomethyl-l,3-dimethoxy-2-methyl-benzene
  • the title compound was obtained from (3,5-dimethoxy-4-methyl-pheny ⁇ )- methanol according to the general procedure 2.5.
  • Step 3 6-Chloro-9-(3,5-dimethoxy-4-methyl-benzyl)-9H-purin-2- ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 5-bromomethyl-l,3-dimethoxy-4-methyl benzene according to the general procedure 1.1.
  • Example 108 9-(2-Bromo-3,5-dimethoxy-4-methyl-benzyl)-6-chloro-9H-purin-2- ylamine
  • the title compound was obtained by brominating 6-chloro-9-(3,5-dimethoxy-4- methyl-benzyl)-9H-purin-2-ykmine with bromine according to the general procedure 3.1.
  • Example 109 8-Bromo-9-(2-bromo-3,5-dimethoxy-4-methyl-benzyl)-6-chloro-9H- purin-2-ylamine
  • the title compound was obtained by brominating 6-chloro-9-(3,5-dimethoxy-4- methyl-benzyl)-9H-purin-2-ykmine with excess bromine according to the general procedure 3.1.
  • Example 110 2,6-Dichloro-9-(4-methoxy-3,5-dimethyI-pyridin-2-ylmethyl)-9H- purine The title compound was obtained by alkylation of 2-amino-6-chloropurine with
  • Example 111 8-butyl-6-chloro-9-(3,4,5-trimethoxy-benzyI)-9H-purin-2-ylamine
  • Step 1 6-Chloro-N4-(3,4,5-trimethoxy-benzyl)-pyrimidine-2,4,5- triamine
  • the title compound was obtained by refluxing 4,6-dichloro-pyrimidine-2,5- diamine (see Seek et al. Helv. Chim. Acta. 1986, 69, 1602-1613 and US Patent No.
  • Example 112 6-Chloro-9-(3,4,5-trimethoxy-benzyl)-9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 3,4,5-trimethoxybenzyl according to the general procedure 1.1.
  • the title compound was also obtained by treating a solution of 6-chloro-N-4-(3 ,4,5-trimethoxy-benzyl)- pyrimidine-2,4,5-triamine in triethyl orthoformate with a catalytic amount of cone.
  • HCl at r.t. for 20 min.
  • HPLC Rt 4.906 min.
  • Example 113 Acetic acid 4-(2-amino-6-chIoro-purin-9-ylmethy ⁇ )-3-bromo-2,6- dimethoxy-phenyl ester
  • Step 1 Acetic acid 4-hydroxymethyl-2,6-dimethoxy-phenyl ester
  • a solution of acetic acid4-formyl-2,6-dimethoxy-phenyl ester (25 mmol) in MeOH (100 mL) was treated with NaBEU (1 equiv.) at 0 °C for 15 min. After quenching with acetone and evaporating the solvent, work-up (CH 2 C1 2 ) and evaporation gave the title compound as a white solid (85% yield).
  • Example 114 4-(2-amino-6-chloro-purin-9-ylmethyl)-3-bromo-2,6-dimethoxy- phenol
  • the title compound was obtained by deacetytechnische-like substance (see previous example) in NH 3 /MeOH at r.t. for 0.5 h or K 2 C0 3 in methanol according to the general procedure 2.3.
  • Example 115 9-(2-bromo-3,4,5-trimethoxy-benzyl)-6-chIoro-9H-purin-2-ylamine
  • the title compound was obtained by 0-methykom of 4-(2-amino-6-chloro- purin-9-ylmethyl)-3-bromo-2,6-dimethoxy-phenol (see previous example) according to the general procedure 2.6.
  • the title compound could also be obtained by bromination of 6-chloro-9-(3,4,5-trimethoxy-benzyl)-9H-purin-2-ykmine (see example 48) in acetate buffer according to the general procedure 3.1.
  • HPLC Rt 5.742 min.
  • Example 116 9-(4-allyloxy-2-bromo-3,5-dimethoxy-benzyl)-6-chloro-9H-purin-2- ylamine
  • the title compound was obtained by alkylation of 4-(2-amino-6-chloro-purin-9- ylmethyl)-3-bromo-2,6-dimethoxy-phenol (see example 50) with 3-bromo-propene in DMF in the presence of K 2 C0 3 at 70 °C for 0.25-1 h.
  • HPLC Rt 6.309 min.
  • Example 117 9-(2-bromo-4-chloromethoxy-3,5-dimethoxy-benzyl)-6-chIoro-9H- purin-2-ylamine
  • the title compound was obtained by alkylation of 4-(2-amino-6-chloro-purin-9- ylmethyl)-3-bromo-2,6-dimethoxy-phenol (see example 50) with chloroiodomethane in DMF in the presence of K 2 C0 3 at 70 °C for 0.25-1 h.
  • HPLC Rt 6.109 min.
  • Example 118 9-[2-bromo-4-(2-chIoro-ethoxy)-3,5-dimethoxy-benzyI]-6-chloro-9H- purin-2-ylamine
  • the title compound was obtained by alkylation of 4-(2-amino-6-chloro-purin-9- ylmethyl)-3-bromo-2,6-dimethoxy-phenol (see example 50) with l-bromo-2-chloro- ethane in DMF in the presence of K 2 C0 3 at 70 °C for 0.25-1 h.
  • HPLC Rt 6.285 min.
  • Example 119 9-(2-bromo-4-cycIopropylmethoxy-3,5-dimethoxy-benzyl)-6-chloro- 9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 4-(2-amino-6-chloro-purin-9- ylmethyl)-3-bromo-2,6-dimethoxy-phenol (see example 50) with bromomethyl- cyclopropane in DMF in the presence of K 2 C0 3 at 70 °C for 0.25-1 h.
  • HPLC Rt 6.512 min.
  • Example 120 9-(2-bromo-4-ethoxy-3,5-dimethoxy-benzyl)-6-chloro-9H-purin-2- ylamine
  • the title compound was obtained by alkylation of 4-(2-amino-6-chloro-purin-9- ylmethyl)-3-bromo-2,6-dimethoxy-phenol (see example 50) with Etl in DMF in the presence of K 2 C0 3 at 70 °C for 0.25-1 h.
  • HPLC Rt 6.112 min.
  • Example 121 9-(2-bromo-3,5-dimethoxy-4-propoxy-benzyl)-6-chIoro-9H-purin-2- ylamine
  • the title compound was obtained by alkylation of 4-(2-amino-6-chloro-purin-9- ylmethyl)-3-bromo-2,6-dimethoxy-phenol (see example 50) with Prl in DMF in the presence of K 2 C0 3 at 70 °C for 0.25-1 h.
  • HPLC Rt 6.594 min.
  • Example 122 9-(2-bromo-4-butoxy-3,5-dimethoxy-benzyI)-6-chloro-9H-purin-2- ylamine
  • the title compound was obtained by alkylation of 4-(2-amino-6-chloro-purin-9- ylmethyl)-3-bromo-2,6-dimethoxy-phenol (see example 50) with Bui in DMF in the presence of K 2 C0 3 at 70 °C for 0.25-1 h.
  • HPLC Rt 6.594 min.
  • Example 123 6-chloro-9-(3-methoxymethoxy-6-methyI-pyridm-2-ylmethyl)-9H- purin-2-yIamine
  • Step 1 (3-methoxymethoxy-6-methyl-pyridin-2-yl)-methanol
  • the title compound was obtained by 0-alkykom of 2-hydroxymethyl-6-methyl- pyridin-3-ol with chloromethyl methyl ether according to the general procedure 2.6.
  • 'H- NMR (CDC1 3 ) ⁇ 7.28-7.30 (d, IH), 6.98-7.00 (d, IH), 5.17 (s, 2H), 4.71 (s, 2H), 4.50 (s, 2H), 3.45 (s, 3H), 2.49 (s, 3H).
  • Step 2 2-Bromomethyl-3-methoxymethoxy-6-methyl-pyridine
  • the title compound was obtained from (3-methoxymethoxy-6-methyl-pyridin-2- yl)-methanol according to the general procedure 2.5.
  • 'H-NMR (CDC1 3 ) ⁇ 7.32-7.40 (d IH), 7.08-7.10 (d, 1H),5.30 (s, 2H), 4.67 (s, 2H), 3.55 (s, 3H), 2.54 (s, 3H).
  • Step 3 6-Chloro-9-(3-methox3 ⁇ nethoxy-6-methyl-pyridin-2-ylmethyl)- 9H-purin-2-ykmine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 2-bromomethyl-3-methoxymethoxy-6-methyl-pyridine according to the general procedure 1.1.
  • HPLC Rt 3.884 min.
  • Example 124 3-(2-Amino-6-chloro-purin-9-ylmethyl)-3H-benzothiazole-2-thione
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 3-chloromethyl-3H-benzothiazole-2-thione according to the general procedure 1.1.
  • Example 125 6-Chloro-9-(2,5-dimethyl-benzyl)-9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 2-chloromethyl-l,4-dimethyl-benzene according to the general procedure 1.1.
  • HPLC Rt 5.920 min.
  • Example 126 6-Chloro-9-isoquinolin-l-ylmethyl-9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 1-bromomethyl-isoquinoline according to the general procedure 1.1.
  • Example 127 9-benzo [l,2,5]thiadiazol-5-ylmethyI-6-chloro-9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 5-bromomethyl-benzo[l,2,5]thiadiazole according to the general procedure 1.1.
  • Example 128 9-(l-methyl-lH-benzotriazol-5-ylmethyl)-6-chloro-9H-purin-2- ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 6-bromomethyl-l -methyl- lH-benzotriazole according to the general procedure 1.1.
  • Example 129 6-ehIoro-9-(6-chloro-benzo[l,2,5]thiadiazol-5-ylmethyl)-9H-purin-2- ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 5-bromomethyl-6-chloro-benzo[ 1 ,2,5]thiadiazole according to the general procedure 1.1.
  • HPLC Rt 5.400 min.
  • Example 130 9-benzo [l,2,5]thiadiazol-4-yImethyl-6-chloro-9H-purin-2-yIamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 4-bromomethyl-benzo[l,2,5]thiadiazole according to the general procedure 1.1.
  • HPLC Rt 5.027 min.
  • Example 131 6-chloro-9-(6-fluoro-4a,8a-dihydro-4H-benzo[l,3]dioxin-8-ylmethyl)- 9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with
  • Example 132 l-[3-(2-Amino-6-chloro-purin-9-yImethyl)-4-methoxy-phenyl]- ethanone
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-(3-chloromethyl-4-methoxy-phenyl)-ethanone according to the general procedure 1.1.
  • Example 133 6-chloro-9-(3-trifluoromethoxy-benzyl)-9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-chloromethyl-3-trifluoromethoxy-benzene according to the general procedure 1.1.
  • Example 134 6-chIoro-9-(2-fluoro-3-trifluoromethyl-benzyl)-9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-bromomethyl-2-fluoro-3-trifluoromethyl-benzene according to the general procedure 1.1.
  • Example 135 6-ChIoro-9-(2-fluoro-4,5-dimethoxy-benzyl)-9H-purin-2-ylamine
  • Step 1 (2-Fluoro-4,5-dimethoxy-phenyl)-methanol
  • a solution of 2-fluoro-4,5-dimethoxy-benzaldehyde (6.0 mmol) in MeOH (10 mL) was treated with NaBH 4 (1.2 equiv.) at 0-23 °C for 0.5 h.
  • work-up CH 2 C1 2
  • drying MgS0 4
  • evaporation gave the title compound as a crude oily product (94% yield).
  • Example 136 6-chloro-9-(2,3-dimethoxy-benzyl)-9H-purin-2-ylamine Step 1: l-Bromomethyl-2,3-dimethoxy-benzene
  • Step 1 l-Bromomethyl-2,3-dimethoxy-benzene
  • the title compound was obtained from (2,3-dimethoxy-phenyl)-methanol according to the general procedure 2.5.
  • Step 2 6-Chloro-9-(2,3-dimethoxy-benzyl)-9H-purin-2-ykmine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-bromomethyl-2,3-dimethoxy-benzene according to the general procedure 1.1.
  • HPLC Rt 5.200.
  • Example 137 6-chloro-9-(3,4-dimethoxy-benzyl)-9H-purin-2-ylamine
  • Step 1 4-Bromomethyl-l,2-dimethoxy-benzene
  • the title compound was obtained from (3,4-dimethoxy-phenyl)-methanol according to the general procedure 2.5.
  • Step 2 6-Chloro-9-(3,4-dimethoxy-benzyl)-9H-purin-2-ykmine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 4-bromomethyl-l,2-dimethoxy-benzene according to the general procedure 1.1.
  • HPLC Rt 4.753.
  • Example 138 9-(2-chloro-3,4,5-trimethoxy-benzyl)-6-methyl-9H-purin-2-ylamine
  • Example 139 6-chIoro-9-(2-chIoro-4,5-dimethoxy-benzyl)-9H-purin-2-ylamine
  • Step 1 (2-Chloro-4,5-dimethoxy-phenyl)-methanol
  • the title compound was obtained by chlorination of (3,4-dimethoxy-phenyl)- methanol according to the general procedure 3.1.
  • Step 2 l-Bromomethyl-2-chloro-4,5-dimethoxy-benzene
  • the title compound was obtained from (2-chloro-4,5-dimethoxy-phenyl)- methanol according to the general procedure 2.5.
  • Step 3 6-Chloro-9-(2-chloro-4,5-dimethoxy-benzyl)-9H-purin-2-ykmine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-bromomethyl-2-chloro-4,5-dimethoxy-benzene according to the general procedure 1.1.
  • HPLC Rt 5.366 min.
  • Example 140 6-chloro-9-(2-io do-4,5-dimethoxy-benzyl)-9H-purin-2-yIamine
  • Step 1 4-Bromomethyl-l,2-dimethoxy-benzene
  • the title compound was obtained from (3,4-dimethoxy-phenyl)-methanol according to the general procedure 2.5.
  • Step 2 l-Bromomethyl-2-iodo-4,5-dimethoxy-benzene
  • the title compound was obtained by iodination of 4-bromomethyl-l,2- dimethoxy-benzene according to the general procedure 3.1.
  • Step 3 6-Chloro-9-(2-iodo-4,5-dimethoxy-benzyl)-9H-purin-2-ykmine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-bromomethyl-2-iodo-4,5-dimethoxy-benzene according to the general procedure 1.1.
  • HPLC Rt 5.470 min.
  • Example 141 6-Bromo-9-(2-chloro-3,4,5-trimethoxy-benzyl)-9H-purin-2-ylamine
  • Step 1 2-Chloro-l-chloromethyl-3,4,5-trimethoxy-benzene
  • the title compound was obtained by chlorination of 5-chloromethyl-l,2,3- trimethoxy-benzene according to the general procedure 3.1.
  • Step 2 Synthesis of 6-chloro-9-(2-chloro-3,4,5-trimethoxy-benzyl)-9H- purin-2-ykmine
  • the title compound was obtained by alkylation of 6-bromoguanine with 2-chloro- l-chloromethyl-3,4,5-trimethoxy-benzene according to the general procedure 1.1.
  • HPLC Rt 5.676 min.
  • Example 142 6-chloro-9-(6-chloro-benzo[l,3]dioxol-5-ylmethyl)-9H-purin-2- ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 5-chloro-6-chloromethyl-benzo[l,3]dioxole according to the general procedure 1.1.
  • Example 143 6-chloro-9-(2,4-dimethoxy-3-methyl-benzyl)-9H-purin-2-yIamine
  • Step 1 l-Bromomethyl-2,4-dimethoxy-3-methyl-benzene
  • Step 2 6-Chloro-9-(2,4-dimethoxy-3-methyl-benzyl)-9H-purin-2- ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-bromomethyl-2,4-dimethoxy-3-methyl-benzene according to the general procedure 1.1.
  • Example 144 6-Chloro-9-(2-chloro-3,4-dimethoxy-benzyl)-9H-purin-2-ylamine
  • Step 1 l-Bromomethyl-2-chloro-3,4-dimethoxy-benzene
  • Step 2 6-Chloro-9-(2-chloro-3 ,4-dimethoxy-benzyl)-9H-purin-2-ykmine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-bromomethyl-2-chloro-3,4-dimethoxy-benzene according to the general procedure 1.1.
  • Example 146 6-Chloro-9-(2,6-dibromo-3,5-dimethoxy-benzyl)-9H-purin-2-ylamine
  • Step 1 2-Bromo-l-chloromethyl-3,5-dimethoxy-benzene and 2,4- dibromo-3 -chloromethyl- 1 , 5-dimethoxy-benzene
  • Bromination of l-chloromethyl-3, 5-dimethoxy-benzene according to the general procedure 3.1 gave a mixture of the two title compounds, which were separated by flash chromatography.
  • Step 2 6-Chloro-9-(2,6-dibromo-3,5-dimethoxy-benzyl)-9H-purin-2- ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 2,4-dibromo-3-chloromethyl-l, 5-dimethoxy-benzene according to the general procedure 1.1.
  • HPLC Rt 6.022 min.
  • Example 147 9-(2-Bromo-3,5-dimethoxy-benzyl)-6-chloro-9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 2-bromo- l-chloromethyl-3, 5-dimethoxy-benzene (see previous example, step 1) according to the general procedure 1.1.
  • Example 148 6-chIoro-9-(3,5-dimethoxy-benzyl)-9H-purin-2-yIamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-chloromethyl-3,5-dimethoxy-benzene according to the general procedure 1.1.
  • HPLC Rt 5.257 min.
  • Example 149 N-[6-chloro-9-(3,4,5-trimethoxy-benzyl)-9H-purin-2-yl]-acetamide
  • a solution of 6-chloro-9-(3,4,5-trimethoxy-benzyl)-9H-purin-2-ykmine in acetic acid was treated with fuming HNO 3 at 0 °C for 15 min.
  • Work-up and preparative TLC (EtOAc:hexane 1:1) gave N-[6-chloro-9-(3,4,5-trimethoxy-benzyl)-9H-purin-2-yl]- acetamide.
  • Example 150 6-chloro-9-(2,5-dimethoxy-benzyl)-9H-purin-2-yIamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-chloromethyl-2,5-dimethoxy-benzene according to the general procedure 1.1.
  • Example 151 8-bromo-6-chloro-9-(2,5-dimethoxy-benzyI)-9H-purin-2-ylamine
  • the title compound was obtained by bromination of 6-chloro-9-(2,5-dimethoxy- benzyl)-9H-purin-2-ykmine according to the general procedure 1.2.
  • Example 152 6-chloro-9-(4,5-dimethoxy-2-nitro-benzyl)-9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-bromomethyT4,5-dimethoxy-2-nitro-benzene according to the general procedure 1.1.
  • Example 153 8-bromo-6-chloro-9-(4,5-dimethoxy-2-nitro-benzyl)-9H-purin-2- ylamine
  • the title compound was obtained by brominating 6-chloro-9-(4,5-dimethoxy-2- nitro-benzyl)-9H-purin-2-ykmine (see previous example) according to the general procedure 1.2.
  • Example 154 6-chloro ⁇ 9-(2,5-dichloro-benzyI)-9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 2-bromomethyl-l,4-dichloro-benzene according to the general procedure 1.1.
  • Example 155 6-chloro-9-(2,3,5-trifluoro-benzyl)-9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-bromomethyl-2,3,5-trifluoro-benzene according to the general procedure 1.1.
  • Example 156 (2-amino-6-chloro-purin-9-yl)-(3,4,5-trimethoxy-phenyl)-methanone
  • a solution of 6-chloro-9H-purin-2-ykmine in pyridine was treated with 3,4,5- trimethoxybenzoyl chloride at r.t. for 2 h.
  • Work-up and purification by preparative TLC (EtOAc:hexane 1 : 1) gave the title compound.
  • Example 157 N-[9-(2-Bromo-3,4,5-trimethoxy-benzyl)-6-chloro-9H-purin-2-yl]- acetamide
  • a suspension of 9-(2-bromo-3,4,5-trimethoxy-benzyl)-6-chloro-9H-purin-2- ylamine (example 51) in acetic anhydride was treated with a catalytic amount of cone. H S0 at r.t. for 3 h. Work-up and purification by preparative TLC (EtOAc.hexane 9:1) gave the title compound. HPLC Rt: 5.603 min.
  • Example 158 N-[9-(2-bromo-3,4,5-trimethoxy-benzyl)-6-chloro-9H-purin-2-yl]-N- methyl-acetamide
  • a mixture of N-[9-(2-bromo-3,4,5-trimethoxy-benzyl)-6-chloro-9H-purin-2-yl]- acetamide and NaH in DMF was stirred at r.t. for 15 mi ⁇ , before adding Mel. Stirring was prolonged for 2 h at 50 °C. Work-up and purification by preparative TLC (EtOAc:hexane 1:1) gave the title compound. HPLC Rt: 6.422 min.
  • Example 159 6-chloro-9-(3,5-dichloro-benzyl)-9H-purin-2-yIamine
  • Step 1 l-Bromomethyl-3,5-dichloro-benzene
  • Step 2 6-chloro-9-(3,5-dichloro-benzyl)-9H-purin-2-ykmine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with l-bromomethyl-3,5-dichloro-benzene.
  • HPLC Rt 6.074 min.
  • Example 1 0 6-chIoro-9-(3,4-dichIoro-benzyl)-9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with
  • Example 161 8-bromo-6-chloro-9-(3,4-dichloro-benzyl)-9H-purin-2-ylamine
  • the title compound was obtained by bromination of 6-chloro-9-(3,4-dichloro- benzyl)-9H-purin-2-ykmine (see previous example) according to the general procedure 1.2.
  • Example 162 6-chloro-9-(2-chloro-3,4,5-trimethoxy-benzyl)-9H-purin-2-ylamine Chlorination of 6-chloro-9-(3 ,4, 5-trimethoxy-benzyl)-9H-purin-2-ykmine according to the general procedure 3.1 gave a mixture of the title compound and of 6- chloro-9-(2,6-dichloro-3 ,4,5-trimethoxy-benzyl)-9H-purin-2-ykmine. The two compounds were isolated by preparative TLC. HPLC Rt: 5.626 min.
  • Example 164 2-amino-9-(2-chloro-3,4,5-trimethoxy-benzyl)-9H-purin-6-ol
  • the title compound was obtained by heating a solution of 6-chloro-9-(2-chloro- 3,4,5-trimethoxy-benzyl)-9H-purin-2-ykmine (see example 98) in IN HCl for 4 h. Solvent was evaporated and the residue was washed with EtOAc to give the title compound. HPLC Rt: 4.603 min.
  • Example 165 6-bromo-9-(3,4,5-trimethoxy-benzyl)-9H-purin-2-ylamine The title compound was obtained by alkylation of 6-bromoguanine with 3- chloromethyl-3,4,5-trimethoxy benzene according to the general procedure 1.1. HPLC Rt: 4.947 min.
  • Example 166 6-bromo-9-(2-bromo-3,4,5-trimethoxy-benzyl)-9H-purin-2-ylamine
  • the title compound was obtained by bromination of 6-bromo-9-(3,4,5- trimethoxy-benzyl)-9H-purin-2-ykmine (see previous example) according to the general procedure 3.1.
  • Example 167 9-(2-bromo-3,4,5-trimethoxy-benzyl)-6-ethylsulfanyl-9H-purin-2- ylamine
  • Example 168 9-(2-bromo-3,4,5-trimethoxy-benzyl)-6-methoxy-9H-purin-2-ylamine A solution of 9-(2-bromo-3 ,4,5-trimethoxy-benzyl)-6-chloro-9H-purin-2-ykmine
  • Example 169 9-(2-bromo-3,4,5-trimethoxy-benzy ⁇ )-9H-purine-2,6-diamine
  • a solution of 9-(2-bromo-3,4,5-trimethoxy-benzyl)-6-chloro-9H-purin-2-ylamine (see example 51) in MeOH was treated with NH 3 (7N in MeOH) in a pressure vessel at 90 °C for 16 h.
  • Work-up and purification by preparative TLC (EtOAc:hexane 3:1) gave the title compound.
  • Example 170 6-chloro-9-(2-iodo-3,4,5-trimethoxy-benzyl)-9H-purin-2-ylamine
  • the title compound was obtained by iodination of 6-chloro-9-(3,4,5-trimethoxy- benzyl)-9H-purin-2-ykmine (see example 48) according to the general procedure 3.1.
  • Example 171 9-(2-bromo-3,5-dimethoxy-4-methoxymethoxy-benzyl)-6-chloro-9H- purin-2-ylamine
  • the title compound was obtained by alkylation of 4-(2-amino-6-chloro-purin-9- ylmethyl)-3-bromo-2,6-dimethoxy-phenol (see example 50) chloromethyl methyl ether according to the general procedure 2.6 (NaOH, THF, r.t.) HPLC Rt: 5.817 min. 'H-
  • Example 172 9-benzothiazol-2-ylmethyI-6-chloro-9H-purin-2-ylamine
  • the title compound was obtained by alkylation of 2-amino-6-chloropurine with 2-bromomethyl-benzothiazole according to the general procedure 1.1.
  • HPLC Rt 5.055 min.
PCT/US2004/031248 2003-09-18 2004-09-20 Novel heterocyclic compounds as hsp90-inhibitors WO2005028434A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
BRPI0414533-0A BRPI0414533A (pt) 2003-09-18 2004-09-20 composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
AU2004274507A AU2004274507B2 (en) 2003-09-18 2004-09-20 Novel heterocyclic compounds as HSP90-inhibitors
NZ546611A NZ546611A (en) 2003-09-18 2004-09-20 Novel heterocyclic compounds as HSP90-inhibitors
MXPA06002997A MXPA06002997A (es) 2003-09-18 2004-09-20 Novedosos compuestos heterociclicos como inhibidores- hsp90.
JP2006527162A JP2007505933A (ja) 2003-09-18 2004-09-20 Ｈｓｐ９０インヒビターとしての新規なヘテロ環化合物
EA200600594A EA010160B1 (ru) 2003-09-18 2004-09-20 Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
CN2004800335230A CN1882589B (zh) 2003-09-18 2004-09-20 作为hsp90-抑制剂的新的杂环化合物
CA002539548A CA2539548A1 (en) 2003-09-18 2004-09-20 Novel heterocyclic compounds as hsp90-inhibitors
EP04788954A EP1670802A4 (en) 2003-09-18 2004-09-20 NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF HSP90 PROTEIN
IL174375A IL174375A0 (en) 2003-09-18 2006-03-16 Novel heterocyclic compounds as hsp90-inhibitors
NO20061396A NO20061396L (no) 2003-09-18 2006-03-27 Nye heterocykliske forbindelser som HSP90-inhibitorer
AU2010202750A AU2010202750B2 (en) 2003-09-18 2010-06-30 Novel heterocyclic compounds as HSP90-inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50413503P 2003-09-18 2003-09-18
US60/504,135 2003-09-18
US59146704P 2004-07-26 2004-07-26
US60/591,467 2004-07-26

Publications (2)

Publication Number Publication Date
WO2005028434A2 true WO2005028434A2 (en) 2005-03-31
WO2005028434A3 WO2005028434A3 (en) 2006-03-23

Family

ID=34381103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/031248 WO2005028434A2 (en) 2003-09-18 2004-09-20 Novel heterocyclic compounds as hsp90-inhibitors

Country Status (14)

Country Link
US (8) US7138402B2 (US07138402-20061121-C00200.png)
EP (2) EP2145888A1 (US07138402-20061121-C00200.png)
JP (1) JP2007505933A (US07138402-20061121-C00200.png)
KR (1) KR20060070572A (US07138402-20061121-C00200.png)
CN (1) CN101906106A (US07138402-20061121-C00200.png)
AU (2) AU2004274507B2 (US07138402-20061121-C00200.png)
BR (1) BRPI0414533A (US07138402-20061121-C00200.png)
CA (1) CA2539548A1 (US07138402-20061121-C00200.png)
EA (1) EA010160B1 (US07138402-20061121-C00200.png)
IL (1) IL174375A0 (US07138402-20061121-C00200.png)
MX (1) MXPA06002997A (US07138402-20061121-C00200.png)
NO (1) NO20061396L (US07138402-20061121-C00200.png)
NZ (1) NZ546611A (US07138402-20061121-C00200.png)
WO (1) WO2005028434A2 (US07138402-20061121-C00200.png)

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035629A1 (fr) 2006-09-19 2008-03-27 Daiichi Sankyo Company, Limited Dérivé de pyrazolopyrimidine
FR2907453A1 (fr) * 2006-10-24 2008-04-25 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
WO2008093075A2 (en) * 2007-02-01 2008-08-07 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
JP2008536867A (ja) * 2005-04-14 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 増殖疾患を処置する際に有用なｈｓｐ９０インヒビターとしての２−アミノ−キナゾリン−５−オン
JP2008537751A (ja) * 2005-04-13 2008-09-25 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2012791A2 (en) * 2006-02-07 2009-01-14 Conforma Therapeutics Corporation 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2009114470A2 (en) * 2008-03-10 2009-09-17 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
US7595401B2 (en) 2006-05-12 2009-09-29 Myriad Pharmaceuticals, Inc. Therapeutic compounds and their use in cancer
JP2010500870A (ja) * 2006-08-03 2010-01-14 セルゾーム アーゲー Ｐｉ３ｋ相互作用分子の同定のための方法およびｐｉ３ｋの精製のための方法
US7763624B2 (en) 2005-08-22 2010-07-27 Amgen Inc. Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors
WO2010098344A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 三環性ピラゾロピリミジン誘導体
US7960420B2 (en) 2007-12-21 2011-06-14 Joyant Pharmaceuticals, Inc Diazonamide analogs with improved solubility
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
US7989482B2 (en) 2008-04-29 2011-08-02 Joyant Pharmaceuticals, Inc. Indoline anti-cancer agents
US8093229B2 (en) 2005-03-30 2012-01-10 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
WO2012026433A1 (ja) 2010-08-23 2012-03-01 第一三共株式会社 三環性ピラゾロピリミジン誘導体のフリー体結晶
WO2012026434A1 (ja) 2010-08-23 2012-03-01 第一三共株式会社 三環性ピラゾロピリミジン誘導体の結晶
US8153619B2 (en) 2008-05-22 2012-04-10 Joyant Pharmaceuticals, Inc. Diazonamide analogs
WO2012083181A1 (en) * 2010-12-16 2012-06-21 Indiana University Research And Technology Corporation Alpha helix mimetics and methods for using
WO2012145255A2 (en) 2011-04-22 2012-10-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
WO2012160464A1 (en) 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
US8324240B2 (en) 2007-03-20 2012-12-04 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
EP2571361A1 (en) * 2010-05-19 2013-03-27 The University of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US8642554B2 (en) 2007-04-12 2014-02-04 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
WO2014055624A1 (en) 2012-10-02 2014-04-10 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
US8722703B2 (en) 2009-01-16 2014-05-13 Curis, Inc. Fused amino pyridines for the treatment of brain tumors
US20140243359A1 (en) * 2011-07-20 2014-08-28 Medestea Research & Production S.P.A. Adenine derivatives having immunomodulating anti-inflammatory and analgesic activity
WO2014145576A2 (en) * 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
EP2784076A1 (en) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
TWI460177B (zh) * 2009-07-10 2014-11-11 Taiho Pharmaceutical Co Ltd An azabicyclo compound or a salt thereof
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2015140386A1 (es) * 2014-03-21 2015-09-24 Universidad De Granada Derivados de purina como inhibidores de dapk-1
WO2015157128A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapuetic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
US9163021B2 (en) 2012-10-04 2015-10-20 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
US9273056B2 (en) 2011-10-03 2016-03-01 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US9340546B2 (en) 2012-12-07 2016-05-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
KR20160059366A (ko) * 2014-11-18 2016-05-26 한국과학기술연구원 신규한 피롤로 피리미딘 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US9512111B2 (en) 2010-11-08 2016-12-06 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9567326B2 (en) 2012-05-22 2017-02-14 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9657033B2 (en) 2012-05-08 2017-05-23 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US9670215B2 (en) 2014-06-05 2017-06-06 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9745311B2 (en) 2012-08-10 2017-08-29 Incyte Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
US9801889B2 (en) 2015-02-20 2017-10-31 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
KR20180040037A (ko) * 2016-10-11 2018-04-19 한국과학기술연구원 2-아미노 퓨린 유도체 화합물, 이를 제조하는 방법, 및 이의 용도
WO2018079988A1 (ko) * 2016-10-26 2018-05-03 울산과학기술원 Trap1 저해제로서 유용한 화합물 및 이를 포함하는 항암용 조성물
US10040790B2 (en) 2013-04-19 2018-08-07 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10160760B2 (en) 2013-12-06 2018-12-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
US10213427B2 (en) 2010-12-22 2019-02-26 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
WO2019122059A1 (fr) * 2017-12-21 2019-06-27 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
US10584121B2 (en) 2015-10-27 2020-03-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
KR20220007447A (ko) * 2020-07-10 2022-01-18 이화여자대학교 산학협력단 Trap1 선택적 억제제로서의 화합물 및 이를 포함하는 암 예방 또는 치료용 조성물
US11261192B2 (en) 2018-03-09 2022-03-01 Recurium Ip Holdings, Llc Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones
US11274108B2 (en) 2015-07-20 2022-03-15 Genzyme Corporation Colony stimulating factor-1 receptor (CSF-1R) inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US11518767B2 (en) 2017-12-21 2022-12-06 Galderma Research & Development MTOR inhibitor compounds
US11530216B2 (en) 2020-12-23 2022-12-20 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6992188B1 (en) * 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
KR100850727B1 (ko) * 2000-11-02 2008-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90에 결합하기 위한 소분자 조성물
AU2002315389A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
CA2464031A1 (en) * 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
WO2005028434A2 (en) * 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
US20080280878A1 (en) * 2004-11-02 2008-11-13 Castro Januario E Methods and Compositions for Treating Chronic Lymphocytic Leukemia
US8741578B2 (en) * 2004-11-02 2014-06-03 The Regents Of The University Of California Methods of detecting chronic lymphocytic leukemia with Hsp90 and ZAP-70
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212012B2 (en) * 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US20060258691A1 (en) * 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
WO2007013964A1 (en) * 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
EP1931352B1 (en) * 2005-08-22 2016-04-13 The Regents of The University of California Tlr agonists
WO2007024789A1 (en) * 2005-08-24 2007-03-01 Lexicon Genetics Incorporated Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
WO2007058852A2 (en) * 2005-11-10 2007-05-24 Smithkline Beecham Corporation Inhibitors of akt activity
WO2007058879A2 (en) * 2005-11-10 2007-05-24 Smithkline Beecham Corporation Inhibitors of akt activity
CA2634723A1 (en) * 2005-12-22 2007-07-05 Conforma Therapeutics Corporation Orally active purine-based inhibitors of heat shock protein 90
WO2007097839A2 (en) * 2006-02-16 2007-08-30 Massachusetts Eye And Ear Infirmary Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
EP2700638A1 (en) * 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
EP3305297A1 (en) * 2006-06-30 2018-04-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
US20080009508A1 (en) * 2006-07-10 2008-01-10 Lucie Szucova 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin
WO2008045529A1 (en) * 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) * 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
WO2008094602A2 (en) * 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-h-pyrazolo (3,4b) pyrimidine derivatives and their use as modulators of mitotic kinases
CA2677733A1 (en) 2007-02-07 2008-09-25 The Regents Of The University Of California Conjugates of synthetic tlr agonists and uses therefor
US8143265B2 (en) * 2007-04-16 2012-03-27 Meharry Medical College Method of treating atherosclerosis
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
DE102007028521A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
US8119616B2 (en) * 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
US8466140B2 (en) * 2007-09-10 2013-06-18 University Of Massachusetts Mitochondria-targeted anti-tumor agents
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8895701B2 (en) 2008-01-05 2014-11-25 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
US20090202626A1 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
US8190543B2 (en) * 2008-03-08 2012-05-29 Tokyo Electron Limited Autonomous biologically based learning tool
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
LT5623B (lt) 2008-04-30 2010-01-25 Biotechnologijos Institutas, , 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti
US20110124634A1 (en) * 2008-05-13 2011-05-26 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
CA2730106A1 (en) 2008-07-08 2010-01-14 Intellikine, Inc. Kinase inhibitors and methods of use
US20100022635A1 (en) * 2008-07-28 2010-01-28 University Of Kansas Heat shock protein 90 inhibitor dosing methods
GB0819102D0 (en) * 2008-10-17 2008-11-26 Chroma Therapeutics Ltd Pyrrolo-pyrimidine compounds
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US8741910B2 (en) * 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
DK2414844T3 (en) * 2009-03-30 2015-03-02 Nordic Bioscience As Biomarker for fibrosis
TW201102391A (en) * 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
US8940752B2 (en) 2009-06-29 2015-01-27 Incyte Corporation Pyrimidinones as PI3K inhibitors
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
WO2011041593A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
CN105924443A (zh) 2009-10-07 2016-09-07 斯隆-凯特林癌症研究院 用作Hsp90抑制剂的嘌呤衍生物
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
US8680108B2 (en) * 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
US9173935B2 (en) 2010-04-30 2015-11-03 Telormedix Sa Phospholipid drug analogs
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
CN105859735B (zh) 2010-12-16 2018-03-09 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
KR20130116358A (ko) * 2011-02-09 2013-10-23 에프. 호프만-라 로슈 아게 Pi3 키나아제 억제제로서 헤테로사이클릭 화합물
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
BR112013025761A2 (pt) 2011-04-05 2018-05-29 Sloan Kettering Inst Cancer Res inibidores de hsp90
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
CA2846652C (en) 2011-09-02 2019-11-05 Incyte Corporation Heterocyclylamines as pi3k inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AU2013263420A1 (en) * 2012-05-15 2015-01-22 Calasia Pharmaceuticals, Inc. Pyrimidine diamine derivatives as inhibitors of cytosolic Hsp90
CN103724269B (zh) * 2012-10-11 2016-12-21 中国科学院上海药物研究所 苯基1,2-异噁唑或苯基1,2-吡唑类化合物及其用途
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
EP3024457A4 (en) 2013-07-26 2017-06-28 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
KR102319582B1 (ko) 2013-08-16 2021-11-04 메모리얼 슬로안 케터링 캔서 센터 선택적 ｇｒｐ９４ 저해제 및 이의 용도
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CN113521314A (zh) 2014-09-17 2021-10-22 纪念斯隆-凯特琳癌症中心 Hsp90-靶向炎症和感染成像及治疗
MY187502A (en) 2015-02-27 2021-09-24 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
US10472361B2 (en) * 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
CN107857763A (zh) * 2017-11-28 2018-03-30 江苏杏睿生物科技有限公司 一种邻硝基芳酰化衍生物类化合物、制备方法及其应用
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN116332940A (zh) * 2023-02-14 2023-06-27 广西民族大学 一种7-脱氮嘌呤衍生物及其制备方法和应用

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB884151A (en) 1957-12-06 1961-12-06 Ciba Ltd New pyrazolo-pyrimidines substituted in the pyrazole nucleus, and process for their manufacture
IL64501A (en) * 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4921859A (en) 1983-10-31 1990-05-01 Warner-Lambert Company Purine derivatives
US5098906A (en) * 1983-10-31 1992-03-24 Warner-Lambert Company Purine derivatives
US4806642A (en) * 1984-10-05 1989-02-21 Warner-Lambert Company Purine derivatives
US4547573A (en) * 1983-12-02 1985-10-15 Ici Pharma Process for preparing cephalosporin derivatives
DE3578499D1 (de) 1984-02-02 1990-08-09 Merck & Co Inc 5-(amino oder substituiertes amino)-1,2,3-triazole.
US4748177A (en) 1984-03-26 1988-05-31 Warner-Lambert Company Guanine derivatives
US4617304A (en) 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
IT1196261B (it) * 1984-09-20 1988-11-16 Pierrel Spa Derivati nucleosidici e purinici 8-sostituiti
US4772606A (en) 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
ZA857647B (en) * 1984-10-12 1986-05-28 Warner Lambert Co Purine derivatives
IL76546A (en) 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
JO1406B1 (en) 1984-11-02 1986-11-30 سميث كلاين اند فرينش لابوراتوريز ليمتد Chemical compounds
DE3650349T2 (de) 1985-03-15 1995-12-14 Antivirals Inc Immunotestmittel für polynukleotid und verfahren.
US5217866A (en) * 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
IL78643A0 (en) 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
GB8515934D0 (en) 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US4918162A (en) 1986-05-06 1990-04-17 The Regents Of The University Of California Assays and antibodies for N-MYC proteins
DE3623099C3 (de) * 1986-07-09 1998-08-13 Spoetzl Markus Dipl Ing Fh Blasformmaschine
US5002950A (en) 1986-10-24 1991-03-26 Warner-Lambert Co. 7-deazaguanines as immunomodulators
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5204353A (en) 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
JPH0821101B2 (ja) 1987-07-21 1996-03-04 三洋電機株式会社 硬貨選別装置
SE8801729D0 (sv) 1988-05-06 1988-05-06 Astra Ab Purine derivatives for use in therapy
US4923885A (en) * 1988-08-19 1990-05-08 Merck & Co., Inc. 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents
EP0363320A3 (de) 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
ATE133678T1 (de) 1990-07-04 1996-02-15 Merrell Dow Pharma 9-purinyl-phosphonsäurederivate
GB9020931D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
ES2139588T3 (es) 1991-03-05 2000-02-16 Ajinomoto Kk Derivado de ciclopropano.
US5939420A (en) 1991-04-08 1999-08-17 Duquesne University Of The Holy Ghost Pyrrolo 2,3d!derivatives
WO1992021032A1 (en) * 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
US6025126A (en) * 1991-10-28 2000-02-15 Arch Development Corporation Methods and compositions for the detection of chromosomal aberrations
CA2093403C (en) 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
JPH0680670A (ja) 1992-09-03 1994-03-22 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
US6005107A (en) 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US5744492A (en) 1993-09-17 1998-04-28 United States Of America Method for inhibiting angiogenesis
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
JP3769737B2 (ja) 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH0841035A (ja) 1994-08-05 1996-02-13 Ajinomoto Co Inc シクロプロパン誘導体及びその製造法
US5846749A (en) 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
JPH08208687A (ja) 1994-11-25 1996-08-13 Sankyo Co Ltd グリセリルオリゴヌクレオチド
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US6177460B1 (en) * 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
JPH0920776A (ja) 1995-06-30 1997-01-21 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法及びその誘導体を有効成分とする抗ウイルス剤
JPH09169758A (ja) 1995-10-18 1997-06-30 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法、及びそれを用いた抗ウイルス剤
JPH1025294A (ja) 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
WO1998001448A1 (fr) 1996-07-03 1998-01-15 Japan Energy Corporation Nouveaux derives de purine
US6723727B1 (en) * 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US5861503A (en) * 1997-04-30 1999-01-19 The Regents Of The University Of California Process for producing 8-fluoropurines
ATE460423T1 (de) 1997-05-14 2010-03-15 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
CN1268137A (zh) 1997-07-03 2000-09-27 杜邦药品公司 治疗神经失调的咪唑并嘧啶和咪唑并吡啶
WO1999002162A1 (en) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
GB9717849D0 (en) 1997-08-23 1997-10-29 Seal Sands Chemicals Limited Preparation of pyridene derivatives
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
CN1130363C (zh) 1997-11-12 2003-12-10 三菱化学株式会社 嘌呤衍生物以及含有其作为有效成分的药物
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
US5985060A (en) 1998-07-25 1999-11-16 Breed Automotive Technology, Inc. Gas generant compositions containing guanidines
SI20022A (sl) 1998-07-29 2000-02-29 Kemijski inštitut Alkilno substituirani purinovi derivati in njihova priprava
JP2000072773A (ja) 1998-08-28 2000-03-07 Zeria Pharmaceut Co Ltd プリン誘導体
US6369092B1 (en) * 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
DE60042731D1 (de) * 1999-01-06 2009-09-24 Univ Southern California Methode und zubereitung zur hemmung von angiogenese
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1150982B1 (en) 1999-02-01 2005-10-12 Cv Therapeutics, Inc. PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-alpha
FR2790702B1 (fr) 1999-03-08 2001-07-20 Sidel Sa Unite de moulage et machine d'extrusion-soufflage munie d'une telle unite
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
WO2000068230A1 (en) 1999-05-05 2000-11-16 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors
US6660845B1 (en) * 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
CO5271715A1 (es) 1999-12-21 2003-04-30 Sugen Inc 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
WO2001049688A1 (en) 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
AU2001247759A1 (en) 2000-03-24 2001-10-08 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ES2788383T3 (es) 2000-04-25 2020-10-21 Icos Corp Inhibidores de delta fosfatidilo-inositol 3-quinasa humana
US6887853B2 (en) 2000-06-29 2005-05-03 The Trustees Of Boston University Use of geldanamycin and related compounds for treatment of fibrogenic disorders
CA2417495C (en) 2000-07-28 2013-04-30 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
US6613089B1 (en) 2000-10-25 2003-09-02 Sdgi Holdings, Inc. Laterally expanding intervertebral fusion device
JP2004512381A (ja) 2000-11-02 2004-04-22 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０インヒビターの使用により細胞毒性剤の効力を増強させる方法
KR100850727B1 (ko) * 2000-11-02 2008-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90에 결합하기 위한 소분자 조성물
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
MY141789A (en) 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
CA2440809A1 (en) 2001-03-01 2002-09-12 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
US6881567B2 (en) * 2001-03-16 2005-04-19 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agricultural And Agri-Food Canada Pre-emergent biological control agents
ES2314042T3 (es) 2001-04-17 2009-03-16 Dainippon Sumitomo Pharma Co., Ltd. Derivados nuevos de adenina.
US20020156277A1 (en) 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
US20030022864A1 (en) 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
EP1404871A4 (en) 2001-05-23 2006-10-04 Sloan Kettering Inst Cancer METHOD OF TREATING CANCERS ASSOCIATED WITH LEVELS OF HER-2 STUDENTS
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
WO2003000200A2 (en) 2001-06-22 2003-01-03 Pharmasset Ltd. β-2'-OR 3'-HALONUCLEOSIDES
JP4381804B2 (ja) 2001-06-27 2009-12-09 サイクラセル リミテッド ２，６，９−置換プリン誘導体及び増殖性疾患の治療におけるその使用
US6962991B2 (en) * 2001-09-12 2005-11-08 Epoch Biosciences, Inc. Process for the synthesis of pyrazolopyrimidines
DK1499277T3 (da) 2001-09-24 2009-05-11 Imp Innovations Ltd PYY-36 til reduktion eller forebyggelse af obesitet
US7579462B2 (en) 2001-09-24 2009-08-25 Conforma Therapeutics Corporation Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins
JP2003113181A (ja) 2001-10-04 2003-04-18 Sumika Fine Chemicals Co Ltd ６−ハロプリンの製造方法
CA2464031A1 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
EP1450784A4 (en) 2001-11-09 2005-02-09 Conforma Therapeutics Corp HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
WO2004024082A2 (en) * 2002-09-13 2004-03-25 Irm, Llc Highly specific modulators of gtpases for target validation
US7601694B2 (en) * 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
EP1781659B1 (en) * 2003-07-16 2008-11-05 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
CN100404536C (zh) * 2003-07-16 2008-07-23 詹森药业有限公司 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
WO2005028434A2 (en) 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
WO2006009245A1 (ja) * 2004-07-23 2006-01-26 Tanabe Seiyaku Co., Ltd. 含窒素縮合二環式化合物
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
US9809805B2 (en) 2015-03-13 2017-11-07 Acro Biotech Co., Ltd. Zinc binding fusion protein of glutathione S-transferase and metallothionein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1670802A4 *

Cited By (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093229B2 (en) 2005-03-30 2012-01-10 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
JP2008537751A (ja) * 2005-04-13 2008-09-25 アステックス、セラピューティックス、リミテッド 医薬化合物
JP2008536867A (ja) * 2005-04-14 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 増殖疾患を処置する際に有用なｈｓｐ９０インヒビターとしての２−アミノ−キナゾリン−５−オン
US7763624B2 (en) 2005-08-22 2010-07-27 Amgen Inc. Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors
EP2012791A2 (en) * 2006-02-07 2009-01-14 Conforma Therapeutics Corporation 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
EP2012791A4 (en) * 2006-02-07 2010-09-22 Conforma Therapeutics Corp 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGUES AS INHIBITORS OF HSP90
JP2009536960A (ja) * 2006-05-12 2009-10-22 ミリアド ジェネティクス， インコーポレイテッド 治療用化合物および癌におけるそれらの使用
US8476285B2 (en) 2006-05-12 2013-07-02 Myrexis, Inc. Purine-core inhibitors of HSP90 and their use in treating cancer
US7595401B2 (en) 2006-05-12 2009-09-29 Myriad Pharmaceuticals, Inc. Therapeutic compounds and their use in cancer
JP2010500870A (ja) * 2006-08-03 2010-01-14 セルゾーム アーゲー Ｐｉ３ｋ相互作用分子の同定のための方法およびｐｉ３ｋの精製のための方法
JP5252636B2 (ja) * 2006-09-19 2013-07-31 第一三共株式会社 ピラゾロピリミジン誘導体
KR101485199B1 (ko) 2006-09-19 2015-01-22 다이이찌 산쿄 가부시키가이샤 피라졸로피리미딘 유도체
US8158638B2 (en) 2006-09-19 2012-04-17 Daiichi Sankyo Company, Limited Pyrazolopyrimidine derivative
WO2008035629A1 (fr) 2006-09-19 2008-03-27 Daiichi Sankyo Company, Limited Dérivé de pyrazolopyrimidine
US8163750B2 (en) 2006-10-24 2012-04-24 Sanofi-Aventis Fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90
JP2010507634A (ja) * 2006-10-24 2010-03-11 サノフイ−アベンテイス 新規フルオレン誘導体、これを含む組成物、およびタンパク質シャペロンｈｓｐ９０の阻害剤としてのこれらの使用
FR2907453A1 (fr) * 2006-10-24 2008-04-25 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
WO2008049994A1 (fr) 2006-10-24 2008-05-02 Sanofi-Aventis Nouveaux derives du fluorene, compositions les contenant et utilisation comme inhibiteurs de la proteine chpaerone hsp90
US7799781B2 (en) 2007-02-01 2010-09-21 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors
WO2008093075A2 (en) * 2007-02-01 2008-08-07 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
WO2008093075A3 (en) * 2007-02-01 2008-10-02 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
US8324240B2 (en) 2007-03-20 2012-12-04 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
US8642554B2 (en) 2007-04-12 2014-02-04 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
US7960420B2 (en) 2007-12-21 2011-06-14 Joyant Pharmaceuticals, Inc Diazonamide analogs with improved solubility
WO2009114470A3 (en) * 2008-03-10 2010-01-14 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
WO2009114470A2 (en) * 2008-03-10 2009-09-17 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
US7989482B2 (en) 2008-04-29 2011-08-02 Joyant Pharmaceuticals, Inc. Indoline anti-cancer agents
US8153619B2 (en) 2008-05-22 2012-04-10 Joyant Pharmaceuticals, Inc. Diazonamide analogs
US8722703B2 (en) 2009-01-16 2014-05-13 Curis, Inc. Fused amino pyridines for the treatment of brain tumors
US8445504B2 (en) 2009-02-25 2013-05-21 Daiichi Sankyo Company, Limited Tricyclic pyrazolopyrimidine derivatives
US8236813B2 (en) 2009-02-25 2012-08-07 Daiichi Sankyo Company, Limited Tricyclic pyrazolopyrimidine derivatives
WO2010098344A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 三環性ピラゾロピリミジン誘導体
RU2520966C2 (ru) * 2009-02-25 2014-06-27 Дайити Санкио Компани, Лимитед Производное трициклического пиразолопиримидина
TWI460177B (zh) * 2009-07-10 2014-11-11 Taiho Pharmaceutical Co Ltd An azabicyclo compound or a salt thereof
EP2784076A1 (en) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
US8685974B2 (en) 2009-12-21 2014-04-01 Bayer Cropscience Ag Thienylpyri(mi)dinylazole
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
US9744172B2 (en) 2010-05-19 2017-08-29 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2571361A4 (en) * 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2571361A1 (en) * 2010-05-19 2013-03-27 The University of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2012026433A1 (ja) 2010-08-23 2012-03-01 第一三共株式会社 三環性ピラゾロピリミジン誘導体のフリー体結晶
US8815880B2 (en) 2010-08-23 2014-08-26 Daiichi Sankyo Company, Limited Crystal of tricyclic pyrazolopyrimidine derivative
WO2012026434A1 (ja) 2010-08-23 2012-03-01 第一三共株式会社 三環性ピラゾロピリミジン誘導体の結晶
US8846703B2 (en) 2010-08-23 2014-09-30 Daiichi Sankyo Company, Limited Crystal of a free tricyclic pyrazolopyrimidine derivative
EP2810945A1 (en) 2010-08-23 2014-12-10 Daiichi Sankyo Company, Limited Dihydrochloride salt of a tricyclic pyrazolopyrimidine derivative
US9512111B2 (en) 2010-11-08 2016-12-06 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
WO2012083181A1 (en) * 2010-12-16 2012-06-21 Indiana University Research And Technology Corporation Alpha helix mimetics and methods for using
US10213427B2 (en) 2010-12-22 2019-02-26 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10813930B2 (en) 2010-12-22 2020-10-27 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
WO2012145255A2 (en) 2011-04-22 2012-10-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
WO2012160464A1 (en) 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
US8980911B2 (en) 2011-05-26 2015-03-17 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
US9364466B2 (en) 2011-05-26 2016-06-14 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US20140243359A1 (en) * 2011-07-20 2014-08-28 Medestea Research & Production S.P.A. Adenine derivatives having immunomodulating anti-inflammatory and analgesic activity
US9273056B2 (en) 2011-10-03 2016-03-01 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US9795606B2 (en) 2011-10-03 2017-10-24 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US9802958B2 (en) 2012-05-08 2017-10-31 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
US10208061B2 (en) 2012-05-08 2019-02-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10377768B2 (en) 2012-05-08 2019-08-13 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9657033B2 (en) 2012-05-08 2017-05-23 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US9567326B2 (en) 2012-05-22 2017-02-14 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US10131667B2 (en) 2012-06-13 2018-11-20 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11840534B2 (en) 2012-06-13 2023-12-12 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9745311B2 (en) 2012-08-10 2017-08-29 Incyte Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014055624A1 (en) 2012-10-02 2014-04-10 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
EP3795694A2 (en) 2012-10-02 2021-03-24 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
US9163021B2 (en) 2012-10-04 2015-10-20 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US9340546B2 (en) 2012-12-07 2016-05-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11370798B2 (en) 2012-12-07 2022-06-28 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11117900B2 (en) 2012-12-07 2021-09-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9650381B2 (en) 2012-12-07 2017-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10787452B2 (en) 2012-12-07 2020-09-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10392391B2 (en) 2012-12-07 2019-08-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9718827B2 (en) 2012-12-07 2017-08-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014145576A2 (en) * 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014145576A3 (en) * 2013-03-15 2014-12-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
US9981968B2 (en) 2013-03-15 2018-05-29 Northwestern University Substituted pyrrolo[2,3-d]pyrimidines for the treatment of cancer and proliferative disorders
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10450313B2 (en) 2013-04-19 2019-10-22 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10947230B2 (en) 2013-04-19 2021-03-16 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US10040790B2 (en) 2013-04-19 2018-08-07 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10160760B2 (en) 2013-12-06 2018-12-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10815239B2 (en) 2013-12-06 2020-10-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11485739B2 (en) 2013-12-06 2022-11-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10221146B2 (en) 2013-12-20 2019-03-05 Lycera Corporation Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
US10745364B2 (en) 2013-12-20 2020-08-18 Lycera Corporation Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
WO2015140386A1 (es) * 2014-03-21 2015-09-24 Universidad De Granada Derivados de purina como inhibidores de dapk-1
US9555031B2 (en) 2014-04-11 2017-01-31 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
WO2015157127A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapuetic uses of selected pyrimidine compounds with anti-mer tyrosine kinase activity
WO2015157128A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Therapuetic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
US9555030B2 (en) 2014-04-11 2017-01-31 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity
US10004755B2 (en) 2014-04-11 2018-06-26 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
US9649309B2 (en) 2014-04-11 2017-05-16 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity
WO2015157123A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrrolopyrimidine compounds
US9603850B2 (en) 2014-04-11 2017-03-28 The University Of North Carolina At Chapel Hill MerTK-specific pyrazolopyrimidine compounds
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10364237B2 (en) 2014-05-05 2019-07-30 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
US10442798B2 (en) 2014-05-05 2019-10-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10800781B2 (en) 2014-06-05 2020-10-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9670215B2 (en) 2014-06-05 2017-06-06 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10093676B2 (en) 2014-06-05 2018-10-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
KR20160059366A (ko) * 2014-11-18 2016-05-26 한국과학기술연구원 신규한 피롤로 피리미딘 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
US10251892B2 (en) 2015-02-20 2019-04-09 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10738048B2 (en) 2015-02-20 2020-08-11 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9801889B2 (en) 2015-02-20 2017-10-31 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10632126B2 (en) 2015-02-20 2020-04-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en) 2015-02-20 2023-06-06 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10016438B2 (en) 2015-02-20 2018-07-10 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10214528B2 (en) 2015-02-20 2019-02-26 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US11059796B2 (en) 2015-06-11 2021-07-13 The Regents Of The University Of Michigan Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US11274108B2 (en) 2015-07-20 2022-03-15 Genzyme Corporation Colony stimulating factor-1 receptor (CSF-1R) inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US10584121B2 (en) 2015-10-27 2020-03-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
US10689369B2 (en) 2015-10-27 2020-06-23 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
KR20180040037A (ko) * 2016-10-11 2018-04-19 한국과학기술연구원 2-아미노 퓨린 유도체 화합물, 이를 제조하는 방법, 및 이의 용도
KR101896616B1 (ko) * 2016-10-11 2018-09-07 한국과학기술연구원 2-아미노 퓨린 유도체 화합물, 이를 제조하는 방법, 및 이의 용도
KR102053933B1 (ko) * 2016-10-26 2019-12-11 울산과학기술원 Trap1 저해제로서 유용한 화합물 및 이를 포함하는 항암용 조성물
KR20180045781A (ko) * 2016-10-26 2018-05-04 울산과학기술원 Trap1 저해제로서 유용한 화합물 및 이를 포함하는 항암용 조성물
WO2018079988A1 (ko) * 2016-10-26 2018-05-03 울산과학기술원 Trap1 저해제로서 유용한 화합물 및 이를 포함하는 항암용 조성물
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11731973B2 (en) 2017-12-21 2023-08-22 Galderma Research & Development Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors
WO2019122059A1 (fr) * 2017-12-21 2019-06-27 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
US11518767B2 (en) 2017-12-21 2022-12-06 Galderma Research & Development MTOR inhibitor compounds
FR3075794A1 (fr) * 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
AU2018391799B2 (en) * 2017-12-21 2023-05-18 Galderma Research & Development Novel mTOR inhibitor compounds
US11261192B2 (en) 2018-03-09 2022-03-01 Recurium Ip Holdings, Llc Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
KR102516260B1 (ko) * 2020-07-10 2023-03-31 울산과학기술원 Trap1 선택적 억제제로서의 화합물 및 이를 포함하는 암 예방 또는 치료용 조성물
KR20220007447A (ko) * 2020-07-10 2022-01-18 이화여자대학교 산학협력단 Trap1 선택적 억제제로서의 화합물 및 이를 포함하는 암 예방 또는 치료용 조성물
US11530216B2 (en) 2020-12-23 2022-12-20 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Also Published As

Publication number Publication date
AU2004274507B2 (en) 2010-08-19
US20070111997A1 (en) 2007-05-17
AU2010202750B2 (en) 2011-09-01
BRPI0414533A (pt) 2006-11-07
WO2005028434A3 (en) 2006-03-23
US20050113339A1 (en) 2005-05-26
EP2145888A1 (en) 2010-01-20
US20070185064A1 (en) 2007-08-09
US20050119282A1 (en) 2005-06-02
AU2010202750A1 (en) 2010-07-22
US20050107343A1 (en) 2005-05-19
EA010160B1 (ru) 2008-06-30
EP1670802A4 (en) 2010-07-07
US7138401B2 (en) 2006-11-21
JP2007505933A (ja) 2007-03-15
EA200600594A1 (ru) 2006-10-27
US20070111996A1 (en) 2007-05-17
US20050113340A1 (en) 2005-05-26
EP1670802A2 (en) 2006-06-21
US7148228B2 (en) 2006-12-12
CN101906106A (zh) 2010-12-08
US20070173483A1 (en) 2007-07-26
CA2539548A1 (en) 2005-03-31
AU2004274507A1 (en) 2005-03-31
MXPA06002997A (es) 2007-02-08
US7129244B2 (en) 2006-10-31
KR20060070572A (ko) 2006-06-23
US7138402B2 (en) 2006-11-21
NO20061396L (no) 2006-06-16
IL174375A0 (en) 2006-08-01
NZ546611A (en) 2010-02-26

Similar Documents

Publication Publication Date Title
AU2004274507B2 (en) Novel heterocyclic compounds as HSP90-inhibitors
AU2002343604C1 (en) Purine analogs having HSP90-inhibiting activity
US20080096903A1 (en) Sulfamoyl-containing derivatives and uses thereof
US8093229B2 (en) Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
WO2007092496A2 (en) 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO1998042711A1 (fr) DERIVES [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINIQUES
Rao et al. An assessment study of known pyrazolopyrimidines: Chemical methodology and cellular activity
JP2009521446A (ja) 熱ショックタンパク質９０の経口活性なプリンベースの阻害剤
ZA200602786B (en) Novel heterocyclic compounds as HSP90-inhibitors
JP2001519350A (ja) ナフト−イミダゾ［１，２−ａ］ピリジン誘導体、その製造及び中枢神経系障害の処置におけるその使用

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480033523.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/002997

Country of ref document: MX

Ref document number: 174375

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2539548

Country of ref document: CA

Ref document number: 12006500572

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2006527162

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1585/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004274507

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006/02786

Country of ref document: ZA

Ref document number: 200602786

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004788954

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067007478

Country of ref document: KR

Ref document number: 546611

Country of ref document: NZ

Ref document number: 200600594

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2004274507

Country of ref document: AU

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 2004788954

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067007478

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0414533

Country of ref document: BR